

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
7 October 2004 (07.10.2004)

PCT

(10) International Publication Number  
WO 2004/084798 A2

(51) International Patent Classification<sup>7</sup>:

A61K

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:

PCT/IL2004/000275

(22) International Filing Date: 25 March 2004 (25.03.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10/396,578 26 March 2003 (26.03.2003) US

(71) Applicant (for all designated States except US): TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. [IL/IL]; Senate House, Technion City, Haifa 32 000 (IL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): REITER, Yoram [IL/IL]; 20 HaSahlav Street, Haifa 34 790 (IL). COHEN, Cyril [IL/IL]; 4 Hashitah Street, Nesher 36 800 (IL).

(74) Agent: G.E. EHRLICH (1995) LTD.; 11 Menachem Begin Street, Ramat Gan 52 521 (IL).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/084798 A2

(54) Title: ANTIGEN-PRESENTING COMPLEX-BINDING COMPOSITIONS AND USES THEREOF

(57) Abstract: A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen is disclosed.

## ANTIGEN-PRESENTING COMPLEX-BINDING COMPOSITIONS AND USES THEREOF

### FIELD AND BACKGROUND OF THE INVENTION

5 The present invention relates to compositions-of-matter capable of specifically binding particular antigen-presenting molecule (APM):antigen complexes. More particularly, the present invention relates to compositions-of-matter capable of specifically binding a particular human APM:pathogen-derived antigen complex.

10 Diseases caused by pathogens, such as viruses, mycoplasmas, bacteria, fungi, and protozoans, account for a vast number of diseases, including highly debilitating/lethal diseases, affecting all human individuals at numerous instances during their lifetime. For example, diseases caused by retroviruses are associated with various immunological, neurological, and neoplastic disorders. For example, diseases caused by lymphotropic retroviruses, such as acquired immunodeficiency 15 syndrome (AIDS) caused by human immunodeficiency virus (HIV), or the closely related human T-cell lymphotropic virus (HTLV), a causative agent of various lethal pathologies (for general references, refer, for example to: Johnson JM. *et al.*, 2001. *Int J Exp Pathol.* 82:135-47; and Bangham CR., 2000. *J Clin Pathol.* 53:581-6), account for lethal disease epidemics of devastating human and economic impact.

20 However, satisfactory methods of diagnosing, characterizing, and treating many kinds of pathogen-associated diseases such as diseases associated with lymphotropic viruses such as HIV or HTLV are unavailable.

HTLV-1 was the first human retrovirus identified (Poiesz B.J. *et al.*, 1980. *Proc Natl Acad Sci U S A.* 77:7415-7419). It infects both CD4+ and CD8+ T-25 lymphocytes and is associated with a variety of diseases, including adult T-lymphocyte leukemia/lymphoma (ATLL; Yoshida M. *et al.*, 1982. *Proc Natl Acad Sci U S A.* 79:2031-2035) and a non neoplastic inflammatory neurological syndrome called human T lymphotropic type I (HTLV-1)-associated myelopathy/tropical virus spastic paraparesis (HAM/TSP; Osame M. *et al.*, 1986. *Lancet* 1:1031-1032; reviewed 30 in Ribas JG. and Melo GC., 2002. *Rev Soc Bras Med Trop.* 35:377-84; and Plumelle Y., 1999. *Med Hypotheses.* 52:595-604). Other diseases linked to HTLV-1 infection on the basis of seroepidemiological studies include Sjogren's syndrome, inflammatory arthropathies, polymyositis, and pneumopathies (Coscoy L. *et al.*, 1998. *Virology* 248: 332-341). The HTLV protein Tax seems to play a major role in the pathogenesis

of HTLV-1 associated diseases. Tax protein is known to stimulate the transcription of viral and cellular genes such as the genes coding for interleukin-2 (IL-2) and other cytokines, interleukin-2 receptor (IL-2R), proto-oncogenes, c-jun and c-fos, and major histocompatibility complex (MHC) molecules (Yoshida M., 1993. Trends Microbiol. 5 1:131-135). The transforming potential of Tax has been demonstrated in different experimental systems. It has been shown that rodent fibroblastic cell lines expressing Tax form colonies in soft agar and tumors in nude mice (Tanaka A. *et al.*, 1990. Proc Natl Acad Sci U S A. 87:1071-1075). Also, Tax transforms primary fibroblasts in cooperation with the Ras protein (Pozzatti R. *et al.*, 1990. Mol Cell Biol. 10:413-417), and immortalizes primary T-lymphocytes in the presence of IL-2 (Grassmann R. *et al.*, 1989. Proc Natl Acad Sci U S A. 86:3351-3355). Transgenic mice carrying the tax gene develop different types of tumors (Grossman W.J. *et al.*, 1995. Proc Natl Acad Sci U S A. 92:1057-1061). Tax binds directly to DNA but acts in cooperation with several cellular transcription factors, but the role of these different interactions in 10 the cell transformation mediated by Tax is still unclear (Coscoy L. *et al.*, 1998. Virology 248: 332-341).

HAM/TSP is a progressive chronic demyelinating disorder affecting the white matter of the central nervous system (CNS) and the spinal cord. The disease affects approximately twice as many females as males, and typically the time of disease onset 20 occurs during the fourth decade of life. The disease causes numerous highly debilitating symptoms, with common early symptoms and signs including gait disturbance and weakness and stiffness of the lower limbs. The disease affects the lower extremities to a much greater degree than upper extremities, spasticity may be moderate to severe, and lower back pain commonly occurs. Disease progression is 25 associated with bowel and bladder dysfunction, and sensory loss and dysesthesia. Patients examined via magnetic resonance imaging may exhibit nonspecific lesions in the brain as well as spinal cord atrophy. Immune manifestations associated with HAM/TSP include inflammatory infiltrates in the central nervous system consisting predominantly of monocytes, and large numbers of CD8+ T-cells which are primarily reactive with peptides of the HTLV-1 Tax protein. The frequency of such T-cells in 30 the peripheral blood and cerebrospinal fluid (CSF) has been shown to be proportional to the amount of HTLV-1 proviral load and the levels of HTLV-1 tax mRNA expression. It has further been shown that in patients carrying the HLA-A2 allele, the

immune response is dominated by CD8+ T-lymphocytes that recognize the Tax<sub>11-19</sub> peptide (Bieganowska K. *et al.*, 1999. *J Immunol.* 162:1765-1771; Nagai, M. *et al.*, 2001. *J Inf Dis.* 183:197-205). Thus, immunological determinants, such as the Tax<sub>11-19</sub> peptide and antigenic mimics thereof, shared by thymus, brain and HTLV-1 are thought to direct lymphocytic neurotropism and demyelination in nervous tissues. It is thought that the specificity of thoracic spinal cord involvement could be linked to shared thymic and thoracic spinal cord determinants, genetically peculiar to HAM/TSP patients. In a first stage, disease onset may be dependent on CD4+ T-lymphocytes specific for such determinants, reactivated in response to HTLV-1 infection, and that demyelination during this stage could potentially be initiated as a result of stoppage in the synthesis of myelin following alteration of expression of oligodendrocytic and neuronal adhesion molecules. The second stage of the disease, involving chronic inflammatory manifestations, may depend on CD8+ T-lymphocytes specific for viral peptides, but also on CD8+ T-lymphocytes specific for peptides generated as a result of proteolysis of myelin layer, and other central nervous system proteins.

While, at best, therapy of HAM/TSP with corticosteroids, and IFN-gamma may result transient responses, similarly to numerous diseases associated with lymphotropic viruses there is currently no effective treatment for HAM/TSP, nor does the state of the art currently enable optimal prediction, diagnosis, staging, monitoring, and prognosis of the disease in patients.

The immune system employs two types of immune responses to provide antigen specific protection from pathogens; humoral immune responses, and cellular immune responses, which involve specific recognition of pathogen antigens via antibodies and T-lymphocytes, respectively.

T-lymphocytes, by virtue of being the antigen specific effectors of cellular immunity, play a central and direct role in the body's defense against diseases mediated by intracellular pathogens, such as viruses, intracellular bacteria, mycoplasmas, and intracellular parasites, by directly cytolyzing cells infected by such pathogens. However, helper T-lymphocytes also play a critical role in humoral immune responses against non intracellular pathogens by providing T-cell help to B lymphocytes in the form of interleukin secretion to stimulate production of antibodies specific for antigens of such pathogens.

The specificity of T-lymphocyte responses is conferred by, and activated through T-cell receptors (TCRs). T-cell receptors are antigen specific receptors clonally distributed on individual T-lymphocytes whose repertoire of antigenic specificity is generated via somatic gene rearrangement mechanisms analogously to those involved in generating the antibody gene repertoire. T-cell receptors are composed of a heterodimer of transmembrane molecules, the main type being composed of an alpha-beta dimer and a smaller subset of a gamma-delta dimer. T-lymphocyte receptor subunits comprise a transmembrane constant region and a variable region in the extracellular domain, similarly to immunoglobulins, and signal transduction triggered by TCRs is indirectly mediated via CD3/zeta, an associated multi-subunit complex comprising signal transducing subunits.

The two main classes of T-lymphocytes, helper T-lymphocytes and cytotoxic T-lymphocytes (CTLs), are distinguished by expression of the surface markers CD4 and CD8, respectively. As described hereinabove, the main function of helper T-lymphocytes is to secrete cytokines, such as IL-2, promoting activation and proliferation of CTLs and B lymphocytes, and the function of CTLs is to induce apoptotic death of cells displaying immunogenic antigens.

T-lymphocyte receptors, unlike antibodies, do not recognize native antigens but rather recognize cell-surface displayed complexes comprising an intracellularly processed fragment of a protein or lipid antigen in association with a specialized antigen-presenting molecule (APM): major histocompatibility complex (MHC) for presentation of peptide antigens; and CD1 for presentation of lipid antigens, and to a lesser extent, peptide antigens. Peptide antigens displayed by MHC molecules and lipid antigens displayed by CD1 molecules have characteristic chemical structures are referred to as MHC-restricted peptides and CD1 restricted lipids, respectively. Major histocompatibility complex molecules are highly polymorphic, comprising more than 40 common alleles for each individual gene. "Classical" MHC molecules are divided into two main types, class I and class II, having distinct functions in immunity.

Major histocompatibility complex class I molecules are expressed on the surface of virtually all cells in the body and are dimeric molecules composed of a transmembrane heavy chain, comprising the peptide antigen binding cleft, and a smaller extracellular chain termed  $\beta_2$ -microglobulin. MHC class I molecules present 9- to 11-amino acid residue peptides derived from the degradation of cytosolic

proteins by the proteasome a multi-unit structure in the cytoplasm, (Niedermann G., 2002. *Curr Top Microbiol Immunol.* 268:91-136; for processing of bacterial antigens, refer to Wick MJ, and Ljunggren HG., 1999. *Immunol Rev.* 172:153-62). Cleaved peptides are transported into the lumen of the endoplasmic reticulum (ER) by TAP 5 where they are bound to the groove of the assembled class I molecule, and the resultant MHC:antigen complex is transported to the cell membrane to enable antigen presentation to T-lymphocytes (Yewdell JW., 2001. *Trends Cell Biol.* 11:294-7; Yewdell JW. and Bennink JR., 2001. *Curr Opin Immunol.* 13:13-8).

Major histocompatibility complex class II molecules are expressed on a 10 restricted subset of specialized antigen-presenting cells (APCs) involved in T-lymphocyte maturation and priming. Such APCs in particular include dendritic cells and macrophages, cell types which internalize, process and display antigens sampled from the extracellular environment. Unlike MHC class I molecules, MHC class II molecules are composed of an alpha-beta transmembrane dimer whose antigen 15 binding cleft can accommodate peptides of about 10 to 30, or more, amino acid residues.

The antigen presenting molecule CD1, whose main function, as described hereinabove, is presentation of lipid antigens, is a heterodimer comprising a transmembrane heavy chain paired with beta<sub>2</sub>-microglobulin, similarly to MHC class 20 I, and is mainly expressed on professional APCs, similarly to MHC class II (Sugita M. and Brenner MB., 2000. *Semin Immunol.* 12:511). CD1:antigen complexes are specifically recognized by TCRs expressed on CD4<sup>-</sup>CD8<sup>-</sup> T-lymphocytes and NKT lymphocytes and play a significant role in microbial immunity, tumor immunology, and autoimmunity.

25 The cells of the body are thus scanned by T-lymphocytes during immune surveillance or during maturation of T-lymphocytes for their intracellular protein or lipid content in the form of such APM:antigen complexes.

One strategy which has been proposed to enable optimal diagnosis, 30 characterization, and treatment of diseases, such as HAM/TSP, associated with an infection by a pathogen involves using molecules capable of specifically binding APM:antigen complexes composed of a particular combination of APM and an antigen derived from such a pathogen. Such molecules, for example, could be conjugated to functional moieties, such as detectable moieties or toxins, and the

resultant conjugates could be used to detect such complexes or cells displaying such complexes, or to kill cells displaying such complexes. Hence, such conjugates could be used to diagnose/characterize and treat a pathogen infection in an individual, respectively. Alternately, molecules capable of specifically binding such complexes 5 could be used to bind such complexes on cells so as to block activation of T-lymphocytes bearing TCRs specific for such complexes. Such molecules could further be used, for example, to isolate such complexes, or cells displaying such complexes, such as cells infected with a pathogen, or APCs exposed to a pathogen-derived antigen.

10 Several prior art approaches have been described involving molecules capable of binding particular APM:antigen complexes.

One approach involves using TCRs or derivatives thereof specific for particular MHC:peptide complexes in attempts to provide reagents capable of specifically binding such complexes.

15 Another approach involves using antibodies or derivatives thereof specific for particular mouse MHC:peptide complexes in attempts to provide reagents capable of specifically binding such complexes (Aharoni, R. *et al.*, 1991. *Nature* 351:147-150; Andersen, P.S. *et al.*, 1996. *Proc. Natl. Acad. Sci. U. S. A* 93:1820-1824; Dadaglio, G. *et al.*, 1997. *Immunity* 6:727-738; Day, P.M. *et al.*, 1997. *Proc. Natl. Acad. Sci. U. 20 S. A.* 94:8064-8069; Krogsgaard, M. *et al.*, 2000. *J. Exp. Med.* 191:1395-1412; Murphy, D.B. *et al.*, 1989. *Nature* 338:765-768; Porgador, A. *et al.*, 1997. *Immunity* 6:715-726; Reiter, Y. *et al.*, *Proc. Natl. Acad. Sci. U. S. A.* 94:4631-4636; Zhong, G. *et al.*, 1997. *Proc. Natl. Acad. Sci. U. S. A.* 94:13856-13861; Zhong, G. *et al.*, 1997. *J. Exp. Med.* 186:673-682).

25 A further approach involves utilizing antibodies or derivatives thereof specific for the human MHC class I molecule HLA-A1 in complex with an HLA-A1 restricted peptide derived from the melanoma specific tumor associated antigen melanoma associated antigen (MAGE)-A1 in attempts to provide reagents capable of specifically binding such a complex (Chames, P. *et al.*, 2000. *Proc. Natl. Acad. Sci. U. S. A.* 30 97:7969-7974).

An additional approach involves employing antibodies or derivatives thereof specific for the human MHC class I molecule HLA-A2 in complex with an HLA-A2 restricted peptide derived from the melanoma specific tumor associated antigen gp100

in attempts to provide reagents capable of specifically binding such a complex (Denkberg, G. *et al.*, 2002. Proc. Natl. Acad. Sci. U. S. A. 99:9421-9426).

Yet another approach involves using antibodies or derivatives thereof specific for human MHC class I molecule HLA-A2 in complex with an HLA-A2 restricted peptide derived from human telomerase catalytic subunit (hTERT) in attempts to provide reagents capable of specifically binding such a complex (Lev, A. *et al.*, 2002. Cancer Res. 62:3184-3194).

However, all of the aforementioned prior art approaches suffer from significant disadvantages: (i) approaches involving the use TCRs or portions thereof as compounds capable of specifically binding particular MHC:peptide complexes are suboptimal due to the relatively low intrinsic binding affinity of TCRs for such complexes; (ii) approaches involving the use of antibodies or portions thereof specific for MHC:peptide complexes comprising non-human MHC are not suitable for human application; and (iii) approaches involving antibodies or portions thereof specific for MHC:non-pathogen-derived antigen complexes are not suitable for specifically binding complexes comprising pathogen-derived antigens.

Thus, all prior art approaches have failed to provide an adequate solution for providing molecules capable of specifically binding with high specificity and affinity a particular human APM:pathogen-derived antigen complex.

There is thus a widely recognized need for, and it would be highly advantageous to have, molecules devoid of the above limitation.

#### SUMMARY OF THE INVENTION

According to one aspect of the present invention there is provided a method of detecting an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen, the method comprising: (a) exposing the antigen-presenting portion of the complex to a composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding the antigen-presenting portion of the complex, to thereby obtain a conjugate of the antigen-presenting portion of the complex and the antibody or antibody fragment; and (b) detecting the antibody or antibody fragment of the conjugate, thereby detecting an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen.

According to further features in preferred embodiments of the invention described below, the complex is displayed or expressed by a target cell, and step (a) is effected by exposing the target to the composition-of-matter.

According to still further features in the described preferred embodiments the 5 method of detecting an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen further comprises: (c) obtaining the target cell from an individual.

According to another aspect of the present invention there is provided a method of detecting in a biological sample an antigen-presenting portion of a complex 10 composed of an antigen-presenting molecule and an antigen, the method comprising: (a) attaching the biological sample to a surface; (b) exposing the biological sample to a composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding the antigen-presenting portion of the complex, to thereby obtain a conjugate of the antigen-presenting portion of the 15 complex and the antibody or antibody fragment; and (c) detecting the antibody or antibody fragment of the conjugate, thereby detecting in a biological sample an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen.

According to further features in preferred embodiments of the invention 20 described below, the method of detecting in a biological sample an antigen-presenting portion of a complex composed of an antigen-presenting molecule and an antigen further comprises: (d) obtaining the biological sample from an individual.

According to still further features in the described preferred embodiments, step 25 (b) is effected by administering the composition-of-matter to an individual.

According to still further features in the described preferred embodiments, the antigen is derived from a pathogen.

According to still further features in the described preferred embodiments, the biological sample is infected with the pathogen.

According to still further features in the described preferred embodiments, the 30 biological sample is a cell sample or a tissue sample.

According to yet another aspect of the present invention there is provided a method of diagnosing an infection by a pathogen in an individual, the method comprising: (a) exposing a target cell of the individual to a composition-of-matter

comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from the pathogen, to thereby obtain a conjugate of the antigen-presenting portion of the complex and the antibody or antibody fragment; and (b) detecting the antibody or antibody fragment of the conjugate, thereby diagnosing an infection by a pathogen in an individual.

According to further features in preferred embodiments of the invention described below, the method of diagnosing an infection by a pathogen in an individual further comprises: (c) obtaining the target cell from the individual.

According to still further features in the described preferred embodiments, step (a) is effected by administering the composition-of-matter to the individual.

According to still further features in the described preferred embodiments, the composition-of-matter further comprises a detectable moiety attached to the antibody or antibody fragment, and detecting the antibody or antibody fragment of the conjugate is effected by detecting the detectable moiety attached to the antibody or antibody fragment of the conjugate.

According to still another aspect of the present invention there is provided a method of killing or damaging a target cell expressing or displaying an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen, the method comprising exposing the target cell to a composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding the antigen-presenting portion of the complex, thereby killing or damaging a target cell expressing or displaying an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen.

According to further features in preferred embodiments of the invention described below, the method of killing or damaging a target cell expressing or displaying an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen further comprises the step of obtaining the target cell from an individual.

According to still further features in the described preferred embodiments, exposing the target cell to the composition-of-matter is effected by administering the composition-of-matter to an individual.

According to still further features in the described preferred embodiments, the target cell is infected with the pathogen.

According to still further features in the described preferred embodiments, the target cell is a T-lymphocyte or an antigen presenting cell.

5 According to still further features in the described preferred embodiments, the antigen presenting cell is a B cell or a dendritic cell.

According to a further aspect of the present invention there is provided a method of treating a disease associated with a pathogen in an individual, the method comprising administering to the individual a therapeutically effective amount of a 10 pharmaceutical composition comprising as an active ingredient, a composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from the pathogen, thereby treating a disease associated with a pathogen in an individual.

15 According to a yet a further aspect of the present invention there is provided an isolated polynucleotide comprising a first nucleic acid sequence encoding an antibody fragment, the antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen.

20 According to further features in preferred embodiments of the invention described below, the isolated polynucleotide further comprises a second nucleic acid sequence encoding a polypeptide selected from the group consisting of a coat protein of a virus, a detectable moiety, and a toxin.

According to still further features in the described preferred embodiments, the 25 second nucleic acid sequence is translationally fused with the first nucleic acid sequence.

According to still a further aspect of the present invention there is provided a nucleic acid construct comprising the isolated polynucleotide and a promoter sequence for directing transcription of the isolated polynucleotide in a host cell.

30 According to further features in preferred embodiments of the invention described below, the promoter sequence is a T7 promoter sequence.

According to still further features in the described preferred embodiments, the promoter sequence is capable of driving expression of the nucleic acid sequence in a

prokaryote.

According to still further features in the described preferred embodiments, the promoter sequence is capable of driving inducible expression of the nucleic acid sequence.

5 According to an additional aspect of the present invention there is provided a host cell comprising the nucleic acid construct.

According to further features in preferred embodiments of the invention described below, the host cell is a prokaryotic cell.

10 According to still further features in the described preferred embodiments, the prokaryotic cell is an *E. coli* cell.

According to yet an additional aspect of the present invention there is provided a virus comprising the nucleic acid construct.

15 According to still an additional aspect of the present invention there is provided a virus comprising a coat protein fused to an antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen.

According to further features in preferred embodiments of the invention described below, the virus is a filamentous phage and the coat protein is pIII.

20 According to another aspect of the present invention there is provided a composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen.

25 According to yet another aspect of the present invention there is provided a pharmaceutical compositions comprising as an active ingredient the composition-of-matter and a pharmaceutically acceptable carrier.

30 According to still another aspect of the present invention there is provided a composition-of-matter comprising a multimeric form of an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen.

According to a further aspect of the present invention there is provided a pharmaceutical composition comprising as an active ingredient the composition-of-matter comprising a multimeric form of an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen, and a pharmaceutically acceptable carrier.

According to further features in preferred embodiments of the invention described below, the antibody is a monoclonal antibody.

According to still further features in the described preferred embodiments, the antibody fragment is a monoclonal antibody fragment.

According to still further features in the described preferred embodiments, the antibody fragment is selected from the group consisting of an Fd fragment, an Fab, and a single chain Fv.

According to still further features in the described preferred embodiments, the antigen-binding region includes an amino acid sequence selected from the group consisting of SEQ ID NOs: 14 to 97.

According to still further features in the described preferred embodiments, the antibody or antibody fragment, or a part of the antibody or antibody fragment is of human origin.

According to still further features in the described preferred embodiments, the part of the antibody or antibody fragment is a portion of a constant region of the antibody or antibody fragment, or a constant region of the antibody or antibody fragment.

According to still further features in the described preferred embodiments, the binding of the antibody or antibody fragment to the antigen-presenting portion of the complex is characterized by an affinity having a dissociation constant selected from the range consisting of  $1 \times 10^{-2}$  molar to  $5 \times 10^{-16}$  molar.

According to still further features in the described preferred embodiments, the composition-of-matter further comprises a toxin or detectable moiety attached to the antibody or antibody fragment.

According to still further features in the described preferred embodiments, the detectable moiety is selected from the group consisting of a recognition sequence of a biotin protein ligase, a biotin molecule, a streptavidin molecule, a fluorophore, an

enzyme, and a polyhistidine tag.

According to still further features in the described preferred embodiments, the biotin protein ligase is BirA.

According to still further features in the described preferred embodiments, the 5 fluorophore is phycoerythrin.

According to still further features in the described preferred embodiments, the enzyme is horseradish peroxidase.

According to still further features in the described preferred embodiments, the toxin is *Pseudomonas* exotoxin A or a portion thereof.

10 According to still further features in the described preferred embodiments, the portion of *Pseudomonas* exotoxin A is a translocation domain and/or an ADP ribosylation domain.

According to still further features in the described preferred embodiments, the human antigen-presenting molecule is a major histocompatibility complex molecule.

15 According to still further features in the described preferred embodiments, the major histocompatibility complex molecule is a major histocompatibility complex class I molecule.

According to still further features in the described preferred embodiments, the major histocompatibility complex class I molecule is an HLA-A2 molecule.

20 According to still further features in the described preferred embodiments, the human antigen-presenting molecule is a single chain antigen-presenting molecule.

According to still further features in the described preferred embodiments, the pathogen is a viral pathogen.

25 According to still further features in the described preferred embodiments, the viral pathogen is a retrovirus.

According to still further features in the described preferred embodiments, the retrovirus is human T lymphotropic virus-1.

According to still further features in the described preferred embodiments, the antigen derived from a pathogen is restricted by the antigen-presenting molecule.

30 According to still further features in the described preferred embodiments, the antigen derived from a pathogen is a polypeptide.

According to still further features in the described preferred embodiments, the polypeptide is a segment of a Tax protein, or a polypeptide having an amino acid

sequence as set forth in SEQ ID NO: 3.

The present invention successfully addresses the shortcomings of the presently known configurations by providing a composition-of-matter comprising an antibody or antibody fragment capable of binding with optimal specificity/affinity a human 5 APM:pathogen-derived antigen complex.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present 10 invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

15

#### BRIEF DESCRIPTION OF THE DRAWINGS

The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of 20 illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the 25 invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.

In the drawings:

FIG. 1 is a histogram depicting specific binding of recombinant Fab-phage clones to HLA-A2:Tax<sub>11-19</sub> complex, as determined by ELISA. TAX - HLA-A2:Tax<sub>11-19</sub> complex, gp100-154 - HLA-A2:G9-154 peptide complex, MUC1-D6 - HLA-A2:MUC1-D6 peptide complex, MART 27 - HLA-A2:MART 27 peptide complex.

FIGs. 2a-c are photographs depicting Western immunoblotting assays of

expression and purification of Fab's selected for specific binding to HLA-A2:Tax<sub>11-19</sub> complex. Shown are SDS-PAGE analyses of purified Fab protein after metal affinity chromatography, inclusion bodies from BL21 cultures expressing Fab T3F2 light chain and Fd fragment, and purified *in vitro* refolded non-reduced (NR) and reduced (R) Fab T3F2 (Figures 2a-c, respectively). M – molecular weight markers.

FIGs. 3a-c are histograms depicting specific binding of soluble purified Fab's T3D4, T3E3, and T3F2, respectively, to immobilized HLA-A2:Tax<sub>11-19</sub> complex, but not to HLA-A2:control peptide complexes, as determined by ELISA.

FIGs. 4a-b are data plots depicting the binding characteristics of Fab's T3E3 and T3F2, respectively, as determined by titration ELISA using single chain HLA-A2:Tax<sub>11-19</sub> complex as binding target.

FIG. 4c is a competitive binding analysis data plot depicting the ability of purified Fab T3F2 to inhibit the binding of [125]iodine labeled Fab T3F2 to immobilized HLA-A2:Tax complex. The apparent binding affinity of the recombinant Fab was determined as the concentration of competitor (soluble purified Fab) required for 50 percent inhibition of the binding of the [125]iodine labeled tracer.

FIGs. 5a-f are flow cytometry histograms depicting specific detection of HLA-A2:Tax<sub>11-19</sub> complex on the surface of APCs. RMAS-HHD, JY, and human dendritic (DC) cells (Figures 5a-b, 5c-d, and 5e-f, respectively) were loaded with Tax<sub>11-19</sub> peptide or negative control melanoma gp100-derived peptide G9-154, as described in the experimental procedures. Peptide-loaded cells were then incubated with the soluble purified HLA-A2:Tax<sub>11-19</sub> complex specific Fab's T3E3 (Figures 5a, 5c, and 5e) or T3F2 (Figures 5b, 5d, and 5f). Note specific staining of cells loaded with Tax<sub>11-19</sub> but not negative control peptide. Control unloaded cells are shown in black trace. Control assays were performed using the 10 different negative control HLA-A2 restricted peptides listed under Materials and Methods.

FIGs. 6a-c are flow cytometry histograms depicting specific detection of HLA-A2:Tax<sub>11-19</sub> complex on the surface of antigen-presenting cells (APCs) using Fab T3F2 tetramer. RMAS-HHD, JY, or HLA-A2 positive mature dendritic cells (Figures 6a-c, respectively) were pulsed with Tax<sub>11-19</sub> peptide. Peptide pulsed cells were then incubated with phycoerythrin conjugated T3F2 tetramer or monomer, as indicated. Fab monomer binding was detected using phycoerythrin conjugated anti

human Fab antibody. Control unloaded cells stained with the T3F2 tetramer are shown.

FIGs. 7a-d depict specific detection of cell surface displayed HLA-A2:Tax<sub>11-19</sub> complex by T3F2 after naturally occurring active intracellular processing. Figures 7a-5 b are flow cytometry histograms depicting specific detection of HLA-A2:Tax<sub>11-19</sub> complex on the surface of HLA-A2 positive JY cells, but not HLA-A2 negative APD cells, respectively. Cells were transfected with pcDNA control vector or with pcDNA containing the intact full length Tax gene (pcTAX), and 12 to 24 hours following 10 transfection, cells were stained by flow cytometry using Fab T3F2 or the negative control Fab G2D12 specific for HLA-A2:G9-154 complex. Figure 7c is a bar graph depicting the efficiency of Tax gene transduction into JY and APD cells, as monitored by transfection of the pcDNA vector carrying the GFP gene. Figure 7d is a flow 15 cytometry histogram depicting staining of HLA-A2 positive RSCD4 and HLA-A2 negative HUT102 cells (which are lines of human CD4 positive T-cells infected with HTLV-1) with phycoerythrin conjugated Fab T3F2 tetramer, or negative control G2D12, as indicated.

FIGs. 8a-b depict quantitation of the number of HLA-A2:Tax<sub>11-19</sub> complexes on the surface of Tax<sub>11-19</sub> peptide pulsed cells. JY APCs were pulsed with various 20 concentrations of Tax<sub>11-19</sub> peptide and surface display of HLA-A2-Tax<sub>11-19</sub> peptide complex on the cells was analyzed by flow cytometry using phycoerythrin conjugated T3F2 Fab. Figure 8a is a bar graph depicting the calculated number of complexes per cell with various concentration of peptide. The level of fluorescence intensity on 25 stained cells was quantitated flow cytometrically using calibration beads conjugated to graded numbers of phycoerythrin molecules (QuantiBRITE PE beads, Becton- Dickinson). Figure 8b is a flow cytometry histogram depicting fluorescence intensity as a function of Tax<sub>11-19</sub> peptide concentration.

FIGs. 8c-d depict high-sensitivity quantitative detection of HLA-A2:Tax<sub>11-19</sub> complex on the surface JY APCs transfected with the Tax gene mixed at different 30 ratios within a non-transfected cell population. The mixed population was stained with Fab T3F2 and detection sensitivity was monitored by single-color flow cytometry. Figure 8c is a set of overlapping flow cytometry histograms shown in large-scale (left panel) or zoomed (right panel) depicting quantitative detection of transfected cells mixed into populations of non-transfected cells at the various ratios,

as indicated. Figure 8d is a data table depicting sensitivity of detection of HLA-A2:Tax<sub>11-19</sub> complex as a function of the percentage of transfected cells admixed within a population of non-transfected cells, on the basis of a transfection efficiency of 62.1 percent. Note detection of HLA-A2:Tax<sub>11-19</sub> complex-displaying cells present 5 in a population of non-transfected cells in a proportion as low as 1 percent.

FIGs. 9a-f are photomicrographs depicting immunohistochemical detection of HLA-A2:Tax<sub>11-19</sub> complex by Fab T3F2 following intracellular processing. Figures 9a-b depict  $\times 60$  and  $\times 40$  original magnification views, respectively, of Tax transfected JY cells stained with Fab T3F2. Figure 9c depicts control non transfected JY cells 10 stained with Fab T3F2. Figure 9d depicts staining of Tax transfected JY cells with negative control Fab G2D12 specific for HLA-A2:G9-154 complex. Figures 9e-f depict HLA-A2 negative cells transfected for expression of Tax or not transfected, respectively, stained with T3F2. Cells were adsorbed onto poly-L-lysine coated glass 15 slips 12 to 24 hours following transfection, and stained with Fab T3F2. As a negative control Fab G2D12 was used.

FIG. 10 is a data plot depicting specific and efficient killing of target cells displaying a specific human MHC:viral peptide complex by a fusion protein consisting of an anti specific human MHC:viral peptide complex Fab conjugated to a toxin. A cytotoxicity assay was performed using T3F2-PE38KDEL fusion protein, 20 consisting of anti HLA-A2:Tax<sub>11-19</sub> complex Fab fused to the PE38KDEL truncated form of pseudomonas exotoxin A. To assay cytolysis by the fusion protein, JY cells loaded with Tax<sub>11-19</sub> peptide, loaded with control HLA-A2 restricted peptides, or not peptide loaded were incubated with T3F2-PE38KDEL. Note specific and efficient 25 T3F2-PE38KDEL mediated killing of cells loaded with Tax<sub>11-19</sub> peptide, but not of control JY cells loaded control peptide, or of JY cells not peptide loaded.

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is of compositions-of-matter capable of specifically binding particular antigen-presenting molecule (APM):antigen complexes, and to 30 methods of using such compositions-of-matter to detect, characterize or kill/damage cells/tissues expressing/displaying such complexes. In particular, the present invention can be used to optimally detect, characterize or kill/damage human cells/tissues displaying/expressing a particular human APM:pathogen-derived antigen

complex, such as cells/tissues infected with a pathogen, or antigen-presenting cells (APCs) exposed to the pathogen, or an antigen thereof. As such the compositions-of-matter of the present invention can be used, for example, to optimally diagnose, characterize, and treat a pathogen infection in a human.

5 Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the 10 purpose of description and should not be regarded as limiting.

Molecules capable of binding with optimal specificity/affinity a particular human APM:pathogen-derived antigen complex would be of significant and unique utility since they would enable optimal diagnosis, characterization, and treatment of pathogen infections in humans.

15 Various molecules capable of binding specific APM:antigen complexes have been described by the prior art.

For example, one approach involves using antibodies or derivatives thereof specific for mouse MHC:peptide complexes in attempts to provide compounds capable of specifically binding such murine complexes.

20 Another approach involves using antibodies or derivatives thereof specific for human MHC:tumor-associated antigen (TAA) peptide complexes in attempts to provide compounds capable of specifically binding such human tumor antigen-presenting complexes.

25 A further approach involves using antibodies or derivatives thereof specific for human MHC:telomerase-derived peptide complexes in attempts to provide compounds capable of specifically binding such human telomerase antigen-presenting complexes.

30 However, all such prior art approaches suffer from significant drawbacks. Prior art approaches involving molecules capable of specifically binding complexes comprising non-human APMs do not have utility for human applications, and prior art approaches involving compositions-of-matter capable of specifically binding complexes comprising non-pathogen-derived antigens do not have utility for applications requiring molecules capable of specifically binding complexes

comprising pathogen-derived antigens, such as diagnosis, characterization, and treatment of pathogen infections in humans.

Thus, the prior art has failed to provide molecules capable of binding particular human APM:pathogen-derived antigen complexes with optimal specificity and affinity.

While reducing the present invention to practice molecules capable of binding particular human APM:pathogen-derived antigen complexes with optimal specificity and affinity were unexpectedly uncovered. Such a capacity is unique relative to all prior art molecules capable of binding particular APM:antigen complexes.

It was also unexpectedly uncovered that attaching such molecules to a detectable moiety or toxin could be used, respectively, to detect/characterize, or kill/damage with optimal efficiency/specification cells/tissues displaying such complexes. Such capacities are also unique relative to all prior art molecules capable of binding particular APM:antigen complexes.

Thus, in sharp contrast to prior art molecules capable of binding particular APM:antigen complexes, the molecules of the present invention can be used to detect, or characterize with optimal specificity and sensitivity, or kill with optimal efficiency and specificity human cells/tissues infected with a pathogen, or antigen-presenting cells exposed to a pathogen, or an antigen thereof.

Thus, according to one aspect of the present invention there is provided a composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of an APM and an antigen derived from a pathogen.

The composition-of-matter is optimal for use in essentially any application benefiting from a reagent having the capacity to specifically bind the antigen-presenting portion of a complex composed of a particular APM and a particular antigen derived from a pathogen which is restricted by such an APM (referred to hereinafter as "complex" or "the complex"). Such applications particularly include those involving: (i) specific detection of the antigen-presenting portion of the complex, in particular for diagnosing a disease associated with the pathogen; (ii) killing/damaging cells/tissues displaying/expressing the antigen-presenting portion of the complex (referred to herein as "target cells/tissues"), including pathogen-infected cells or APCs exposed to an antigen of the pathogen; and (iii) blocking binding of the

antigen-presenting portion of the complex to a cognate T-cell receptor (TCR); and (iv) and isolating the complex or a cell displaying/expressing the complex.

As used herein, the term "antibody" refers to a substantially whole or intact antibody molecule.

5 As used herein, the phrase "antibody fragment" refers to molecule comprising a portion or portions of an antibody capable of specifically binding an antigenic determinant or epitope, such as the antigen-presenting portion of the complex.

As used herein, the phrase "antigen-binding region", when relating to the antibody or antibody fragment, refers to a portion of the antibody or antibody or 10 antibody fragment (typically a variable portion) capable of specifically binding a particular antigenic determinant or epitope, or particular set of antigenic determinants or epitopes.

15 As used herein, the term "APM" refers to an antigen-presenting molecule such as an MHC molecule, a CD1 molecule, and a molecule structurally and/or functionally analogous to an MHC or CD1 molecule. A specific APM is typically capable of binding any of a particular set of distinct antigens so as to form an antigen-presenting complex therewith which can be specifically bound by a variable portion of a TCR. Antigen-presenting molecules forming complexes whose antigen-presenting portions comprise antigenic determinants or epitopes which can be 20 specifically bound by the antibody or antibody fragment comprised in the composition-of-matter are described in further detail hereinbelow.

As used herein, the term "antigen" refers to a molecule or portion thereof (typically a peptide or a lipid), where such a molecule or portion thereof is capable of 25 specifically binding an antigen-binding groove of an APM. Such an antigen is commonly referred to in the art as being "restricted" by such an APM. A typical antigen, such as a pathogen-derived antigen, is typically generated in a human cell by intracellular processing of a larger molecule derived from the pathogen. Such cells typically include a cell infected with the pathogen—in particular an intracellular pathogen, or an APC exposed to an antigen derived from the pathogen. The antigen 30 generally has a characteristic dimension and/or chemical composition—for example, a characteristic amino acid length and set of anchor residues, respectively, in the case of a peptide antigen—enabling it to specifically bind the antigen-binding groove of a particular APM so as to form an APM:antigen complex therewith having an antigen

presenting portion capable of specifically binding a variable region of a cognate TCR.

As used herein, the phrase "antigen-presenting portion", when relating to the complex, refers to any portion of the complex which can be specifically bound by the antibody or antibody fragment, such that the antibody or antibody fragment is effectively incapable of specifically binding: (i) the APM of the complex not bound to the antigen of the complex; (ii) an APM:antigen complex composed of the APM of the complex and an antigen other than that of the complex; or (iii) an APM:antigen complex composed of an APM other than that of the complex and any antigen restricted by such an APM, including the antigen of the complex.

As mentioned hereinabove, the antigen-presenting portion of the complex is typically a portion of the complex capable of specifically binding a cognate TCR variable region. Antigen-presenting portions of complexes which can be specifically bound by the antibody or antibody fragment comprised in the composition-of-matter of the present invention are described in further detail hereinbelow.

As used herein, the term peptide refers to a polypeptide composed of 50 amino acid residues or less.

Depending on the application and purpose, the composition-of-matter may comprise an antibody or an antibody fragment.

Preferably, the composition-of-matter comprises an antibody fragment.

Antibody fragments, various types of which are described in further detail hereinbelow, have the advantage of generally being smaller than an antibody while retaining essentially a substantially identical binding specificity of a whole antibody comprising the immunoglobulin variable regions of the antibody fragment. Thus, a composition-of-matter of the present invention comprising an antibody fragment will be generally smaller than one comprising an antibody, and will thereby generally have superior biodistribution, and diffusion properties (for example, systemically *in-vivo*, or in isolated tissues) than the latter. A smaller composition-of-matter will have the additional advantage of being less likely to include moieties capable of causing steric hindrance inhibiting binding of the antibody or antibody fragment comprised in the composition-of-matter to the antigen-presenting portion of the complex. Also, the absence of some or all of an antibody constant region (referred to herein as "constant region"), such as an Fc region, from a composition-of-matter of the present invention

comprising an antibody fragment lacking such an Fc region will be advantageous for applications involving exposure of the composition-of-matter to a molecule capable of specifically binding such a constant region and in which such binding is undesirable. Typically this may involve an undesired binding of an Fc region comprised in a 5 composition-of-matter of the present invention exposed to a cognate Fc receptor, or an Fc-binding complement component (for example, complement component C1q, present in serum). Fc receptors are displayed on the surface of numerous immune cell types, including: professional APCs, such as dendritic cells; B lymphocytes; and granulocytes such as neutrophils, basophils, eosinophils, monocytes, macrophages, 10 and mast cells. In particular, the absence of a functional constant region, such as the Fc region, from the composition-of-matter will be particularly advantageous in applications in which the composition-of-matter is exposed to a specific ligand of a constant region, such as a cognate Fc receptor or an Fc binding complement component, capable of activating an undesired immune response, such as an Fc 15 receptor-mediated immune cell activation or complement component-mediated complement cascade, respectively, via interaction with the constant region.

It will be appreciated by the ordinarily skilled artisan that in various contexts, the aforementioned Fc receptor-displaying cell types will function as APCs displaying/expressing the complex. Hence a composition-of-matter of the present 20 invention comprising an antibody fragment lacking an Fc region may be advantageous for preventing undesired binding of the antibody or antibody fragment by Fc receptors displayed by such cells, or for preventing consequent activation of such cells.

Alternately, an antibody or antibody fragment of the present invention comprising such a functional constant region may be advantageous in applications in 25 which such an immune response is desirable. This will be particularly desirable in applications involving use of the composition-of-matter to kill/damage target cells/tissues, as described in further detail hereinbelow. A composition-of-matter of the present invention comprising an antibody or an antibody fragment including a constant region, such as an Fc region, which may be conveniently attached to a 30 functional moiety will also be advantageous for applications in which such attachment is desirable.

Furthermore, the use of a composition-of-matter of the present invention comprising an antibody fragment will be advantageous relative to one employing a

whole antibody when employing recombinantly producing the antibody or antibody fragment due to antibody fragments being more economical and efficient to synthesize due to their smaller size relative to whole antibodies.

Depending on the application and purpose, the composition-of-matter may 5 advantageously comprise an antibody or antibody fragment having any of various structural and/or functional characteristics. In particular, according to the teachings of the present invention, the composition-of-matter may advantageously comprise: (i) a monoclonal or polyclonal antibody or antibody fragment; (ii) a monomeric or multimeric form of antibody or antibody fragment; (iii) an antibody or antibody 10 fragment of any of various configurations or types (such as those described hereinbelow); (iv) an antibody or antibody fragment, or portion thereof, originating from any of various mammalian species; (v) an antibody or antibody fragment attached to any of various functional moieties; (vi) an antibody or antibody fragment capable of specifically binding any of various particular complexes; and/or (vii) an 15 antibody or antibody fragment capable of specifically binding the antigen-presenting portion of the complex with a desired affinity.

As mentioned hereinabove, depending on the application and purpose, the antibody or antibody fragment may be polyclonal or monoclonal.

As used herein, a composition-of-matter of the present invention comprising a 20 "polyclonal" or "monoclonal" antibody or antibody fragment is a population of molecules of the composition-of-matter comprising a polyclonal or monoclonal population of the antibody or antibody fragment, respectively.

As used herein, a composition-of-matter of the present invention comprising a "polyclonal" or "monoclonal" antibody or antibody fragment is a population of 25 composition-of-matter molecules of the present invention each comprising a monoclonal antibody or antibody fragment or a population thereof.

Methods of generating monoclonal or polyclonal antibodies or antibody fragments are described hereinbelow.

Preferably, according to the teachings of the present invention, the antibody or 30 antibody fragment is monoclonal.

For applications benefiting from optimal reproducibility, standardization, or precision, such as analytical applications, as described in further detail hereinbelow, a composition-of-matter comprising a monoclonal antibody or antibody fragment will

generally be superior to one comprising a polyclonal antibody or antibody fragment directed at the antigen-presenting portion of the same complex. A monoclonal antibody or antibody fragment will be particularly advantageous in instances where the antibody or antibody fragment has been characterized as having a desired binding 5 affinity/specificity for the antigen-presenting portion of the complex. A composition-of-matter of the present invention comprising such an antibody or antibody fragment will thus be optimal for an application, as will generally be the case, benefiting from a composition-of-matter comprising an antibody or antibody fragment capable of binding the antigen-presenting portion of the complex with the highest 10 affinity/specificity possible.

As is described and demonstrated in the Examples section below, a composition-of-matter comprising a monoclonal antibody fragment can be used to optimally practice various aspects of the present invention, including applications involving specific detection of the complex, or killing/damaging of target 15 cells/tissues.

Alternately, for applications wherein a composition-of-matter capable of binding one or more complexes with a spectrum of, or with various distinct affinities/specificities is desirable, a composition-of-matter of the present invention comprising a polyclonal antibody or antibody fragment will be advantageous. In any 20 case, where no monoclonal antibody or antibody fragment having a desired binding affinity/specificity for the antigen-presenting portion of the complex is available, a composition-of-matter comprising a polyclonal antibody or antibody fragment will nevertheless often be adequate since the heterogeneity of a polyclonal antibody or antibody fragment mixture will often include one or more antibodies or antibody 25 fragments having an adequate binding affinity/specificity for the antigen-presenting portion of the complex.

As mentioned hereinabove, depending on the application and purpose, the antibody fragment may be any of various configurations or types.

Suitable antibody fragments include a complementarity-determining region 30 (CDR) of an immunoglobulin light chain (referred to herein as "light chain"), a CDR of an immunoglobulin heavy chain (referred to herein as "heavy chain"), a variable region of a light chain, a variable region of a heavy chain, a light chain, a heavy chain, an Fd fragment, an Fv, a single chain Fv, an Fab, an Fab', and an F(ab')<sub>2</sub>.

Antibody fragments among the aforementioned antibody fragments which comprise whole or essentially whole variable regions of both light and heavy chains are defined as follows: (i) Fv, a fragment of an antibody molecule consisting of the light chain variable domain ( $V_L$ ) and the heavy chain variable domain ( $V_H$ ) expressed as two chains (typically obtained via genetic engineering of immunoglobulin genes); (ii) single chain Fv (also referred to in the art as "scFv"), a single chain molecule including the variable region of the light chain and the variable region of the heavy chain, linked by a suitable polypeptide linker (a single-chain Fv is typically obtained via genetic engineering of immunoglobulin genes and polypeptide linker-encoding DNA); (iii) Fab, a fragment of an antibody molecule containing essentially a monovalent antigen-binding portion of an antibody generally obtained by suitably treating the antibody with the enzyme papain to yield the intact light chain and the heavy chain Fd fragment (the Fd fragment consists of the variable and  $C_{H1}$  domains of the heavy chain); (iv) Fab', a fragment of an antibody molecule containing a monovalent antigen-binding portion of an antibody typically obtained by suitably treating the antibody molecule with the enzyme pepsin, followed by reduction of the resultant  $F(ab')_2$  fragment (two Fab' fragments are obtained per antibody molecule); and (v)  $F(ab')_2$ , a fragment of an antibody molecule containing a monovalent antigen-binding portion of an antibody molecule typically obtained by suitably treating the antibody molecule with the enzyme pepsin (i.e., an  $F(ab')_2$  consists of two Fab's connected by a pair of disulfide bonds).

Depending on the application and purpose, the antibody fragment is preferably an Fab, or a single chain Fv.

As is described and illustrated in the Examples section which follows, and as described in further detail below, a composition-of-matter of the present invention comprising an Fab may be employed to effectively practice the present invention, in particular aspects thereof involving using the composition-of-matter to detect the antigen-presenting portion of the complex.

As is described and illustrated in the Examples section which follows, and as described in further detail below, a composition-of-matter of the present invention comprising a single chain Fv may be utilized to effectively practice the present invention, in particular aspects thereof involving utilizing the composition-of-matter to kill/damage target cells/tissues.

It will be appreciated by the ordinarily skilled artisan that, due to an Fab' being essentially similar in structure to an Fab, a composition-of-matter of the present invention comprising an Fab' may be employed interchangeably with one comprising an Fab, where such Fab' and Fab comprise essentially the same heavy and light chain variable regions. For applications, as will usually be the case, benefiting from a composition-of-matter of the present invention comprising an antibody fragment capable of binding the antigen-presenting portion of the complex with the highest possible affinity, a composition-of-matter of the present invention comprising an  $F(ab')_2$  may be advantageously employed over one comprising a monovalent antibody fragment, such as an Fab, an Fab' or a single chain Fv, due to the divalent binding of an  $F(ab')_2$  to the antigen-presenting portion of the complex relative to the monovalent binding of such a monovalent antibody fragment.

As mentioned hereinabove, depending on the application and purpose, the antibody or antibody fragment may originate from any of various mammalian species.

15 Preferably, the antibody or antibody fragment is of human origin.

An antibody or antibody fragment of human origin may be derived as described further hereinbelow, or as described in the Examples section which follows.

20 A composition-of-matter of the present invention comprising an antibody or antibody fragment of human origin will generally be preferable for applications involving administration of the composition-of-matter to an individual. For example, such an antibody or antibody fragment will generally tend to be better tolerated immunologically than one of non human origin since non variable portions of non human antibodies will tend to trigger xenogeneic immune responses more potent than the allogeneic immune responses triggered by human antibodies which will typically 25 be allogeneic with the individual. It will be preferable to minimize such immune responses since these will tend to shorten the half-life, and hence the effectiveness, of the composition-of-matter in the individual. Furthermore, such immune responses may be pathogenic to the individual, for example by triggering harmful inflammatory reactions.

30 As used herein, the term "individual", refers to a human.

Alternately, an antibody or antibody fragment of human origin, or a humanized antibody, will also be advantageous for applications in which a functional physiological effect, for example an immune response against a target cell, activated

by a constant region of the antibody or antibody fragment in the individual is desired. Such applications particularly include those in which the functional interaction between a functional portion of the antibody or antibody fragment, such as an Fc region, with a molecule such as an Fc receptor or an Fc-binding complement component, is optimal when such a functional portion is, similarly to the Fc region, of human origin.

Depending on the application and purpose, a composition-of-matter of the present invention comprising an antibody or antibody fragment including a constant region, or a portion thereof, of any of various isotypes may be employed. Preferably, 10 the isotype is selected so as to enable or inhibit a desired physiological effect, or to inhibit an undesired specific binding of the composition-of-matter via the constant region or portion thereof. For example, for inducing antibody-dependent cell mediated cytotoxicity (ADCC) by a natural killer (NK) cell, the isotype will preferably be IgG; for inducing ADCC by a mast cell/basophil, the isotype will 15 preferably be IgE; and for inducing ADCC by an eosinophil, the isotype will preferably be IgE or IgA. For inducing a complement cascade the composition-of-matter will preferably comprise an antibody or antibody fragment comprising a constant region or portion thereof capable of initiating the cascade. For example, the antibody or antibody fragment may advantageously comprise a Cgamma2 domain of 20 IgG or Cmu3 domain of IgM to trigger a C1q-mediated complement cascade.

Conversely, for avoiding an immune response, such as the aforementioned one, or for avoiding a specific binding via the constant region or portion thereof, the composition-of-matter will preferably not comprise a constant region, or a portion thereof, of the relevant isotype.

25 As mentioned hereinabove, depending on the application and purpose, the antibody or antibody fragment may be attached to any of various functional moieties. An antibody or antibody fragment, such as that of the present invention, attached to a functional moiety may be referred to in the art as an "immunoconjugate".

30 Preferably, the functional moiety is a detectable moiety or a toxin. An antibody or antibody fragment attached to a toxin may be referred to in the art as an immunotoxin.

As is described and demonstrated in further detail hereinbelow, a detectable moiety or a toxin may be particularly advantageously employed in applications of the

present invention involving use of the composition-of-matter to detect the antigen-presenting portion of the complex, or to kill/damage target cells/tissues, respectively.

The composition-of-matter may comprise an antibody or antibody fragment attached to any of numerous types of detectable moieties, depending on the 5 application and purpose.

For applications involving using the composition-of-matter to detect the antigen-presenting portion of the complex, the detectable moiety attached to the antibody or antibody fragment is preferably a reporter moiety enabling specific detection of the antigen-presenting portion of the complex bound by the antibody or 10 antibody fragment of the composition-of-matter.

While various types of reporter moieties may be utilized to detect the antigen-presenting portion of the complex, depending on the application and purpose, the reporter moiety is preferably a fluorophore or an enzyme. Alternately, the reporter moiety may be a radioisotope, such as [125]iodine, as is described and illustrated in 15 the Examples section below.

A fluorophore may be advantageously employed as a detection moiety enabling detection of the antigen-presenting portion of the complex via any of numerous fluorescence detection methods. Depending on the application and purpose, such fluorescence detection methods include, but are not limited to, 20 fluorescence activated flow cytometry (FACS), immunofluorescence confocal microscopy, fluorescence *in-situ* hybridization (FISH), fluorescence resonance energy transfer (FRET), and the like.

Various types of fluorophores, depending on the application and purpose, may be employed to detect the antigen-presenting portion of the complex.

25 Examples of suitable fluorophores include, but are not limited to, phycoerythrin (PE), fluorescein isothiocyanate (FITC), Cy-chrome, rhodamine, green fluorescent protein (GFP), blue fluorescent protein (BFP), Texas red, PE-Cy5, and the like.

Preferably, the fluorophore is phycoerythrin.

30 As is described and illustrated in the Examples section below, a composition-of-matter of the present invention comprising an antibody or antibody fragment attached to a fluorophore, such as phycoerythrin, can be used to optimally detect the antigen-presenting portion of the complex using various immunofluorescence-based

detection methods.

Ample guidance regarding fluorophore selection, methods of linking fluorophores to various types of molecules, such as an antibody or antibody fragment of the present invention, and methods of using such conjugates to detect molecules which are capable of being specifically bound by antibodies or antibody fragments comprised in such immunoconjugates is available in the literature of the art [for example, refer to: Richard P. Haugland, "Molecular Probes: Handbook of Fluorescent Probes and Research Chemicals 1992-1994", 5th ed., Molecular Probes, Inc. (1994); U.S. Pat. No. 6,037,137 to Oncoimmunin Inc.; Hermanson, "Bioconjugate Techniques", Academic Press New York, N.Y. (1995); Kay M. *et al.*, 1995. Biochemistry 34:293; Stubbs *et al.*, 1996. Biochemistry 35:937; Gakamsky D. *et al.*, "Evaluating Receptor Stoichiometry by Fluorescence Resonance Energy Transfer," in "Receptors: A Practical Approach," 2nd ed., Stanford C. and Horton R. (eds.), Oxford University Press, UK. (2001); U.S. Pat. No. 6,350,466 to Targesome, Inc.]. While various methodologies may be employed to detect the antigen-presenting portion of the complex using a fluorophore, such detection is preferably effected as described and demonstrated in the Examples section below.

Alternately, an enzyme may be advantageously utilized as the detectable moiety to enable detection of the antigen-presenting portion of the complex via any of various enzyme-based detection methods. Examples of such methods include, but are not limited to, enzyme linked immunosorbent assay (ELISA; for example, to detect the antigen-presenting portion of the complex in a solution), enzyme-linked chemiluminescence assay (for example, to detect the complex in an electrophoretically separated protein mixture), and enzyme-linked immunohistochemical assay (for example, to detect the complex in a fixed tissue).

Numerous types of enzymes may be employed to detect the antigen-presenting portion of the complex, depending on the application and purpose.

Examples of suitable enzymes include, but are not limited to, horseradish peroxidase (HPR), beta-galactosidase, and alkaline phosphatase (AP).

Preferably, the enzyme is horseradish peroxidase.

As is described in the Examples section which follows, a composition-of-matter of the present invention comprising an antibody or antibody fragment attached to an enzyme such as horseradish peroxidase can be used to effectively detect the

antigen-presenting portion of the complex, such as via ELISA, or enzyme-linked immunohistochemical assay.

Ample guidance for practicing such enzyme-based detection methods is provided in the literature of the art (for example, refer to: Khatkhatay MI. and Desai M., 1999. *J Immunoassay* 20:151-83; Wisdom GB., 1994. *Methods Mol Biol.* 32:433-40; Ishikawa E. *et al.*, 1983. *J Immunoassay* 4:209-327; Oellerich M., 1980. *J Clin Chem Clin Biochem.* 18:197-208; Schuurs AH. and van Weemen BK., 1980. *J Immunoassay* 1:229-49). While various methodologies may be employed to detect the antigen-presenting portion of the complex using an enzyme, such detection is preferably effected as described in the Examples section below.

The functional moiety may be attached to the antibody or antibody fragment in various ways, depending on the context, application and purpose.

A polypeptidic functional moiety, in particular a polypeptidic toxin, may be advantageously attached to the antibody or antibody fragment via standard recombinant techniques broadly practiced in the art (for Example, refer to Sambrook *et al.*, *infra*, and associated references, listed in the Examples section which follows). While various methodologies may be employed, attaching a polypeptidic functional moiety to the antibody or antibody fragment is preferably effected as described and illustrated in the Examples section below.

A functional moiety may also be attached to the antibody or antibody fragment using standard chemical synthesis techniques widely practiced in the art [for example, refer to the extensive guidelines provided by The American Chemical Society (for example at: <http://www.chemistry.org/portal/Chemistry>)]. One of ordinary skill in the art, such as a chemist, will possess the required expertise for suitably practicing such chemical synthesis techniques.

Alternatively, a functional moiety may be attached to the antibody or antibody fragment by attaching an affinity tag-coupled antibody or antibody fragment of the present invention to the functional moiety conjugated to a specific ligand of the affinity tag.

Various types of affinity tags may be employed to attach the antibody or antibody fragment to the functional moiety.

Preferably, the affinity tag is a biotin molecule, more preferably a streptavidin molecule.

A biotin or streptavidin affinity tag can be used to optimally enable attachment of a streptavidin-conjugated or a biotin-conjugated functional moiety, respectively, to the antibody or antibody fragment due to the capability of streptavidin and biotin to bind to each other with the highest non covalent binding affinity known to man (i.e., with a  $K_d$  of about  $10^{-14}$  to  $10^{-15}$ ). A biotin affinity tag may be highly advantageous for applications benefiting from, as will oftentimes be the case, a composition-of-matter of the present invention comprising a multimeric form of the antibody or antibody fragment, which may be optimally formed by conjugating multiple biotin-attached antibodies or antibody fragments of the present invention to a streptavidin molecule, as described in further detail below.

As used herein the term "about" refers to plus or minus 10 percent.

Various methods, widely practiced in the art, may be employed to attach a streptavidin or biotin molecule to a molecule such as the antibody or antibody fragment to a functional moiety.

For example, a biotin molecule may be advantageously attached to an antibody or antibody fragment of the present invention attached to a recognition sequence of a biotin protein ligase. Such a recognition sequence is a specific polypeptide sequence serving as a specific biotinylation substrate for the biotin protein ligase enzyme. Ample guidance for biotinyling a target polypeptide such as an antibody fragment using a recognition sequence of a biotin protein ligase, such as the recognition sequence of the biotin protein ligase BirA, is provided in the literature of the art (for example, refer to: Denkberg, G. *et al.*, 2000. Eur. J. Immunol. 30:3522-3532). Preferably, such biotinylation of the antibody or antibody fragment is effected as described and illustrated in the Examples section below.

Alternately, various widely practiced methods may be employed to attach a streptavidin molecule to an antibody fragment, such as a single chain Fv (for example refer to Cloutier SM. *et al.*, 2000. Molecular Immunology 37:1067-1077; Dubel S. *et al.*, 1995. J Immunol Methods 178:201; Huston JS. *et al.*, 1991. Methods in Enzymology 203:46; Kipriyanov SM. *et al.*, 1995. Hum Antibodies Hybridomas 6:93; Kipriyanov SM. *et al.*, 1996. Protein Engineering 9:203; Pearce LA. *et al.*, 1997. Biochem Molec Biol Intl 42:1179-1188).

Functional moieties, such as fluorophores, conjugated to streptavidin are commercially available from essentially all major suppliers of immunofluorescence

flow cytometry reagents (for example, Pharmingen or Becton-Dickinson). Standard recombinant DNA chemical techniques are preferably employed to produce a fusion protein comprising streptavidin fused to a polypeptidic functional moiety. Standard chemical synthesis techniques may also be employed to form the streptavidin-functional moiety conjugate. Extensive literature is available providing guidance for the expression, purification and uses of streptavidin or streptavidin-derived molecules (Wu SC. *et al.*, 2002. *Protein Expression and Purification* 24:348-356; Gallizia A. *et al.*, 1998. *Protein Expression and Purification* 14:192-196), fusion proteins comprising streptavidin or streptavidin-derived molecules (Sano T. and Cantor CR., 2000. *Methods Enzymol.* 326:305-11), and modified streptavidin or streptavidin-derived molecules (see, for example: Sano T. *et al.*, 1993. *Journal of Biological Chemistry* 270:28204-28209), including for streptavidin or streptavidin-derived molecules whose gene sequence has been optimized for expression in *E. coli* (Thompson LD. and Weber PC., 1993. *Gene* 136:243-6).

The use of a composition-of-matter of the present invention comprising an antibody or antibody fragment attached to a functional moiety for various purposes other than detection of the antigen-presenting portion of the complex, or killing/damaging target cells/tissues is also envisaged by the present invention. In particular, a composition-of-matter of the present invention comprising an antibody or antibody fragment attached to an affinity tag, or any substance, particle, virus or cell displaying/expressing such a composition-of-matter, can be conveniently isolated or purified using an affinity purification method employing as a capture ligand a specific ligand of the affinity tag. Preferably, for such purposes, the affinity tag is a polyhistidine tag, and the purification method is effected using nickel as the specific ligand of the affinity tag.

A histidine tag is a peptide typically consisting of 4 to 8 histidine amino acid residues. Preferably a histidine tag composed of 6 histidine residues, commonly referred to as a hexahistidine tag in the art, is employed. Such histidine tags specifically bind nickel-containing substrates. Ample guidance regarding the use of histidine tags is available in the literature of the art (for example, refer to Sheibani N., 1999. *Prep Biochem Biotechnol.* 29:77). Purification of molecules comprising histidine tags is routinely effected using nickel-based affinity purification techniques. An alternate suitable capture ligand for histidine tags is the anti histidine tag single-

chain antibody 3D5 (Kaufmann, M. *et al.*, 2002. *J Mol Biol.* 318, 135-47). While various techniques may be employed, purifying a composition-of-matter of the present invention comprising an antibody or antibody fragment attached to a histidine tag is preferably effected as described and illustrated in the Examples section which follows.

The composition-of-matter may be purified using any of various suitable standard and widely employed affinity chromatography techniques. Ample guidance for practicing such techniques is provided in the literature of the art [for example, refer to: Wilchek M. and Chaiken I., 2000. *Methods Mol Biol* 147, 1-6; Jack GW., 1994. *Mol Biotechnol* 1, 59-86; Narayanan SR., 1994. *Journal of Chromatography A* 658, 237-258; Nisnevitch M. and Firer MA., 2001. *J Biochem Biophys Methods* 49, 467-80; Janson JC. and Kristiansen T. in "Packings and Stationary Phases in Chromatography Techniques", Unger KK. (ed), Marcel Dekker, New York, pp. 747 (1990); Clonis YD: *HPLC of Macromolecules: A Practical Approach*, IRL Press, Oxford, pp. 157 (1989); Nilsson J. *et al.*, 1997. *Protein Expr Purif.* 11:1-16].

Various affinity tags, other than those described hereinabove, may also be employed to attach the functional moiety to the antibody or antibody fragment or to purify a composition-of-matter of the present invention comprising an antibody or antibody fragment attached to an affinity tag, or any substance, particle, virus or cell displaying/expressing such a composition-of-matter.

Such affinity tags include, but are not limited to, a streptavidin tag (Strep-tag), an epitope tag (a moiety, usually peptidic, which can be specifically bound with high affinity by a specific monoclonal antibody), a maltose-binding protein (MBP) tag, and a chitin-binding domain (CBD) tag.

Examples of epitope tags include an 11-mer *Herpes simplex* virus glycoprotein D peptide, and an 11-mer N-terminal bacteriophage t7 peptide, being commercially known as HSVTAG and t7TAG, respectively (Novagen, Madison, WI, USA), and 10- or 9-amino acid c-myc or *Haemophilus influenza* hemagglutinin (HA) peptides, which are recognized by the variable regions of monoclonal antibodies 9E10 and 12Ca5, respectively.

A Strep-tag is a peptide having the capacity to specifically bind streptavidin. Ample guidance regarding the use of Strep-tags is provided in the literature of the art (see, for example: Schmidt, TGM. and Skerra, A. 1993. *Protein Eng.* 6:109; Schmidt

TGM. *et al.*, 1996. *Journal of Molecular Biology* 255:753-766; Skerra A. and Schmidt TGM., 1999. *Biomolecular Engineering* 16:79-86; Sano T. and Cantor CR. 2000. *Methods Enzymol.* 326, 305-11; and Sano T. *et al.*, 1998. *Journal of Chromatography B* 715:85-91).

5 A suitable maltose-binding domain tag is *malE*-encoded maltose-binding protein which has the capacity to specifically bind a substrate including amylose such as, for example, an amylose-based affinity purification column. Ample guidance regarding the use of maltose-binding protein as an affinity tag is provided in the literature of the art (see, for example: Guan M. *et al.*, 2002. *Protein Expr Purif.* 26:229-34; Cattoli F and Sarti GC, 2002. *Biotechnol Prog.* 18:94-100).

10 A suitable chitin-binding domain tag is *B. circulans* *cbd*-encoded chitin binding domain which has the capacity to specifically bind chitin. Ample guidance regarding the use of maltose-binding protein as an affinity tag is provided in the literature of the art (see, for example: Humphries HE *et al.*, 2002. *Protein Expr Purif.* 26:243-8; and Chong S. *et al.*, 1997. *Gene* 192:271-81).

15 Thus, the functional moiety may be attached to the antibody or antibody fragment via any of the aforementioned various affinity tags, depending on the application and purpose.

20 As mentioned hereinabove, the functional moiety attached to the antibody or antibody fragment may be a toxin.

For applications of the composition-of-matter involving killing/damaging of target cells/tissues, the toxin is preferably capable of killing/damaging the target cells/tissues when conjugated thereto as a consequence of specific binding of the antibody or antibody fragment to the antigen-presenting portion of the complex.

25 Any of various toxins may be attached to the antibody or antibody fragment, to thereby generate an immunotoxin suitable, for example, to kill/damage target cells/tissues using a composition-of-matter comprising such an immunotoxin.

Preferably, the toxin is *Pseudomonas* exotoxin A, more preferably a portion thereof comprising the translocation domain and/or an ADP ribosylation domain.

30 Preferably, the portion comprising the translocation domain and/or an ADP ribosylation domain is the toxin PE38KDEL. Generation of an immunotoxin comprising PE38KDEL as a toxin moiety is preferably effected as described and illustrated in the Examples section below. Ample guidance for generating such an

immunotoxin is provided in the literature of the art (for example, refer to: Brinkmann U. *et al.*, 1991. Proc. Natl. Acad. Sci. U. S. A. 88:8616-20; and Brinkmann U., 2000. *In-vivo* 14:21-7).

Other types of toxins which may be attached to the antibody or antibody fragment, depending on the application and purpose, in particular to kill/damage a target cell, include, but are not limited to, various bacterial toxins, plant toxins, chemotherapeutic agents, and radioisotopes, respectively. Examples of toxins commonly used to generate immunotoxins include ricin and *Pseudomonas* exotoxin A-derived PE40 toxin. Alternately, immunotoxins may be generated with toxins such as diphtheria toxin, pertussis toxin, or cholera toxin.

Ample guidance for selecting, generating and using immunotoxins is provided in the literature of the art (for example, refer to: Knechtle SJ. 2001. Philos Trans R Soc Lond B Biol Sci. 356:681-9; Hall WA., 2001. Methods Mol Biol. 166:139-54; Brinkmann U., 2000. *In-vivo* 14:21-7; Haggerty HG. *et al.*, 1999. Toxicol Pathol. 27:87-94; Chaplin JW., 1999. Med Hypotheses 52:133-46; Wu M., 1997. Br J Cancer. 75:1347-55; Hall WA. 1996, Neurosurg Clin N Am. 7:537-46; Pasqualucci L. *et al.*, 1995. Haematologica 80:546-56; Siegall CB., 1995. Semin Cancer Biol. 6:289-95; Grossbard ML. *et al.*, Clin Immunol Immunopathol. 76:107-14; Ghetie MA and Vitetta ES., 1994. Curr Opin Immunol. 6:707-14; Grossbard ML and Nadler LM., 1994. Semin Hematol. 31:88-97; Frankel AE., 1993. Oncology (Huntingt) 7:69-78; Pai LH. and Pastan I., 1993. JAMA. 269:78-81; Boon, T. and van der Bruggen, P., 1996. J. Exp. Med. 183:725-729; Renkvist, N. *et al.*, 2001. Cancer Immunol Immunother. 50:3-15; Rosenberg, S.A., 2001. Nature 411:380-384; and U.S. Pat. No. 5,677,274).

As mentioned hereinabove, depending on the application and purpose, the composition-of-matter may advantageously comprise a monomeric or multimeric form of the antibody or antibody fragment.

A composition-of-matter of the present invention comprising a multimeric form of the antibody or antibody fragment will generally bind the antigen-presenting portion of the complex with higher avidity, and thereby with higher affinity, than one comprising a monomeric form of the antibody or antibody fragment. Hence, a composition-of-matter of the present invention comprising a multimeric form of the antibody or antibody fragment may be advantageous for applications benefiting from,

as will usually be the case, a reagent capable of specifically binding the antigen-presenting portion of the complex with the highest affinity possible.

As is described and illustrated in the Examples section below, a composition-of-matter of the present invention comprising a multimeric form of an antibody or 5 antibody fragment may be advantageously employed to effectively practice the method of the present invention, in particular with respect to applications involving using the composition-of-matter to specifically detect the antigen-presenting portion of the complex.

Various methods may be employed to generate a composition-of-matter of the 10 present invention comprising a multimeric form of the antibody or antibody fragment.

Preferably, the multimeric form of the antibody or antibody fragment is generated by binding a plurality of antibodies or antibody fragments attached to an affinity tag to a multimerizing molecule capable of specifically and simultaneously binding such a plurality of affinity tags. Alternately, the multimeric form of the 15 antibody or antibody fragment may be generated by attaching a plurality of antibodies or antibody fragments of the present invention to a moiety capable of automultimerizing, so as to thereby multimerize such a plurality of antibodies or antibody fragments.

Any of various types of multimerizing molecule/affinity tag combinations may 20 be employed to generate the multimeric form of the antibody or antibody fragment of the present invention.

Preferably, such a combination consists of a biotin affinity tag, and a streptavidin multimerizing molecule, which, as described hereinabove, bind to each other with the highest affinity known to man, and hence will normally generate an 25 optimally stable multimeric form of an antibody or antibody fragment of the present invention.

For certain applications a composition-of-matter of the present invention comprising a monomeric form of the antibody or antibody fragment may be advantageous. Such a composition-of-matter, due to its relatively small size may be 30 advantageous for applications, such as *in-vivo* applications, benefiting from optimal biodistribution and/or diffusion thereof.

As is described and illustrated in the Examples section which follows, a composition-of-matter of the present invention comprising a monomeric form of an

antibody or antibody fragment of the present invention may be advantageously utilized, for example, in applications where such an antibody or antibody fragment is attached to a toxin to kill/damage target cells.

Preferably, the composition-of-matter comprises an antibody or antibody fragment capable of specifically binding a complex in which the APM is an MHC class I molecule and the antigen is an MHC class I-restricted antigen (referred to herein as "MHC class I:antigen complex").

Alternately, the composition-of-matter may comprise an antibody or antibody fragment capable of specifically binding the antigen-presenting portion of a complex in which the APM is an MHC class II molecule and the antigen is an MHC class II-restricted antigen ("MHC class II:antigen complex"), or the APM is a CD1 molecule and the antigen is a CD1 molecule and the antigen is a CD1-restricted antigen ("CD1:antigen complex"). The composition-of-matter may also comprise an antibody or antibody fragment capable of specifically binding a complex structurally and/or functionally analogous to an APM:antigen complex such as one of the aforementioned MHC- or CD1-based complexes.

The composition-of-matter may comprise an antibody or antibody fragment capable of specifically binding the antigen-presenting portion of any of various particular MHC class II:antigen complexes. For example, the antigen-presenting portion of an MHC class II:antigen complex having as an APM an HLA-DP, HLA-DQ or HLA-DR molecule.

A composition-of-matter of the present invention may comprise an antibody or antibody fragment capable of specifically binding the antigen-presenting portion of a complex composed of an MHC class II molecule and any of various MHC class II-restricted antigens, which are generally peptides about 10 to 30 amino acid residues in length. Such peptides generally have particular chemical compositions enabling their specific binding to a particular MHC class II molecule (for example, refer to: Fairchild PJ., 1998. J Pept Sci. 4:182; Rammensee HG., 1995. Curr Opin Immunol. 7:85; Sinigaglia F. and Hammer J., 1994. APMIS. 102:241; and Hobohm U. and Meyerhans A., 1993. Eur J Immunol. 23:1271).

The composition-of-matter may comprise an antibody or antibody fragment capable of specifically binding the antigen-presenting portion of any of various particular CD1:antigen complexes. For example, the antigen-presenting portion of a

CD1:antigen complex having as an APM a CD1a, CD1b, CD1c or CD1d molecule.

A composition-of-matter of the present invention may comprise an antibody or antibody fragment capable of specifically binding the antigen-presenting portion of a complex composed of a CD1 molecule and any of various CD1-restricted antigens, 5 which may be either peptides or more typically lipids. For example: CD1b and CD1c molecules both have the capacity to specifically associate with CD1b- or CD1-c-restricted lipoarabinomannan, mycolic acid, or glucose monomycolate antigens; CD1c has the capacity to specifically associate with CD1c-restricted polyisoprenyl 10 glycolipid antigens; and CD1d has the capacity to specifically associate with CD1d-restricted glycophosphatidylinositol (GPI) anchor lipid and glycosylceramide lipid antigens.

The composition-of-matter may comprise an antibody or antibody fragment capable of specifically binding the antigen-presenting portion of any of various 15 particular MHC class I:antigen complexes, for example, an MHC class I:antigen complex having as an MHC class I APM an HLA-A, HLA-B, or HLA-C molecule (referred to herein as "HLA-A:antigen complex", "HLA-B:antigen complex", or "HLA-A:antigen complex", respectively).

While the composition-of-matter may comprise an antibody or antibody fragment capable of specifically binding the antigen-presenting portion of a complex 20 in which the APM is any of various HLA-A molecules, the composition-of-matter is preferably capable of binding the antigen-presenting portion of one in which the HLA-A molecule is HLA-A2, most preferably HLA-A2.1 (alternately termed "HLA-A\*201").

As is described and illustrated in Examples section below, a composition-of- 25 matter of the present invention comprising an antibody or antibody fragment capable of specifically binding a complex having an HLA-A2 molecule as APM can be used to effectively practice various embodiments of the present invention.

A composition-of-matter of the present invention may comprise an antibody or antibody fragment capable of specifically binding the antigen-presenting portion of a 30 complex composed of an MHC class I molecule and any of various MHC class I-restricted antigens, which are typically peptides about 9 to 11 amino acid residues in length. Such peptides generally have particular chemical compositions enabling their specific binding to a particular MHC class I molecule (for example, refer to: Bianco

A. *et al.*, 1998. *J Pept Sci.* 4:471; Fairchild PJ., 1998. *J Pept Sci.* 4:182; Falk K. and Rotzschke O., 1993. *Semin Immunol.* 5:81; Rammensee HG., 1995. *Curr Opin Immunol.* 7:85; and Hobohm U. and Meyerhans A., 1993. *Eur J Immunol.* 23:1271).

As described hereinabove, the composition-of-matter of the present invention 5 comprises an antibody or antibody fragment capable of specifically binding the antigen-presenting portion of a particular complex composed of a human APM and an antigen derived from a pathogen.

While the composition-of-matter may comprise an antibody or antibody fragment capable of specifically binding the antigen-presenting portion of a particular 10 complex comprising an APM-restricted antigen derived from essentially any type of pathogen, the pathogen is preferably an intracellular pathogen.

Alternately, the pathogen may a non-intracellular pathogen, such as a bacterium, a fungus, a protozoan, a mycobacterium, a helminth, and the like.

The composition-of-matter may comprise an antibody or antibody fragment 15 capable of specifically binding the antigen-presenting portion of a complex comprising an APM-restricted antigen derived from any of various intracellular pathogens, including a virus, a mycobacterium, a bacterium (such as, for example, *Listeria monocytogenes*), and a protozoan (such as, for example, *Leishmania* or *Trypanosoma*).

20 Preferably the antibody or antibody fragment is capable of specifically binding the antigen-presenting portion of a complex comprising an APM-restricted antigen derived from a viral pathogen.

Examples of such viral pathogens include retroviruses, circoviruses, 25 parvoviruses, papovaviruses, adenoviruses, herpesviruses, iridoviruses, poxviruses, hepadnaviruses, picornaviruses, caliciviruses, togaviruses, flaviviruses, reoviruses, orthomyxoviruses, paramyxoviruses, rhabdoviruses, bunyaviruses, coronaviruses, arenaviruses, and filoviruses.

While the composition-of-matter may comprise an antibody or antibody fragment capable of specifically binding the antigen-presenting portion of a complex 30 comprising as APM-restricted antigen an antigen derived from any of various retroviruses, the retrovirus is preferably human T lymphotropic virus-1 (HTLV-1; also referred to as human T-cell leukemia virus in the art).

Alternately, the retrovirus may be, for example, HTLV-2, a human

immunodeficiency virus (HIV) causing acquired immunodeficiency syndrome (AIDS) such as HIV-1 or HIV-2, or the like.

5 The composition-of-matter may comprise an antibody or antibody fragment capable of specifically binding the antigen-presenting portion of a complex comprising any of various antigens derived from HTLV-1.

Preferably, a composition-of-matter of the present invention comprising an antibody or antibody fragment capable of specifically binding the antigen-presenting portion of a complex comprising as APM-restricted antigen derived from HTLV-1, an antigen derived from Tax protein.

10 The composition-of-matter may comprise an antibody or antibody fragment capable of specifically binding the antigen-presenting portion of a complex comprising as APM-restricted antigen any of various Tax protein-derived antigens, and having an antigen binding region comprising any of various amino acid sequences.

15 Preferably, the antibody or antibody fragment comprises an antibody or antibody fragment: (i) capable of specifically binding the antigen-presenting portion of a complex comprising as Tax protein-derived APM-restricted antigen a peptide comprising amino acid residues 11 to 19 of Tax protein, a peptide having the amino acid sequence set forth in SEQ ID NO: 3, or preferably both; (ii) having an antigen-20 binding region including a maximal number of amino acid sequences corresponding to one selected from the group of amino acid sequences set forth in SEQ ID NOs: 14 to 97; or (iii) preferably both.

As is described and illustrated in the Examples section below, a composition-of-matter of the present invention comprising an antibody or antibody fragment: (i) 25 capable of specifically binding a complex having as APM-restricted antigen a peptide comprising amino acid residues 11 to 19 of Tax protein having the amino acid sequence set forth in SEQ ID NO: 3; and (ii) having an antigen-binding region including amino acid sequences corresponding to those set forth in SEQ ID NOs: 14 to 97 can be used to effectively practice various embodiments of the present invention, involving using the composition-of-matter for detecting the antigen-presenting portion of the complex, or killing target cells/tissues.

It will be appreciated that a cell infected with a pathogen, and an APC exposed to the pathogen, or an antigen thereof, may express distinct complexes comprising

different APMs and/or different antigens derived from the pathogen, and that hence, the composition-of-matter may be advantageously selected so as to selectively bind one or the other of such cell types. This may be advantageously applied in numerous applications of the present invention, such as, for example, when using the composition-of-matter, as described hereinbelow, to treat a disease associated with a pathogen in an individual by selectively killing/damaging cells infected with the pathogen displaying one particular complex of an APM and an antigen derived from the pathogen without killing/damaging benign or beneficial APCs displaying a different complex of an APM and an antigen derived from the pathogen.

As mentioned hereinabove, depending on the application and purpose, the antibody or antibody fragment may be selected capable of binding the antigen-presenting portion of the complex with a desired affinity.

Preferably, the desired affinity is as high as possible. A composition-of-matter of the present invention comprising an antibody or antibody fragment having as high as possible a binding affinity for the antigen-presenting portion of the complex will generally enable optimally stable conjugation of a functional moiety to the antigen-presenting portion of the complex, and thereby detection of the antigen-presenting portion of the complex with optimal sensitivity, or killing/damaging of target cells/tissues with optimal efficiency.

Preferably, the affinity is characterized by a dissociation constant ( $K_d$ ) selected from the range of  $1 \times 10^{-2}$  molar to  $5 \times 10^{-3}$  molar, more preferably  $5 \times 10^{-3}$  molar to  $5 \times 10^{-4}$  molar, more preferably  $5 \times 10^{-4}$  molar to  $5 \times 10^{-5}$  molar, more preferably  $5 \times 10^{-5}$  molar to  $5 \times 10^{-6}$  molar, more preferably  $5 \times 10^{-6}$  molar to  $5 \times 10^{-7}$  molar, more preferably  $5 \times 10^{-7}$  molar to  $5 \times 10^{-8}$  molar, more preferably  $5 \times 10^{-8}$  molar to  $5 \times 10^{-9}$  molar, more preferably  $5 \times 10^{-9}$  molar to  $5 \times 10^{-10}$  molar, more preferably  $5 \times 10^{-10}$  molar to  $5 \times 10^{-11}$  molar, more preferably  $5 \times 10^{-11}$  molar to  $5 \times 10^{-12}$  molar, more preferably  $5 \times 10^{-12}$  molar to  $5 \times 10^{-13}$  molar, more preferably  $5 \times 10^{-13}$  molar to  $5 \times 10^{-14}$  molar, more preferably  $5 \times 10^{-14}$  molar to  $5 \times 10^{-15}$  molar, and most preferably  $5 \times 10^{-15}$  molar to  $5 \times 10^{-16}$ .

As is illustrated in the Examples section below, an antibody or antibody fragment capable of binding the antigen-presenting portion of a complex with an affinity characterized by a dissociation constant of about  $10^{-9}$  molar can be generated

using the protocol set forth therein.

As is described and illustrated in the Examples section which follows, a composition-of-matter of the present invention comprising an antibody or antibody fragment having a binding affinity for the antigen-presenting portion of the complex characterized by a dissociation constant of about  $10^{-9}$  molar can be used to effectively practice various embodiments of the present invention, including those involving using the composition-of-matter for detecting the antigen-presenting portion of the complex, or for killing/damaging target cells/tissues.

Various methods may be employed to obtain the antibody or antibody fragment capable of specifically binding the antigen-presenting portion of the complex.

Preferably, the antibody or antibody fragment is obtained by screening a combinatorial antibody or antibody fragment display library for an element of the library displaying an antibody or antibody fragment capable of binding the antigen-presenting portion of the complex conjugated to a substrate with the desired affinity. Preferably, where the antibody or antibody fragment is an Fab, this may be advantageously effected by screening an Fab-phage library on substrate-immobilized single-chain MHC:peptide complex, preferably as described in the Examples section below. Ample guidance for identifying an antibody or antibody fragment capable of specifically binding the complex is provided in the literature of the art (for example, for generation of a human-derived antibody or antibody fragment refer, for example, to: Chames, P. *et al.*, 2000. Proc. Natl. Acad. Sci. U. S. A. 97:7969-7974; Denkberg, G. *et al.*, 2002. Proc. Natl. Acad. Sci. U. S. A. 99:9421-9426; and Lev, A. *et al.*, 2002. Cancer Res. 62:3184-3194; for generation of a non human-derived antibody or antibody fragment refer, for example, to: Aharoni, R. *et al.*, 1991. Nature 351:147-150; Andersen, P.S. *et al.*, 1996. Proc. Natl. Acad. Sci. U. S. A 93:1820-1824; Dadaglio, G. *et al.*, 1997. Immunity 6:727-738; Day, P.M. *et al.*, 1997. Proc. Natl. Acad. Sci. U. S. A. 94:8064-8069; Krogsgaard, M. *et al.*, 2000. J. Exp. Med. 191:1395-1412; Murphy, D.B. *et al.*, 1989. Nature 338:765-768; Porgador, A. *et al.*, 1997. Immunity 6:715-726; Reiter, Y. *et al.*, Proc. Natl. Acad. Sci. U. S. A. 94:4631-4636; Zhong, G. *et al.*, 1997. Proc. Natl. Acad. Sci. U. S. A. 94:13856-13861; Zhong, G. *et al.*, 1997. J. Exp. Med. 186:673-682; Orlandi D.R. *et al.*, 1989. Proc Natl Acad Sci U S A. 86:3833-3837; for a general reference, refer to Winter G. *et al.*, 1991.

Nature 349:293-299).

Further guidance for generating the antibody or antibody fragment comprised in the composition-of-matter of the present invention is provided hereinbelow.

It will be appreciated by the ordinarily skilled artisan that generating an antibody or antibody fragment of a desired affinity, for example one characterized by a dissociation constant as high as  $10^{-12}$  for a desired antigenic determinant can be achieved using common art techniques.

The composition-of-matter may be used *per se* or it can be formulated as an active ingredient in a pharmaceutical composition.

Thus, as described hereinabove, the present invention provides, and may be practiced, depending on the application and purpose using, a composition-of-matter comprising: (i) a monoclonal or polyclonal antibody or antibody fragment; (ii) a monomeric or multimeric form of an antibody or antibody fragment; (iii) an antibody or antibody fragment characterized by any of various configurations; (iv) an antibody or antibody fragment or a portion thereof derived from any of various mammalian species; (v) an antibody or antibody fragment capable of specifically binding the antigen-presenting portion of any of various specific human APM:pathogen-derived antigen complexes; and/or (vi) an antibody or antibody fragment capable of specifically binding the antigen-presenting portion of a particular human APM:pathogen-derived antigen complex with a desired affinity.

While further reducing the present invention to practice, genetic sequences encoding an antibody fragment of the present invention were isolated.

Thus, according to another aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding an antibody fragment of the present invention.

Depending on the application and purpose, the isolated polynucleotide preferably further comprises a nucleic acid sequence encoding a coat protein of a virus, a detectable moiety, and a toxin.

Preferably, in order to enable generation of a chimeric polypeptide comprising the antibody fragment fused to the coat protein of the virus, the detectable moiety or the toxin, the nucleic acid sequence encoding the polypeptide is translationally fused with that encoding the antibody fragment. Nucleic acid sequences encoding polypeptides may be translationally fused in a polynucleotide by cloning the structural

sequences of such nucleic acid sequences in-frame relative to each other in the polynucleotide without intervening transcriptional/translational stop codons, or any other sequences, present between such structural sequences capable of preventing production of a chimeric polypeptide comprising the polypeptides encoded by such structural sequences.

An antibody fragment attached to a coat protein of a virus can be used to generate a virus displaying the antibody fragment by virtue of the antibody fragment being fused to the coat protein of the virus. Generating such a virus may be effected as described in further detail hereinbelow, and in the Examples section which follows.

10 While various methods may be used to generate the isolated polynucleotide, the isolated polynucleotide is preferably generated as described in the Examples section, below.

15 As is described and illustrated in the Examples section below, an isolated polynucleotide of the present invention can be used to generate an antibody fragment or conjugate thereof with a coat protein of a virus, a detectable moiety, and/or a toxin suitable for generating the composition-of-matter of the present invention.

While reducing the present invention to practice nucleic acid constructs capable of expressing the polynucleotide of the present invention were isolated or generated.

20 Thus, the present invention provides a nucleic acid construct comprising the isolated polynucleotide of the present invention and a promoter sequence for directing transcription thereof in a host cell.

25 While various promoter sequences may be employed capable of directing transcription of the isolated polynucleotide in various types of host cell, depending on the application and purpose, the promoter sequence is preferably capable of directing transcription thereof in a prokaryote.

The promoter sequence may be capable of directing transcription of the polynucleotide in any of various suitable prokaryotes.

Preferably, the prokaryote is *E. coli*.

30 In order to enable regulatable transcription of the nucleic acid sequence in the host cell, the promoter sequence is preferably further capable of directing inducible transcription of the nucleic acid sequence in the host cell.

Various types of promoter sequences capable of directing transcription or

inducible transcription of the polynucleotide in the host cell, such as a suitable *E. coli* cell may be employed.

Preferably, the promoter sequence is a T7 promoter sequence.

It will be appreciated by the skilled artisan that a construct of the present invention comprising a T7 promoter sequence for directing transcription of the polynucleotide can be used to efficiently inducibly express in a suitable *E. coli* host cell the antibody fragment of the present invention, or a conjugate thereof with a coat protein of a virus, detectable moiety, and/or toxin.

Preferably, the nucleic acid construct is isolated or assembled, and is used to 10 inducibly produce the antibody fragment of the present invention in a host cell as is described and demonstrated in the Examples section below.

As described hereinabove, the nucleic acid construct may be expressed in various types of host cells. For example, the nucleic acid construct may be advantageously expressed in a eukaryotic host cell, such as a mammalian cell or a 15 plant cell.

Methods of expressing nucleic acid constructs encoding antibody fragments in eukaryotic cells are widely practiced by the ordinarily skilled artisan.

Plant cells expressing the nucleic acid construct can be used to generate plants expressing the nucleic acid construct, thereby enabling inexpensive and facile 20 production of large quantities of antibody which can be harvested, processed and stored using existant infrastructure.

Expression of the nucleic acid construct of the present invention in plants can be used to produce plants expressing various forms of the composition-of-matter of the present invention, including immunoconjugates such as immunotoxins.

Ample guidance for expressing nucleic acid constructs encoding antibody 25 fragments, such as nucleic acid constructs encoding immunotoxins, in plant cells, and thereby in plants, is provided in the literature of the art (for example, refer to: Peeters K. *et al.*, 2001. Vaccine 19:2756-61; De Jaeger G. *et al.*, 2000. Plant Mol Biol. 43:419-28; Fischer R. *et al.*, 2000. J Biol Regul Homeost Agents. 14:83-92; Fischer 30 R. *et al.*, 1999. Biotechnol Appl Biochem. 30:101-8; and Russell DA., 1999. Curr Top Microbiol Immunol. 240:119-38).

While reducing the present invention to practice, viruses comprising the nucleic acid construct of the present invention, and a coat protein fused to an antibody

fragment of the present invention were isolated or generated.

Thus, the present invention provides a virus comprising the nucleic acid construct of the present invention and/or a coat protein fused to an antibody fragment of the present invention.

5 The virus of the present invention can be used in various applications, such as, for example, for selecting an antibody fragment of the present invention having a desired binding affinity/specificity for the antigen-presenting portion of the complex. Alternately, such a virus may be used for propagating the antibody fragment or the nucleic acid construct. Preferably, such propagation is effected by using the virus to 10 infect a host cell.

Any of various types of viruses comprising an antibody fragment of the present invention fused to any of various types of coat protein may be used.

Preferably, the virus is a filamentous phage and the coat protein is pIII.

15 While various methods may be employed to obtain and utilize the virus, it is preferably obtained and utilized as described and demonstrated in the Examples section which follows.

While reducing the present invention to practice, host cells comprising the nucleic acid construct were generated and used to produce antibody fragments of the present invention.

20 Thus, the present invention provides a host cell comprising the nucleic acid construct.

While the host cell may be advantageously used in various applications, it is preferably used to produce the antibody fragment, as mentioned hereinabove. Alternately, the host cell may be used to propagate the nucleic acid construct.

25 Various types of host cell may be used to practice the present invention, depending on the application and purpose.

Preferably, the host cell is a prokaryotic cell.

30 Alternately, the host cell may be a mammalian cell (please refer to the antibody/antibody fragment production guidelines herein for description of suitable mammalian cells, and methods of their use).

While any of various types of prokaryotic host cells may be utilized, the prokaryotic cell is preferably an *E. coli* cell.

While various methods may be employed to obtain and utilize the *E. coli* host

cell, for example, to produce the antibody or antibody fragment, it is preferably obtained and utilized as described and demonstrated in the Examples section which follows.

5 While reducing the present invention to practice the capacity of the composition-of-matter to enable specific detection of the antigen-presenting portion of a particular human APM:pathogen-derived antigen complex was demonstrated.

Thus, according to another aspect of the present invention there is provided a method of detecting the antigen-presenting portion of the complex.

10 The method is effected by exposing the antigen-presenting portion of the complex to a composition-of-matter of the present invention to thereby obtain a conjugate of the antigen-presenting portion of the complex and the antibody or antibody fragment comprised in the composition-of-matter. Once the conjugate is formed, the method further comprises detecting the antibody or antibody fragment of the conjugate so as to thereby detect the antigen-presenting portion of the complex.

15 The method according to this aspect of the present invention can be used to detect the antigen-presenting portion of the complex in any of various contexts and applications.

In particular, as described hereinbelow, the method can be used to diagnose an infection by a pathogen in an individual.

20 Depending on the application and purpose, various methods may be utilized to expose the antigen-presenting portion of the complex to the composition-of-matter, according to the teachings of the present invention.

25 When using the method for detecting the antigen-presenting portion of a complex displayed/expressed by target cells/tissues, or of a complex immobilized on a surface, the antigen-presenting portion of the complex is preferably exposed to the composition-of-matter by exposing the target cells/tissues, or the surface-immobilized antigen-presenting portion of the complex, respectively, to the composition-of-matter.

30 For certain applications, the biological sample may be advantageously obtained from an individual prior to contacting the composition-of-matter with the biological sample. Alternately, the composition-of-matter may be contacted with the biological sample by administering the composition-of-matter to the individual.

As described hereinabove, once the composition-of-matter and the antigen-presenting portion of the complex exposed to the composition-of-matter form the

conjugate, the method further comprises detecting the antibody or antibody fragment of the conjugate so as to thereby detect the antigen-presenting portion of the complex.

While various methods may be employed to detect the antibody or antibody fragment of the antigen-presenting portion of the complex, the antigen-presenting portion of the complex is preferably detected by using a composition-of-matter of the present invention comprising an antibody or antibody fragment attached a detectable moiety, and detecting the antibody or antibody fragment by detecting the detectable moiety attached thereto.

As described hereinabove, various detectable moieties may be used to detect the antigen-presenting portion of the complex in the context of various detection assays, depending on the application and purpose.

Preferably, the method according to this aspect of the present invention is used to detect the antigen-presenting portion of a complex in a biological sample. Alternately, the method may be used to detect the antigen-presenting portion of a complex immobilized on a non-cellular surface, such as an the surface of an ELISA plate.

While the method may be used to detect the antigen-presenting portion of the complex in essentially any type of biological sample, it is preferably applied to detect the antigen-presenting portion of a complex displayed/expressed by target cells/tissues.

Preferably, the target cells are pathogen infected cells displaying the complex, or APCs displaying the complex, such as professional APCs, dendritic cells, B lymphocytes, granulocytes, neutrophils, basophils, eosinophils, monocytes, macrophages, and mast cells.

It will be appreciated that since, as described hereinabove, the composition-of-matter may comprise an antibody or antibody fragment capable of specifically binding a complex comprising as APM-restricted antigen an antigen derived from essentially any pathogen, the method according to this aspect of the present invention can be used to detect a complex comprising as APM-restricted antigen, an antigen derived from essentially any pathogen.

Preferably, the method is used to detect target cells displaying/expressing a particular complex comprising as APM-restricted antigen, an HTLV-1-derived antigen

Preferably, the method according to this aspect of the present invention is effected as described in the Examples section which follows.

As is demonstrated in the Examples section below, practicing the method according to the protocol set forth therein can be used in numerous contexts to detect 5 with optimal specificity and sensitivity cells displaying a particular complex comprising as APM-restricted antigen, an HTLV-1-derived antigen, or such a complex immobilized on a non cellular surface.

Thus, the method according to this aspect of the present invention may be used to effectively and potently diagnose and characterize an infection by a pathogen in an 10 individual.

It will be appreciated that since, as described hereinabove, this aspect of method of the present invention can be used to detect essentially any complex in essentially any context with optimal specificity and/or sensitivity, the method according to this aspect of the present invention can be used to optimally diagnose 15 and characterize essentially any infection associated with essentially any pathogen.

For example, as described in the Examples section below, the method according to this aspect of the present invention can be used to optimally detect an APM:retrovirus-derived antigen. Thus, the method can be used to optimally detect in an individual an infection by a retrovirus. Retrovirus are associated with a wide 20 variety of diseases including an array of malignancies, immunodeficiencies (notably AIDS), and neurological disorders, and syndromes as seemingly diverse as arthritis, osteopetrosis, and anemia. Thus, the method according to this aspect of the present invention can be used, for example, to optimally diagnose essentially all such diseases in an individual.

25 Preferably, the method according to this aspect of the present invention is used to diagnose an HTLV-1 infection, or a disease associated with such infection, in an individual, since, as described and demonstrated in the Examples section which follows, the method according to this aspect of the present invention can be used to detect with optimal sensitivity and specificity a target cell displaying a complex 30 comprising as APM-restricted antigen, an HTLV-1-derived antigen. Diseases associated with HTLV-1 infection which may diagnosed and characterized using this according to this aspect of the present invention include adult T-lymphocyte leukemia/lymphoma (ATLL; Yoshida M. *et al.*, 1982. Proc Natl Acad Sci U S A.

79:2031-2035), Sjogren's syndrome, inflammatory arthropathies, polymyositis, and pneumopathies (Coscoy L. *et al.*, 1998. *Virology* 248: 332-341).

Most preferably, this aspect of the present invention can be used for diagnosis and characterization of HTLV-1 associated myelopathy/tropical virus spastic 5 paraparesis (HAM/TSP; Osame M. *et al.*, 1986. *Lancet* 1:1031-1032), as is described in Example 2 of the Examples section which follows.

While reducing the present invention to practice, the capacity of the composition-of-matter of the present invention to enable killing/damaging of target cells was demonstrated.

10 Thus, according to a further aspect of the present invention there is provided a method of killing or damaging target cells.

According to the teachings of the present invention, the method is effected by exposing the target cells to the composition-of-matter of the present invention.

15 The method may be effected so as to kill various types of target cells in various ways, depending on the application and purpose.

Preferably, the method is effected by exposing target cells to a composition-of-matter of the present invention comprising an antibody or antibody fragment attached to a toxin, so as to thereby kill/damage the target cells via the toxin.

20 Alternately, in an *in-vivo* context or an *in-vitro* equivalent thereof, the method may be effected by exposing target cells to a composition-of-matter of the present invention comprising an antibody or antibody fragment including an Fc region, or portion thereof, capable of specifically binding a molecule capable of initiating an immune response, such as a complement cascade or ADCC, directed against target cells bound by such an antibody or antibody fragment, as described hereinabove.

25 While the method according to this aspect of the present invention can be used for killing/damaging target cells in any of various contexts and applications, it is preferably employed to kill/damage target cells so as to treat a disease associated with a pathogen in an individual.

30 It will be appreciated that the method may also be used to kill/damage target cells *in-vitro* or *in-vivo* in an animal model, in particular to test and/or optimize killing/damaging of target cells using the composition-of-matter. Such testing and/or optimizing killing/damaging of target cells using the composition-of-matter may be advantageously applied towards optimizing treatment of the disease in the individual

using the composition-of-matter.

When using the method according to this aspect of the present invention for optimizing use of the composition-of-matter to kill/damage target cells for treating the disease, the method may be advantageously effected by obtaining the target cells from the individual. One of ordinary skill in the art, such as a physician, will possess the necessary expertise to obtain target cells from an individual.

Various types of target cells may be obtained from the individual for optimizing use of the composition-of-matter to kill/damage target cells. Preferably, such target cells are cells infected with the pathogen since such cells will be of particular utility for optimizing killing of target cells infected with the pathogen, and hence for optimizing treatment of the disease in the individual.

It will be appreciated that since, as described hereinabove, the composition-of-matter may comprise an antibody or antibody fragment capable of binding with optimal specificity and affinity a complex comprising as APM-restricted antigen an antigen derived from essentially any pathogen, the method according to this aspect of the present invention can be used to kill/damage cells displaying/expressing a complex comprising as APM-restricted antigen, an antigen derived from essentially any pathogen with optimal efficiency and specificity.

Preferably, the method is used to kill/damage target cells displaying/expressing a particular complex comprising as APM-restricted antigen, an HTLV-1-derived antigen

Preferably, the method according to this aspect of the present invention is effected as described in the Examples section which follows.

As is demonstrated in the Examples section below, practicing the method according to the protocol set forth therein can be used to kill with optimal efficiency and specificity cells displaying a particular complex comprising as APM-restricted antigen, an HTLV-1-derived antigen.

Thus, the present invention provides a method of treating a disease associated with a pathogen in an individual.

The method is effected by administering to the individual a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a composition-of-matter of the present invention comprising as APM-derived antigen, an antigen derived from the pathogen.

As described in detail hereinbelow, the pharmaceutical composition may be administered in various ways.

As described hereinabove, the method according to this aspect of the present invention is preferably effected using a composition-of-matter comprising an immunotoxin.

Ample guidance for treating a disease using an immunotoxin is provided in the literature of the art (for example, for general references refer to: Knechtle SJ. 2001, *Philos Trans R Soc Lond B Biol Sci.* 356:681-93; Kreitman RJ., 2001. *Methods Mol Biol.* 166:111-23; Brinkmann U., 2000. *in-vivo* 14:21-7; Ghetie MA and Vitetta ES., 10 1994. *Curr Opin Immunol.* 6:707-14; Wu M., 1997. *Br J Cancer.* 75:1347-55; Hall WA. 1996, *Neurosurg Clin N Am.* 7:537-46; Boon, T. and van der Bruggen, P., 1996. *J. Exp. Med.* 183:725-729; Renkvist, N. *et al.*, 2001. *Cancer Immunol Immunother.* 15 50:3-15; Rosenberg, S.A., 2001. *Nature* 411:380-384; and U.S. Pat. No. 5,677,274; for treatment of acquired immunodeficiency syndrome (AIDS), refer, for example, to Chaplin JW., 1999. *Med Hypotheses* 52:133-46; for treatment of brain tumors, refer, for example, to Hall WA., 2001. *Methods Mol Biol.* 166:139-54; for treatment of hematological malignancies, refer, for example to: Pasqualucci L. *et al.*, 1995. *Haematologica* 80:546-56; Grossbard ML. *et al.*, *Clin Immunol Immunopathol.* 76:107-14; and Grossbard ML and Nadler LM., 1994. *Semin Hematol.* 31:88-97; for 20 treatment of carcinomas, refer, for example, to Siegall CB., 1995. *Semin Cancer Biol.* 6:289-95; for treatment of cancer, refer, for example, to: Frankel AE., 1993. *Oncology (Huntingt)* 7:69-78; and Pai LH. and Pastan I., 1993. *JAMA.* 269:78-81).

The method can be used to treat various types of diseases associated with a pathogen using various methodologies taught by the present invention.

25 Preferably, the method is used to treat a disease associated with a pathogen by killing/damaging pathogen infected cells. This may be advantageously performed where the pathogenesis of the disease derives predominantly from the pathogen infected cells.

Alternately, the method may be used to treat the disease, where the disease 30 involves a pathogenic immune response directed against pathogen-infected cells by pathogenic T-lymphocytes activated by pathogenic APCs displaying/expressing a complex comprising as APM-restricted antigen, an antigen derived from the pathogen. This is preferably effected, as described hereinabove, by using the

composition-of-matter to kill/damage such pathogenic APCs. Alternately, the pathogenic immune response mediated by such pathogenic APCs may be inhibited as described hereinabove, by using a composition-of-matter of the present invention comprising an antibody or antibody fragment capable of specifically binding the 5 pathogenic complex so as to thereby block activation of the pathogenic T-lymphocytes via engagement of the TCRs thereof by the complex.

It will be appreciated that since, as described hereinabove, this aspect of method of the present invention can be used to kill with optimal efficiency and specificity cells displaying/expressing essentially any particular complex, the method 10 according to this aspect of the present invention can be used to optimally treat essentially any infection associated with essentially any pathogen in an individual.

For example, as described in the Examples section below, the method according to this aspect of the present invention can be used to kill/damage with optimal efficiency and specificity cells displaying a complex comprising as APM-restricted antigen, an antigen derived from a retrovirus. Thus, the method can be used 15 to optimally treat, for example, an infection associated with a retrovirus in an individual

Thus, the method according to this aspect of the present invention can be used, for example, to optimally treat the broad range of diseases associated with a retroviral 20 infection described hereinabove.

Preferably, the method according to this aspect of the present invention is used to treat an HTLV-1 infection in an individual, since, as described and demonstrated in the Examples section which follows, the method according to this aspect of the present invention can be used to kill with optimal efficiency and specificity target 25 cells displaying a complex comprising as APM-restricted antigen, an HTLV-1-derived antigen.

As described hereinabove, the antibody or antibody fragment of the present invention may be generated in numerous ways.

A monoclonal or polyclonal antibody or antibody fragment of the present 30 invention may be generated via methods employing induction of *in-vivo* production of antibody or antibody fragment molecules, or culturing of antibody- or antibody fragment-producing cell lines. Ample guidance for practicing such methods is provided in the literature of the art [for example, refer to Harlow and Lane,

“Antibodies: A Laboratory Manual”, Cold Spring Harbor Laboratory, New York, (1988)].

Cell culture-based methods of generating antibodies include the hybridoma technique, the human B-cell hybridoma technique, and the Epstein-Barr virus (EBV)-  
5 hybridoma technique (Kohler G. *et al.*, 1975. *Nature* 256:495-497; Kozbor D. *et al.*, 1985. *J. Immunol. Methods* 81:31-42; Cote RJ. *et al.*, 1983. *Proc Natl Acad Sci U S A.* 80:2026-2030; Cole SP. *et al.*, 1984. *Mol. Cell. Biol.* 62:109-120).

Generating an antibody or antibody or antibody fragment of the present invention *in-vivo* may be advantageously effected by repeated injection of a target  
10 antigen (e.g., one comprising the antigen-presenting portion of the complex) into a mammal in the presence of adjuvants according to a schedule which boosts production of antibodies in the serum. In cases wherein the target antigen is too small to elicit an adequate immunogenic response (referred to as a “hapten” in the art), the hapten can be coupled to an antigenically neutral carrier such as keyhole limpet  
15 hemocyanin (KLH) or serum albumin [e.g., bovine serum albumin (BSA)] carriers (for example, refer to: US. Pat. Nos. 5,189,178 and 5,239,078). Coupling a hapten to a carrier can be effected using various methods well known in the art. For example, direct coupling to amino groups can be effected and optionally followed by reduction of the imino linkage formed. Alternatively, the carrier can be coupled using  
20 condensing agents such as dicyclohexyl carbodiimide or other carbodiimide dehydrating agents. Linker compounds can also be used to effect the coupling; both homobifunctional and heterobifunctional linkers are available from Pierce Chemical Company, Rockford, Ill. The resulting immunogenic complex can then be injected into suitable mammalian subjects such as mice, rabbits, and the like. Following *in-vivo*  
25 generation of an antibody, its serum titer in the host mammal can readily be measured using immunoassay procedures which are well known in the art. Such a polyclonal antibody containing anti-serum may be utilized as such, following purification thereof to generate a pure polyclonal or monoclonal antibody preparation. Such an anti-serum or purified antibody preparation may also be modified in various  
30 ways, depending on the application and purpose, prior to use. Genetic sequences encoding an antibody isolated from such an anti-serum may be determined using standard art techniques, and used to recombinantly produce the antibody or a modification thereof, such as an antibody fragment.

An antibody fragment of the present invention can be obtained using various methods well known in the art. For example, such an antibody fragment can be prepared by proteolytic hydrolysis of a parental antibody or by recombinant expression in *E. coli* or mammalian cells (e.g., Chinese hamster ovary cell culture or 5 other protein expression systems) of DNA encoding the fragment.

An F(ab')<sub>2</sub> antibody fragment can be produced by enzymatic cleavage of a parental antibody with pepsin to provide a 5S fragment. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages to produce a 3.5S 10 monovalent Fab' antibody fragment.

Enzymatic cleavage of a parental antibody with pepsin can be used to directly produce two monovalent Fab' fragments and an Fc fragment. Ample guidance for practicing such methods is provided in the literature of the art (for example, refer to: Goldenberg, U.S. Pat. Nos. 4,036,945 and 4,331,647; Porter RR., 1959. Biochem J. 15 73:119-126).

As described hereinabove, an Fv is composed of paired heavy chain variable and light chain variable domains. This association may be noncovalent (for example, refer to Inbar *et al.*, 1972. Proc. Natl. Acad. Sci. U. S. A. 69:2659-62). Alternatively, as described hereinabove the variable domains can be linked to generate a single chain 20 Fv by an intermolecular disulfide bond, or such chains may be covalently cross-linked using chemicals such as glutaraldehyde. A single chain Fv may advantageously prepared by constructing a structural gene comprising DNA sequences encoding the heavy chain variable domain and the light chain variable domain connected by an oligonucleotide encoding a peptide linker. The structural gene is inserted into an 25 expression vector, which is subsequently introduced into a host cell such as *E. coli* which will then synthesize such a single chain Fv. Ample guidance for practicing such methods of producing a single chain Fv is provided in the literature of the art (for example, refer to: Whitlow and Filpula, 1991. Methods 2:97-105; Bird *et al.*, 1988. Science 242:423-426; Pack *et al.*, 1993. Bio/Technology 11:1271-77; and Ladner *et* 30 *al.*, U.S. Pat. No. 4,946,778).

Other methods of cleaving an antibody, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragment

bind to the target antigen that is recognized by the intact antibody.

A polypeptide comprising a complementarity determining region (CDR) peptide of an antibody can be obtained via recombinant techniques using genetic sequences encoding such a CDR, for example, by RT-PCR of mRNA of an antibody-producing cell. Ample guidance for practicing such methods is provided in the literature of the art (for example, refer to Larrick and Fry, 1991. Methods 2:106-10).

It will be appreciated that for human therapy or diagnostics, a humanized antibody or antibody fragment may be advantageously used. Humanized non human (e.g., murine) antibodies are genetically engineered chimeric antibodies or antibody fragments having—preferably minimal—portions derived from non human antibodies. Humanized antibodies include antibodies in which complementary determining regions of a human antibody (recipient antibody) are replaced by residues from a complementarity determining region of a non human species (donor antibody) such as mouse, rat or rabbit having the desired functionality. In some instances, Fv framework residues of the human antibody are replaced by corresponding non human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported complementarity determining region or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the complementarity determining regions correspond to those of a non human antibody and all, or substantially all, of the framework regions correspond to those of a relevant human consensus sequence. Humanized antibodies optimally also include at least a portion of an antibody constant region, such as an Fc region, typically derived from a human antibody (see, for example, Jones *et al.*, 1986. Nature 321:522-525; Riechmann *et al.*, 1988. Nature 332:323-329; and Presta, 1992. Curr. Op. Struct. Biol. 2:593-596). Methods for humanizing non human antibodies or antibody fragments are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non human. These non human amino acid residues are often referred to as imported residues which are typically taken from an imported variable domain. Humanization can be essentially performed as described (see, for example: Jones *et al.*, 1986. Nature 321:522-525; Riechmann *et al.*, 1988. Nature 332:323-327; Verhoeyen *et al.*, 1988. Science 239:1534-1536; U.S. Pat. No. 4,816,567) by substituting human complementarity

determining regions with corresponding rodent complementarity determining regions. Accordingly, such humanized antibodies are chimeric antibodies, wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non human species. In practice, humanized antibodies 5 may be typically human antibodies in which some complementarity determining region residues and possibly some framework residues are substituted by residues from analogous sites in rodent antibodies. Human antibodies or antibody fragments can also be produced using various techniques known in the art, including phage display libraries [see, for example, Hoogenboom and Winter, 1991. *J. Mol. Biol.* 10 227:381; Marks *et al.*, 1991. *J. Mol. Biol.* 222:581; Cole *et al.*, "Monoclonal Antibodies and Cancer Therapy", Alan R. Liss, pp. 77 (1985); Boerner *et al.*, 1991. *J. Immunol.* 147:86-95). Humanized antibodies can also be made by introducing sequences encoding human immunoglobulin loci into transgenic animals, e.g., into 15 mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon antigenic challenge, human antibody production is observed in such animals which closely resembles that seen in humans in all respects, including gene rearrangement, chain assembly, and antibody repertoire. Ample guidance for practicing such an approach is provided in the literature of the art (for example, refer to: U.S. Pat. Nos. 5,545,807, 5,545,806, 5,569,825, 5,625,126, 20 5,633,425, and 5,661,016; Marks *et al.*, 1992. *Bio/Technology* 10:779-783; Lonberg *et al.*, 1994. *Nature* 368:856-859; Morrison, 1994. *Nature* 368:812-13; Fishwild *et al.*, 1996. *Nature Biotechnology* 14:845-51; Neuberger, 1996. *Nature Biotechnology* 14:826; Lonberg and Huszar, 1995. *Intern. Rev. Immunol.* 13:65-93).

Once an antibody or antibody or antibody fragment is obtained, it may be 25 advantageously tested for specific binding to the antigen-presenting portion of the complex, for example via ELISA, using surface-immobilized target complex, as described in further detail hereinbelow, and in the Examples section which follows. Following confirmation of specific binding of the antibody or antibody fragment to the antigen-presenting portion of the complex, various methods may be employed to 30 modify the antibody or antibody fragment to display the desired binding affinity for the antigen-presenting portion of the complex. Such methods include those based on affinity maturation (for example, refer to: Chowdhury, P.S., and Pastan, I., 1999. *Nat. Biotechnol.* 17:568-72).

As described hereinabove, the present invention can be used to treat a disease associated with an infection by a pathogen in an individual by administering a pharmaceutical composition comprising as an active ingredient a composition-of-matter of the present invention.

As used herein a "pharmaceutical composition" refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of active ingredients to an organism.

Herein the term "active ingredients" refers to the composition-of-matter accountable for the biological effect.

Hereinafter, the phrases "physiologically acceptable carrier" and "pharmaceutically acceptable carrier" which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered active ingredients. An adjuvant is included under these phrases.

Herein the term "excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.

Techniques for formulation and administration of drugs may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition, which is incorporated herein by reference.

Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections.

Alternately, one may administer the pharmaceutical composition in a local rather than systemic manner, for example, via injection of the pharmaceutical composition directly into a tissue region of a patient.

Pharmaceutical compositions of the present invention may be manufactured by

processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical compositions for use in accordance with the present invention 5 thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

For injection, the active ingredients of the pharmaceutical composition may be 10 formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

For oral administration, the pharmaceutical composition can be formulated 15 readily by combining the active ingredients with pharmaceutically acceptable carriers well known in the art. Such carriers enable the pharmaceutical composition to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient. Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the 20 resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl- 25 cellulose, sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

Alternately, for oral administration, the pharmaceutical composition may 30 comprise an edible part of a plant containing, for example the immunotoxin of the present invention, as described hereinabove. Hence an individual may consume such an immunotoxin in the form of a plant food endogenously expressing the immunotoxin.

5 Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active ingredient doses.

10 Pharmaceutical compositions which can be used orally, include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in 15 dosages suitable for the chosen route of administration.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

20 For administration by nasal inhalation, the active ingredients for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a 25 powder mix of the active ingredients and a suitable powder base such as lactose or starch.

30 The pharmaceutical composition described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. The compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical compositions for parenteral administration include aqueous

solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes.

5 Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.

10 Alternatively, the active ingredients may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.

The pharmaceutical composition of the present invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.

15 Pharmaceutical compositions suitable for use in context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients (nucleic acid construct) effective to prevent, alleviate or ameliorate symptoms of a disorder (e.g., ischemia) or 20 prolong the survival of the subject being treated.

Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

25 For any preparation used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from *in vitro* and cell culture assays. For example, a dose can be formulated in animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.

30 Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures *in vitro*, in cell cultures or experimental animals. The data obtained from these *in vitro* and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of

administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, *et al.*, 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.1).

5 Dosage amount and interval may be adjusted individually to provide plasma or brain levels of the active ingredients sufficient to exert a desired therapeutic effect (minimal effective concentration, MEC). The MEC will vary for each preparation, but can be estimated from *in vitro* data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.

10 Depending on the severity and responsiveness of the condition to be treated, dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.

15 The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.

20 Compositions of the present invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredients. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions 25 or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as if further 30 detailed above.

It is expected that during the life of this patent many relevant medical diagnostic techniques will be developed and the scope of the phrase "method of detecting" is intended to include all such new technologies *a priori*.

Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as 5 claimed in the claims section below finds experimental support in the following examples.

### ***EXAMPLES***

Reference is now made to the following examples, which together with the 10 above descriptions, illustrate the invention in a non limiting fashion.

Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook *et 15 al.*, (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel *et al.*, "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson *et al.*, "Recombinant DNA", Scientific American Books, New York; Birren *et al.* (eds) "Genome Analysis: A 20 Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J. E., ed. (1994); "Current Protocols in Immunology" Volumes 25 I-III Coligan J. E., ed. (1994); Stites *et al.* (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Selected Methods in Cellular Immunology", W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 30 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; "Oligonucleotide Synthesis" Gait, M. J., ed. (1984); "Nucleic Acid Hybridization" Hames, B. D., and Higgins S. J., eds. (1985); "Transcription and Translation" Hames, B. D., and Higgins S. J., eds. (1984); "Animal Cell Culture" Freshney, R. I., ed.

(1986); "Immobilized Cells and Enzymes" IRL Press, (1986); "A Practical Guide to Molecular Cloning" Perbal, B., (1984) and "Methods in Enzymology" Vol. 1-317, Academic Press; "PCR Protocols: A Guide To Methods And Applications", Academic Press, San Diego, CA (1990); Marshak *et al.*, "Strategies for Protein 5 Purification and Characterization – A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader.

10 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below.

15

#### ***EXAMPLE 1***

*Generation of reagents capable of binding with optimal affinity and specificity particular human APM:pathogen-derived antigen complexes applicable towards optimal diagnosis, characterization, and treatment of human pathogen infections*

20 Diseases associated with a pathogen infection, such as a viral infection, include numerous debilitating or lethal diseases of major medical and economic impact, including influenza, the common cold, and acquired immunodeficiency syndrome (AIDS). One theoretically potent approach which has been proposed for diagnosing, characterizing, and treating such pathogen mediated diseases involves 25 using compounds capable of binding specific human antigen-presenting molecule (APM):pathogen-derived peptide complexes. Such compounds could be used to identify and characterize pathogen infected cells/tissues, or APCs exposed to viral antigens with optimal specificity, to deliver cytotoxic agents with optimal selectivity and efficiency to pathogen infected cells, and to serve as uniquely potent tools for 30 studying pathogen mediated pathogenesis involving viral antigen presentation. However, all prior art approaches of generating compounds capable of specifically binding such complexes have failed to provide compounds capable of binding with optimal affinity/specificity human APM:pathogen-derived antigen complexes. While

reducing the present invention to practice, the present inventors have unexpectedly uncovered such compounds, as follows.

**Materials and Methods:**

**Cell lines and antibodies:** RMA-S-HHD is a TAP2 deficient murine cell line which expresses HLA-A2.1/Db- $\beta_2$ -microglobulin single-chain (Pascolo, S. *et al.*, 1997. *J. Exp. Med.* 185:2043-2051). JY is a TAP and HLA-A2 positive EBV transformed B lymphoblast cell line. APD is an HLA-A2 negative/HLA-A1 positive B cell line. HUT 102 and RSCD4 are HLA-A2 negative and positive, HTLV-1 infected human CD4 positive T-lymphocyte cell lines, respectively.

10 G2D12 is an anti HLA-A2:G9-154 complex Fab used as a negative control (peptide G9-154 is derived from the melanoma specific gp100 protein). Monoclonal antibodies w6/32 and BB7.2 specifically bind correctly folded, peptide bound HLA (pan HLA), and HLA-A2, respectively.

**Production of biotinylated soluble HLA-A2:Tax<sub>11-19</sub> complex:** Soluble biotinylated HLA-A2:Tax<sub>11-19</sub> complex was generated as previously described (Denkberg, G. *et al.*, 2000. *Eur. J. Immunol.* 30:3522-3532). Briefly, a construct was assembled for expression of single chain MHC fusion protein containing HLA-A2.1 (alternately termed HLA-A\*201) fused to  $\beta_2$ -microglobulin, the BirA recognition sequence for site specific biotinylation at the C-terminus, and a hexahistidine tag fused to the CH1 domain of the Fd chain. In this single chain fusion protein, HLA-A2 and  $\beta_2$ -microglobulin are fused via a flexible peptide linker. For expression of this single chain *E. coli*, transformants were generated using the construct, inclusion bodies containing the fusion protein were isolated from the periplasmic fraction of transformants by nickel affinity chromatography, and the fusion protein from inclusion bodies was refolded *in-vitro* in the presence of a 5 to 10 fold molar excess of HLA-A2 restricted peptide so as to generate soluble, correctly folded and assembled HLA-A2:Tax<sub>11-19</sub> complexes. Correctly folded HLA-A2:Tax<sub>11-19</sub> complex was isolated and purified by anion exchange Q-Sepharose chromatography (Pharmacia) followed by site specific biotinylation using the BirA enzyme (Avidity, Denver, CO), as previously described (Altman J.D. *et al.*, 1996. *Science* 274:94-96). The homogeneity and purity of the HLA-A2:Tax<sub>11-19</sub> complex were analyzed by various biochemical means including SDS-PAGE, size exclusion chromatography, and enzyme linked immunosorbent assay (ELISA), as previously described (Denkberg, G.

*et al.*, 2000. Eur. J. Immunol. 30:3522-3532).

**Selection of Fab-phages capable of specifically binding HLA-A2:Tax<sub>11-19</sub> complex:** Selection of Fab-phages (Fab-phages) on surface immobilized biotinylated MHC:peptide complex was performed as previously described (Denkberg, G. *et al.*, 2002. Proc. Natl. Acad. Sci. U. S. A. 99:9421-9426; Lev, A. *et al.*, 2002. Cancer Res. 62:3184-3194). Briefly, a large human Fab library containing  $3.7 \times 10^{10}$  different Fab clones (de Haard, H.J. *et al.*, 1999. J Biol. Chem. 274:18218-18230) was used for the selection. Aliquots of  $10^{13}$  phages were pre incubated with 200 microliters of streptavidin coated paramagnetic beads (Dynal, Oslo) to deplete streptavidin binders. The remaining phages were then panned using decreasing amounts of surface immobilized biotinylated HLA-A2:Tax<sub>11-19</sub> complex as binding target (500 nanomolar for the first round, and 100 nanomolar for the following rounds). Bound phages were eluted with 100 millimolar triethylamine, and the eluate was neutralized with 1 molar Tris-HCl pH 7.4. Neutralized phages were then used to infect *E. coli* TG1 cells (OD<sub>600</sub> = 0.5) by incubation for 30 minutes at 37 degrees centigrade.

The diversity of the selected antibodies was determined by DNA fingerprinting. The Fab DNA of different clones was PCR amplified using the primers pUC-reverse [5'-AGCGGATAACAATTTCACACAGG-3' (SEQ ID NO: 1)] and fd-tet-seq24 [5'-TTTGTCTTCCAGACGTTAGT-3' (SEQ ID NO: 2)] followed by digestion with *Bst*NI (New England Biolabs, U. S. A.) by incubation for 2 hours at 60 degrees centigrade. Reaction products were analyzed by agarose gel electrophoresis.

**Expression and purification of soluble recombinant Fab's:** Fab's were expressed and purified as previously described (Denkberg, G. *et al.*, 2000. Eur. J. Immunol. 30:3522-3532). Briefly, cultures of TG1 or BL21 cells transformed with constructs for expression of Fab's under the control of isopropyl beta-D-thiogalactoside (IPTG) inducible regulatory sequences were grown to OD<sub>600</sub> = 0.8 to 1.0. Cultures were induced to express recombinant Fab by addition of 1 millimolar IPTG and further culturing for 3 to 4 hours at 30 degrees centigrade. Periplasmic content was released using B-PER solution (Pierce), and applied onto a pre-washed TALON column (Clontech). Bound Fab was eluted from the column using 0.5 ml of 100 millimolar imidazole dissolved in phosphate buffered saline solution, and dialyzed twice against phosphate buffered saline solution by overnight incubations at

4 degrees centigrade to remove residual imidazole.

**ELISA of Fab-phage clones and purified Fab's:** The binding specificities of individual Fab-phage clones and soluble Fab's for HLA-A2:Tax<sub>11-19</sub> complex were determined by ELISA using biotinylated HLA-A2:Tax<sub>11-19</sub> complex as binding target.

5     ELISA plates (Falcon) were coated overnight with BSA-biotin (1 microgram/well). Coated plates were washed and incubated for 1 hour at room temperature with streptavidin (1 microgram/well). After extensive washing, the plates were incubated for 1 hour at room temperature with 0.5 microgram of HLA-A2:Tax<sub>11-19</sub> complex. The plates were blocked for 30 minutes at room temperature with 2 percent skim

10 milk-phosphate buffered saline solution, and were subsequently incubated for 1 hour at room temperature with about 10<sup>9</sup> phage clones per well, or with various concentrations of soluble purified Fab. The plates were washed and incubated with horseradish peroxidase conjugated anti human Fab antibody for soluble Fab, or with horseradish peroxidase conjugated anti M13 phage antibody for Fab-phages.

15     Detection was performed using TMB reagent (Sigma). The amino acid sequences of the Tax<sub>11-19</sub> target peptide and of HLA-A2 restricted negative control peptides used for screening the Fab-phage clones or purified Fab's are shown in Table 1.

20     Table 1. HLA-A2 restricted peptides used for screening Fab-phage clones or purified soluble Fab's.

Sequence*	Protein	Peptide position
LLFGYPVYV (SEQ ID NO: 3)	TAX	11-19
LLLTVLTVV (SEQ ID NO: 4)	MUC1-D6	13-21
NLTISDVSV (SEQ ID NO: 5)	MUC1-A7	130-138
NLVPMVATV (SEQ ID NO: 6)	CMV-pp65	495-503
SVRDRRLARL (SEQ ID NO: 7)	EBNA-3A	596-604
ILAKFLHWL (SEQ ID NO: 8)	hTERT	540-548
RLVDDFLLV (SEQ ID NO: 9)	hTERT	865-873
IMDQVPFSV (SEQ ID NO: 10)	Gp100	209-217
YLEPGPVTV (SEQ ID NO: 11)	Gp100	280-288
KTWGQVWQV (SEQ ID NO: 12)	Gp100	154-162
EAAGIGILTV (SEQ ID NO: 13)	MART	26-35

**Production of fluorescent Fab T3F2 tetramer:** The genes encoding the light and heavy chains of Fab T3F2 were cloned separately into a pET expression vector for T7-promoter regulated expression of cloned inserts. The light chain gene was

engineered as a fusion protein including the BirA recognition sequence for site specific biotinylation at the carboxy terminus (T3F2 light-BirA). These constructs were expressed separately in *E. coli* BL21 cells and upon induction with IPTG, intracellular inclusion bodies containing large amounts of the recombinant protein 5 were generated. Inclusion bodies containing the T3F2 chains were purified, solubilized, reduced, and refolded *in-vivo* at a 1:1 ratio in a redox shuffling buffer system containing 0.1 molar Tris-HCl, 0.5 molar arginine, and 90 micromolar oxidized glutathione at pH 8.0. Correctly folded Fab was then isolated and purified by anion exchange MonoQ chromatography (Pharmacia). The Fab peak fractions 10 were concentrated using Centricon-30 (Amicon) to 1 milligram per milliliter and the buffer was exchanged to 10 millimolar Tris-HCl pH 8.0. Biotinylation was performed using the BirA enzyme (Avidity, Denver, CO), as previously described (Denkberg, G. *et al.*, 2000. Eur. J. Immunol. 30:3522-3532; Altman J.D. *et al.*, 1996. Science 274:94-96). Excess biotin was removed from biotinylated Fab using a G-25 desalting 15 column. Phycoerythrin labeled streptavidin (Jackson-Immunoresearch) was added at a molar ratio of 1:4 to produce fluorescent tetramers of the biotinylated Fab.

**Flow Cytometry:** The B cell line RMA-S-HHD transformant expressing HLA-A2-beta<sub>2</sub>-microglobulin, the EBV transformed HLA-A2 positive JY cells, mature human HLA-A2 positive dendritic cells, and the HLA-A2 negative B cell line 20 APD-70 were used to determine the reactivity of the recombinant Fab's with cell surface expressed HLA-A2:Tax<sub>11-19</sub> complex. Peptide pulsing was performed as indicated. Briefly, about 10<sup>6</sup> cells were washed twice with serum-free RPMI and incubated overnight at 26 degrees centigrade or 37 degrees centigrade, respectively, in medium containing 1 to 50 micromolar of the peptide. The RMA-S-HHD cells were 25 subsequently incubated at 37 degrees centigrade for 2 to 3 hours to stabilize cell surface expression of HLA-A2:Tax<sub>11-19</sub> complex.

Alternatively, 20 × 10<sup>6</sup> JY or APD cells were transfected with 20 micrograms of the eukaryotic expression vector pcDNA 3.1 (Invitrogen) encoding the TAX protein cDNA (pcTAX). The cDNA was a kind gift of Drs. M.Yutsudo (Osaka 30 University) and T. Oka, (Okayama University). Twelve to twenty four hours after transfection, cells were incubated for 60 to 90 minutes at 4 degrees centigrade with recombinant Fab (20 microgram per milliliter) in a volume of 100 microliters. After incubation, the primarily labeled cells were washed three times, and incubated with 1

microgram of anti human Fab antibody (Jackson-Immunoresearch). The secondarily labeled cells were then washed three times, and resuspended in ice cold phosphate buffered saline solution. All subsequent washes and incubations were performed under ice cold conditions. The cells were analyzed using a FACStar flow cytometer 5 (Becton Dickinson) and the results were analyzed using WINANOMOLARDI software (Trotter J., <http://facs.scripps.edu>). Flow cytometric analysis of peptide loaded cells was performed as previously described (Denkberg, G. *et al.*, 2002. Proc. Natl. Acad. Sci. U. S. A. 99:9421-9426; Lev, A. *et al.*, 2002. Cancer Res. 62:3184-3194).

10 *Competition binding assays:* Flexible ELISA plates were coated with BSA-biotin and 10 micrograms of HLA-A2:Tax<sub>11-19</sub> complex in a volume of 100 microliters were immobilized, as previously described (Lev, A. *et al.*, 2002. Cancer Res. 62:3184-3194; Cohen, CJ. *et al.*, 2002. Cancer Res. 62:5835-5844). Binding of 15 soluble purified Fab was performed via a competitive binding analysis in which the ability of purified Fab to inhibit the binding of [125]iodine-Fab to specific surface immobilized HLA-A2:Tax<sub>11-19</sub> complex was examined. Recombinant Fab was radiolabeled with [125]iodine using the Bolton-Hunter reagent. The radiolabeled Fab was added to the wells as a tracer ( $3 \times 10^5$  to  $5 \times 10^5$  counts per minute per well) in 20 the presence of increasing concentrations of unlabeled Fab as competitor. Binding assays were performed by incubation at room temperature for 1 hour in phosphate buffered saline solution. After incubation, plates were washed 5 times with phosphate buffered saline solution and bound radioactivity was determined using a gamma counter. The apparent affinity of Fab was determined by extrapolating the 25 concentration of competitor necessary to achieve 50 percent inhibition of binding of [125]iodine labeled Fab to the immobilized HLA-A2:Tax<sub>11-19</sub> complex. Non specific binding was determined by adding a 20- to 40-fold excess of unlabeled Fab.

30 *Enzyme-linked immunohistochemical analysis of specific human MHC:viral peptide complexes:* JY or APD cells were transfected with pcTAX vector, as described above. After 24 hours, transfected cells were incubated with 20 micrograms of horseradish peroxidase (HRP) labeled T3F2 Fab tetramer for 1 hour on ice in RMPI supplemented with 10 percent FCS. The cell suspension was applied onto glass slides precoated with 0.1 percent poly-L-lysine (Sigma), as previously described [Harlow, E., and Lane, D. in: "Antibodies: A Laboratory Manual". Cold

Spring Harbor, Cold Spring Harbor Laboratory Press (1988)], and the slides were incubated for 1 hour at room temperature. Following incubation, the slides were washed three times with phosphate buffered saline solution, and incubated with a DAB+ solution (Dako) for 1 minute followed by washing with phosphate buffered saline solution to remove excess staining reagent.

**5 Expression and purification of soluble recombinant anti HLA-A2:Tax<sub>11-19</sub> complex immunotoxin:** The DNA sequences encoding the heavy and light chain variable domains of T3F2 were recovered from Fab-phage clone by PCR amplification and subcloned using the *Nco*I-*Nol*I fragment into bacterial expression vector pIB-NN, for expression of T3F2-PE38, a single chain immunotoxin consisting of the toxin PE38KDEL fused to a single chain Fv of T3F2 via the carboxy terminus of the light chain variable region. Toxin PE38KDEL consists of the translocation and ADP-ribosylation domains of *Pseudomonas* exotoxin A. Expression in BL21 IDE3 cells, refolding from inclusion bodies, and purification of the T3F2-PE38 was 10 performed as previously described (Brinkmann U. *et al.*, 1991. Proc. Natl. Acad. Sci. 15 U. S. A. 88:8616-20).

**Experimental Results:**

**Generation of anti HLA-A2:Tax<sub>11-19</sub> complex antibodies:** The immune response in HTLV-1 infected patients carrying the MHC class I allele HLA-A2 is primarily directed against the HLA-A2 restricted Tax protein-derived Tax<sub>11-19</sub> peptide by clonal expansion of HTLV-1 reactive CD8 positive T-lymphocytes.

Recombinant HLA-A2:Tax<sub>11-19</sub> complex was generated using a previously described single chain MHC-beta<sub>2</sub>-microglobulin fusion protein expression construct (Denkberg, G. *et al.*, 2000. Eur. J. Immunol. 30:3522-3532). Using this construct, the 20 extracellular domains of HLA-A2 are fused to beta<sub>2</sub>-microglobulin using a flexible 15 amino acid long peptide linker. The HLA-A2:Tax<sub>11-19</sub> complex was produced by *in-vitro* refolding of inclusion bodies in the presence of Tax<sub>11-19</sub> peptide. The refolded HLA-A2:Tax<sub>11-19</sub> complex was found to be very pure, homogenous, and monomeric, as determined by SDS-PAGE and size-exclusion chromatography analyses (data not 25 shown). Recombinant HLA-A2:Tax<sub>11-19</sub> complex generated by this strategy has been previously characterized in detail with respect to its biochemical, biophysical, and biological properties, and was found to be correctly folded and functional [Denkberg, G. *et al.*, 2000. Eur. J. Immunol. 30:3522-3532; Harlow, E., and Lane, D. in:

"Antibodies: A Laboratory Manual". Cold Spring Harbor: Cold Spring Harbor Laboratory Press (1988)].

For selection of antibodies capable of specifically binding a specific MHC:peptide complex, a large Fab-phage library consisting of a repertoire of  $3.7 \times 10^{10}$  recombinant human Fab's (de Haard, H.J. *et al.*, 1999. *J. Biol. Chem.* 274:18218-18230) was used. Due to exposure of the Fab's to streptavidin coated plates during selection, the library was first depleted of streptavidin binders, and subsequently used for panning soluble recombinant HLA-A2:Tax<sub>11-19</sub> complex. A 1,300 fold enrichment in phage titer was observed after three rounds of panning (Table 2). The specificity of the selected Fab-phages was determined by a differential ELISA using streptavidin coated wells incubated with biotinylated HLA-A2 in complex with either the Tax<sub>11-19</sub> peptide or negative control HLA-A2 restricted peptides. Phage clones analyzed following the third round of selection exhibited two types of binding patterns toward the HLA-A2:Tax<sub>11-19</sub> complex; one class of antibodies consisted of pan MHC binders which cannot differentiate between the various specific MHC:peptide complexes; the second type consisted of antibodies that specifically bound the HLA-A2:Tax<sub>11-19</sub> complex. The ELISA screen revealed that 87 percent of randomly selected clones (78/90) screened from the third round of panning appeared to specifically bind the HLA-A2:Tax<sub>11-19</sub> complex.

20

*Table 2. Screening of Fab-phages for anti HLA-A2:Tax<sub>11-19</sub> complex Fab's.*

Cycle	Phage input (I)	Phage output (O)	Ratio (O/I)	Fold enrichment	MHC:peptide complex binders	Fraction MHC:peptide complex binders	No. of Fab's
1	$7.2 \times 10^{12}$	$9.6 \times 10^5$	$1.3 \times 10^{-7}$	—	—	—	—
2	$5.8 \times 10^{13}$	$1.1 \times 10^7$	$1.9 \times 10^{-7}$	1.5	15/90 (17 %)	10/90 (11 %)	6
3	$5.2 \times 10^{13}$	$8.7 \times 10^9$	$1.7 \times 10^{-4}$	1,300	78/90 (87 %)	56/90 (62 %)	14

However, an unexpectedly high percentage of Fab's, 62 percent (56/90), were fully Tax<sub>11-19</sub> peptide dependent for binding and specific for HLA-A2:Tax<sub>11-19</sub> complex when tested as Fab-phages in ELISAs using various HLA-A2:control peptide complexes as binding targets. As shown in Table 2, 62 percent of the clones bound only to the HLA-A2:Tax<sub>11-19</sub> complex and not to negative control complexes containing other HLA-A2 restricted peptides. Such clones thus exhibited an MHC restricted peptide specific binding similar to T-cell receptors (TCRs). These apparent

HLA-A2:Tax<sub>11-19</sub> complex specific clones remained specific for HLA-A2:Tax<sub>11-19</sub> complex in a secondary screening using HLA-A2 complexed with other HLA-A2 restricted peptides (listed under Materials and Methods). Figure 1 shows a representative analysis of four Fab clones which reacted only with the HLA-A2:Tax<sub>11-19</sub> complex and not with HLA-A2:negative control peptide complexes displaying melanoma gp100 and MART-1-derived epitopes, and the MUC1-derived D6 epitope.

The diversity pattern of the peptide specific clones (from round two or three) was examined by DNA fingerprint analysis. Twenty different restriction patterns (6 for clones isolated from the second round of panning, and 14 different patterns after the third round of selection) were found, indicating successful selection of several different Fab's capable of specifically binding HLA-A2:Tax<sub>11-19</sub> complex. DNA sequencing analysis confirmed these observations. The variable heavy and variable light chain complementarity determining region sequences of 14 clones specific for HLA-A2:Tax<sub>11-19</sub> complex are shown in Table 3.

15

*Table 3. Amino acid sequences of complementarity determining regions of Fab's specifically binding HLA-A2:Tax<sub>11-19</sub> complex.*

Fab	Chain	CDR1	CDR2	CDR3
T3E3	H	SYTIS (SEQ ID NO: 14)	GIIPIFGTANYAQKFQG (SEQ ID NO: 15)	DTDSSGYYGAVDY (SEQ ID NO: 16)
	L	RASQSVGSYLA (SEQ ID NO: 17)	DASHRAT (SEQ ID NO: 18)	QRQSNWPPMYT (SEQ ID NO: 19)
T3F2	H	SYGMH (SEQ ID NO: 20)	VISYDGSNKYYADSVKG (SEQ ID NO: 21)	DFDYGDSYYYYGMDV (SEQ ID NO: 22)
	L	RSSQSLLHSNGY (SEQ ID NO: 23)	LGSNRAS (SEQ ID NO: 24)	MQALQTPRT (SEQ ID NO: 25)
T3D4	H	NYGIN (SEQ ID NO: 26)	WISAYNGDTKYAQRLQD (SEQ ID NO: 27)	GDSTVGYEYLQY (SEQ ID NO: 28)
	L	QASQGIGKYLN (SEQ ID NO: 29)	VASSLQS (SEQ ID NO: 30)	QQTSSFPPT (SEQ ID NO: 31)
T3D3	H	SYAIS (SEQ ID NO: 32)	RIIPILGIANYAQKFQG (SEQ ID NO: 33)	QGGDYSNYYYYMDV (SEQ ID NO: 34)
	L	RASQSVSSYLA (SEQ ID NO: 35)	DASN RAT (SEQ ID NO: 36)	QHRFNWPVT (SEQ ID NO: 37)
T3D1	H	SYGMH (SEQ ID NO: 38)	VISYDGSNKYYADSVKG (SEQ ID NO: 39)	DQTYYGSGSPRGGLDY (SEQ ID NO: 40)
	L	TGSSGSIANNYVQ (SEQ ID NO: 41)	EDDQRPS (SEQ ID NO: 42)	QSYDNSNSFVV (SEQ ID NO: 43)

Table 3, continued...

T2B12	H	SNSAAWN (SEQ ID NO: 44)	RTYYRSKWKYNDYVSVKS (SEQ ID NO: 45)	GPYDTTGPWGNWFDP (SEQ ID NO: 46)
	L	RASQSVSSDLA (SEQ ID NO: 47)	GASYRAT (SEQ ID NO: 48)	QQYGSSPRT (SEQ ID NO: 49)
T2G7	H	SYGMH (SEQ ID NO: 50)	VISYDGSNKYYADSVKG (SEQ ID NO: 51)	DFDYGDSYYYYGMDV (SEQ ID NO: 52)
	L	RSSQSLLHSNGYNYLD (SEQ ID NO: 53)	LGSNRAS (SEQ ID NO: 54)	MQALQTPRT (SEQ ID NO: 55)
T2H9	H	SYAMS (SEQ ID NO: 56)	AISGGGSTYYADSVKG (SEQ ID NO: 57)	DSLADATGTDY (SEQ ID NO: 58)
	L	RASQTVTANYLA (SEQ ID NO: 59)	DASVRAT (SEQ ID NO: 60)	QQYGSSPIT (SEQ ID NO: 61)
T3A2	H	SYAMS (SEQ ID NO: 62)	GISGGGSTYYADSVKG (SEQ ID NO: 63)	DFDYGGNSGSLFDY (SEQ ID NO: 64)
	L	GASESVGGNYLA (SEQ ID NO: 65)	DASTRAT (SEQ ID NO: 66)	QHYGSSPSTY (SEQ ID NO: 67)
T3A4	H	SSNWWS (SEQ ID NO: 68)	EIYHSGSTNYNPSLKS (SEQ ID NO: 69)	HSYDYLWGTYRFDY (SEQ ID NO: 70)
	L	RASQDIGTWLA (SEQ ID NO: 71)	AATTLES (SEQ ID NO: 72)	QQARSLPYT (SEQ ID NO: 73)
T3B5	H	NYGIN (SEQ ID NO: 74)	WISAYNGDTKYAQRLQD (SEQ ID NO: 75)	GDSTVGYEYLQY (SEQ ID NO: 76)
	L	QASQGIGKYLN (SEQ ID NO: 77)	VASSLQS (SEQ ID NO: 78)	QQTSSFPPT (SEQ ID NO: 79)
T4B7	H	SYGMH (SEQ ID NO: 80)	VISYDGSNKYYADSVKG (SEQ ID NO: 81)	DYNGYGDYVLGY (SEQ ID NO: 82)
	L	RASQSVSSYLA (SEQ ID NO: 83)	DASN RAT (SEQ ID NO: 84)	QQRSNWASYT (SEQ ID NO: 85)
T4D10	H	SYYMH (SEQ ID NO: 86)	IINPSGGSTS YAQKFQG (SEQ ID NO: 87)	DRGGGYDVSPYGM DV (SEQ ID NO: 88)
	L	RASQSISSYLN (SEQ ID NO: 89)	AASN LQT (SEQ ID NO: 90)	QQTYSLPT (SEQ ID NO: 91)
T4B12	H	SYAIS (SEQ ID NO: 92)	GIIPIPGITNYAQKFQG (SEQ ID NO: 93)	RVGYYYGM DV (SEQ ID NO: 94)
	L	AGSGGDIASNFVQ (SEQ ID NO: 95)	EENRRPS (SEQ ID NO: 96)	QSYDGS AW (SEQ ID NO: 97)

H – heavy chain, L – light chain

*Specificity and affinity of anti HLA-A2:Tax<sub>11-19</sub> complex Fab's: Using E.*

5 *coli* BL21 or TG1 cells, soluble Fab's from 3 phage clones exhibiting the most specific binding pattern to HLA-A2:Tax<sub>11-19</sub> complex (analyzed above, Figure 1) were produced.

SDS-PAGE analysis of Fab's purified from the periplasmic fraction of *E. coli* transformants by nickel affinity chromatography revealed homogenous, pure Fab's 10 with the expected molecular weight of 50 kDa (Figure 2a). Quantities of 2 to 4

milligrams of pure Fab was obtained from 1 liter of bacterial shake flask culture. For further manipulation; i.e. to increase the avidity of monomeric Fab's, the Fab's were also produced by *in-vitro* refolding. The light chain and Fd fragment (truncated portion of the heavy chain consisting of the variable region and the CH1 domain of the constant region) were subcloned into pET based expression vectors for T7 promoter regulated expression of cloned inserts, and upon induction with IPTG, large amounts of recombinant protein accumulated as intracellular inclusion bodies (Figure 2b). Upon *in-vitro* redox shuffling refolding, purified monomeric Fab's were obtained in high yield (4 to 6 milligrams of purified Fab was obtained from two 1 liter shake flask cultures, each expressing the Fab light or Fd fragment; Figure 2c).

The fine specificity of the soluble Fab's for HLA-A2:Tax<sub>11-19</sub> complex was analyzed by ELISA using biotinylated HLA-A2:Tax<sub>11-19</sub> complex immobilized to BSA-streptavidin coated wells. The BSA-streptavidin-biotin spacer enables the correct folding of the complex, which may be distorted by direct binding to plastic. To verify correct folding of the bound complex and its stability during binding assays, the ability of the bound complex to react with the conformation specific monoclonal antibody w6/32 which exclusively recognizes correctly folded, peptide complexed HLA was monitored. Figures 3a-c show specific binding of soluble Fab's T3D4, T3E3, and T3F2, respectively, to HLA-A2:Tax<sub>11-19</sub> complex, but not to 10 control HLA-A2:peptide complexes containing viral epitopes derived from CMV or EBV, and a variety of tumor associated epitopes such as telomerase epitopes (540, 865), melanoma gp100 and MART-1-derived epitopes (154,209,280 and MART, respectively), and the MUC1-derived epitopes A7 and D6 (see experimental procedures for list of peptides). Thus, these anti specific MHC:peptide complex Fab's exhibit the binding characteristics and fine specificity of a TCR. In control experiments, the Fab's did not recognize the Tax<sub>11-19</sub> peptide alone when immobilized on the plate, nor immobilized streptavidin or other protein antigens such as BSA, IgG, RNase, or chymotrypsin (data not shown).

The binding affinity properties of two of the soluble Fab's were tested using a saturation ELISA assay using addition of increasing amounts of Fab's to biotinylated HLA-A2:Tax<sub>11-19</sub> bound to streptavidin coated plates. As shown in Figures 4a-b, the binding of Fab's T3E3 and T3F2, respectively, was dose dependent and saturable. Extrapolating the 50 percent binding signal of either fragment revealed

that their affinity was in the nanomolar range.

Finally, the apparent binding affinity of the Fab's for HLA-A2:Tax<sub>11-19</sub> complex was determined using a competition binding assay in which the binding of [125]iodine labeled Fab was competed with increasing concentrations of unlabeled Fab's. These binding studies (Figure 4c) revealed an apparent binding affinity of approximately 25 to 30 nanomolar for the T3F2 antibody. Similar results were observed for the T3E3 antibody (not shown).

***Detection of HLA-A2:Tax<sub>11-19</sub> complex on peptide pulsed antigen-presenting cells (APCs):*** To demonstrate that the isolated Fab's can specifically bind HLA-A2:Tax<sub>11-19</sub> complex not only in the recombinant soluble form but also in the native form, as expressed on the cell surface, murine TAP2 deficient RMA-S cells transfected with the human HLA-A2 gene in a single chain format (Pascolo, S. *et al.*, 1997. *J. Exp. Med.* 185:2043-2051) (HLA-A2.1/Db-beta<sub>2</sub>-microglobulin single chain, RMA-S-HHD cells). The Tax<sub>11-19</sub> peptide and HLA-A2 restricted control peptides were loaded on RMA-S-HHD cells and the ability of the selected Fab's to bind to peptide loaded cells was monitored by flow cytometry. Peptide induced MHC stabilization of the TAP2 mutant RMA-S-HHD cells was demonstrated by reactivity of monoclonal antibodies w6/32 (HLA conformation dependent) and BB7.2 (HLA-A2 specific) with peptide loaded but not unloaded cells (data not shown). Fab's T3E3 and T3F2 reacted only with Tax<sub>11-19</sub> peptide loaded RMA-S-HHD cells but not with cells loaded with the gp100-derived G9-154 peptide (Figures 5a-b, respectively). Similar results were observed using flow cytometric analysis using 10 other HLA-A2 restricted control peptides (data not shown).

Cells of the TAP and HLA-A2 positive EBV transformed B lymphoblast cell line JY were also used as APCs. The cells were incubated with Tax<sub>11-19</sub> peptide, and HLA-A2 restricted control peptides, and following incubation the cells were washed and incubated with the Fab's. The T3E3 or T3F2 Fab's were found to bind only to JY cells incubated with the Tax<sub>11-19</sub> peptide against which they were selected but not to HLA-A2 restricted control peptides (Figures 5c-d, respectively). As a control, peptide loaded HLA-A2 negative/HLA-A1 positive APD B cells were also used. No binding of the Fab's to these cells was observed (data not shown). Fab's T3E3 and T3F2 were also tested for binding to peptide pulsed mature HLA-A2 positive dendritic cells. As shown in Figures 5e-f, respectively, the T3E3 and T3F2 Fab's recognized HLA-A2

positive dendritic cells pulsed with Tax<sub>11-19</sub> peptide but not with a control gp100-derived peptide.

The Fab's were modified for detection of MHC:peptide complex on the surface of cells. Since the density of a particular endogenous HLA:peptide complex on cells is expected to be low compared to that of peptide pulsed APCs, the avidity of Fab T3F2 was increased by making Fab tetramers, which are directly tagged with a fluorescent probe. This approach was used previously to increase the binding avidity of MHC:peptide complexes to TCRs or to increase the sensitivity of recombinant antibody molecules (Cloutier, S.M. *et al.*, 2000. Mol. Immunol. 37:1067-1077).  
10 Another advantage of using fluorescently labeled tetramers is that only a single staining step is required, whereas monomeric unlabeled Fab's require a fluorescently labeled secondary antibody. The Fab tetramers generated with fluorescently labeled streptavidin were thus used to measure the expression of HLA-A2:Tax<sub>11-19</sub> complex on the surface of peptide pulsed APCs. As shown in Figures 6a-c, the intensity of the  
15 binding as measured by flow cytometry with peptide pulsed RMA-S-HHD (Figure 6a), JY cells (Figure 6b), and human dendritic cells (Figure 6c), was dramatically increased by two logs compared to the staining intensity with the T3F2 Fab monomer.

Unexpectedly, the staining pattern of the mature HLA-A2 positive dendritic cells was found to be scattered over a wide range of fluorescence intensities, indicating for the first time that dendritic cell populations display heterogeneous levels of specific MHC:peptide complexes at the cell surface. Such results therefore indicate the potency of the Fab's such as those described herein for studying the biology of specific MHC:peptide complex presentation by APCs.

In particular, these results demonstrate the ability of the Fab's to detect cell  
25 surface displayed HLA-A2:Tax<sub>11-19</sub> complex.

*Cell surface detection of HLA-A2:Tax<sub>11-19</sub> complex formed by intracellular antigen processing:* To examine the ability of the Fab's to detect HLA-A2:Tax<sub>11-19</sub> complex produced by physiological antigen processing, the HTLV-1 Tax gene was transfected into HLA-A2 positive and negative JY or APD cells, respectively.  
30 Twenty four hours following transfection, the reactivity of T3F2 to cell surface displayed HLA-A2:Tax<sub>11-19</sub> complex was tested by flow cytometry. The analysis was performed using the high avidity tetrameric Fab T3F2. Positive staining above control could be clearly seen only with HLA-A2 positive JY cells transfected with the

Tax gene but not with HLA-A2 negative cells transfected with the Tax gene (Figures 7a-b, respectively). Negative control Fab G2D12 specific for HLA-A2:G9-154 complex did not react with the Tax transfected JY cells (Figure 7a). The Tax<sub>11-19</sub> peptide specific, MHC restricted pattern of reactivity by T3F2 was not due to 5 differences in transfection efficiency, or HLA expression of JY and APD cells. As determined via control experiments employing transfection of green fluorescent protein (GFP) into these cells, the percentage of transfected cells with both cell lines using the same transfection protocol used for expression of Fab was similar (Figure 10 7c), and the staining intensity of these cells with w6/32, a pan MHC monoclonal antibody, was similar (data not shown). These results indicate that the Fab's are capable of detecting HLA-A2:Tax<sub>11-19</sub> complex formed by intracellular antigen processing.

The use of Fab T3F2 for detecting HLA-A2:Tax<sub>11-19</sub> complex on virus infected cells was attempted. To this end, HLA-A2 negative HUT 102 and HLA-A2 positive 15 RSCD4 cells (human CD4 positive T-lymphocyte cell lines infected with HTLV-1) were used. As shown in Figure 7d, a significant staining with Fab T3F2 was observed on RSCD4 but not on HUT 102 cells, indicating that the Fab is capable of detecting the specific HLA-A2:Tax<sub>11-19</sub> complex on the surface of virus infected cells. Unexpectedly, the staining pattern revealed two cell subpopulations having moderate 20 or high reactivity, respectively, with the Fab, which may indicate variability in the expression of the HLA-A2:Tax<sub>11-19</sub> complex within subpopulations of RSCD4 HTLV-1 infected cells. Similar variability was observed in staining experiments with an anti Tax protein antibody (not shown). Negative control Fab G2D12 specific for HLA-A2:G9-154 complex did not stain RSCD4 cells (Figure 7d).

25 These results underscore the utility of anti specific MHC:peptide complex Fab's, in particular that of the above described anti HLA-A2:Tax<sub>11-19</sub> complex fragments, for the study of antigen presentation on APCs as well as virus infected cells.

*30 High sensitivity detection and direct quantitation of surface expressed HLA-A2:Tax<sub>11-19</sub> complex on APCs and virus infected cells:* The data presented above demonstrate the high specificity of the HLA-A2:Tax<sub>11-19</sub> complex specific Fab's as well as their ability to detect naturally processed Tax<sub>11-19</sub> peptide complexed with HLA-A2. The sensitivity of specific MHC:peptide recognition by the Fab's *in-vitro*

was tested by staining with Fab T3F2 was tested over a broad range of Tax<sub>11-19</sub> peptide concentrations. As shown in Figures 8a-b, titration of peptide pulsed JY cells using graded concentrations of Tax<sub>11-19</sub> peptide demonstrated staining intensity dependent on the concentration of the peptide used for pulsing, and that the Fab was capable of detecting HLA-A2-Tax<sub>11-19</sub> complex when pulsing Tax<sub>11-19</sub> peptide at a concentration in the low nanomolar range. The staining intensity of peptide pulsed JY cells observed with T3F2 Fab was estimated by comparison to calibration beads displaying graded numbers of phycoerythrin molecules. This comparison enabled determination of the number of HLA-A2:Tax<sub>11-19</sub> complexes displayed on the surface of cells that are pulsed with various concentrations of the Tax<sub>11-19</sub> peptide (Figure 8a and Table 2). Specific detection of as few as 100 HLA-A2-Tax<sub>11-19</sub> complexes per cell was achieved (using 6 nanomolar Tax<sub>11-19</sub> peptide pulsing) and reached saturation at about  $1.1 \times$  to  $1.2 \times 10^5$  complexes per cell when pulsing with 25 to 50 micromolar Tax<sub>11-19</sub> peptide.

These results therefore demonstrate that the sensitivity of specific MHC:peptide complex detection by T3F2 Fab is in the same range as the minimal concentration peptide needed to elicit measurable cytokine secretion (IL-2 or IFN-gamma) from T-lymphocyte hybridomas or target T-lymphocyte lysis by CD8 positive cytotoxic T-lymphocyte lines (Reis e Sousa, C., and Germain, R.N., 1995. J. Exp. Med. 182:841-851; Reis e Sousa, C. *et al.*, 1996. J. Exp. Med. 184:149-157).

A major problem hampering the study of MHC dependent antigen presentation is the unavailability of adequate methods for quantifying surface expression levels on individual cells of specific MHC:peptide complexes produced by intracellular antigen processing. Using flow cytometric analysis of cell surface display of HLA-A2:Tax<sub>11-14</sub> complex using Fab T3F2 and comparison of the fluorescence intensity of T3F2 stained cells with that of calibration beads displaying graded numbers of phycoerythrin sites, it was possible to quantitate the number of specific HLA-A2:Tax<sub>11-19</sub> complexes on the cell surface (Table 4). Namely, JY cells pulsed with 1.5 micromolar Tax<sub>11-19</sub> peptide displayed on their surface  $5 \times 10^3$  complexes per cell, while JY cells transfected with the Tax gene displayed on their surface, after intracellular antigen processing,  $1 \times 10^4$  complexes per cell. The latter result is in complete agreement with recent quantitation of murine H-2<sup>k<sup>b</sup></sup> bound to the ovalbumin peptide SIINFEKL after recombinant *Vaccinia* virus infection of cells *in-vitro* using

an anti specific mouse MHC:peptide complex antibody (Porgador, A. *et al.*, 1997. *Immunity* 6:715-726). As shown in Figure 7d and Table 4, direct detection of HLA-A2:Tax<sub>11-19</sub> complex on HTLV-1 infected cells enabled quantification of the number of complexes displayed on these cells. This analysis, using calibration beads, 5 revealed that virus infected RSCD4 cells display on their surface about  $3 \times 10^4$  HLA-A2:Tax<sub>11-19</sub> complexes per cell. As demonstrated in Figure 7d, Fab T3F2 recognized two subpopulations of HTLV-1 infected RSCD4 cells with high and moderate reactivity. The highly reactive cells express on their surface  $3 \times 10^4$  HLA-A2:Tax<sub>11-19</sub> complexes while the cell population with low to moderate staining intensity expresses 10 several hundred HLA-A2:Tax<sub>11-19</sub> complexes. These results clearly demonstrate the power of such anti specific MHC:peptide complex Fab's to quantitate specific MHC:peptide complex expression on each cell in a population.

15 **Table 4. Quantitation of the number of HLA-A2:Tax<sub>11-19</sub> complexes on the surface of APCs and HTLV-1-infected cells**

Cells	Mean number of sites per cell*
JY (50 mM peptide pulsed)	120,132 $\pm$ 16,934
JY (1.5 mM peptide pulsed)	5,150 $\pm$ 691
JY (Tax-transfected)	12,746 $\pm$ 2,877
RSCD4 (CD4 positive T-cells, HTLV-1-infected)	High: 32,820 $\pm$ 4,910 Low: 456 $\pm$ 72
Background**	32 $\pm$ 13

20 The fluorescence intensity of stained cells in each experiment was compared with fluorescence intensities of calibration beads with known numbers of phycoerythrin (PE) molecules per bead (QuantiBRITE PE beads, Becton-Dickinson) and the number of sites for each experiment was determined. The mean number of non specific sites was determined by the intensity of staining of cells that are HLA-A2 positive but not infected with HTLV-1, HLA-A2 negative cells infected with HTLV-1, or APCs not transfected with the Tax gene. The number of specific sites for each experiment was then calculated for each experiment. The deviation in number of sites depend on the sensitivity of detection and the physiological status of the cells in each individual determination.

25 \*\* The background number of sites was determined as described, using SK-BR3 (HLA-A2 negative/HUT102), FM3D (HLA-A2 positive), and JY (HLA-A2 positive) cells not transfected with the Tax gene as controls.

**Detection of cells displaying HLA-A2:Tax<sub>11-19</sub> complex in a heterogeneous cell population:** At present, there are no reagents available for detecting and 30 phenotyping individual cells displaying specific MHC:peptide complexes in mixed cell populations. Such reagents would have great utility, for example, for detecting or staging tumorigenic cells, or for studying antigen presentation in lymphoid tissues within heterogeneous cell populations. The anti specific MHC:peptide complex Fab's

described above would be ideally suited to conduct such analyses. To simulate a heterogeneous population of cells in which only a small fraction expresses a specific MHC:peptide complex, Tax transfected and control non transfected JY cells were mixed in various ratios, and the reactivity of T3F2 Fab to such cells was analyzed by flow cytometry. As shown in Figure 8c, single color flow cytometric analysis using T3F2 Fab allows accurate identification of the admixed Tax transfected JY cells that express on their surface HLA-A2:Tax<sub>11-19</sub> complex generated by intracellular antigen processing. T3F2 Fab was shown to be able to detect Tax transfected JY cells in a proportion as low as 1 percent within a population of non transfected cells (Figures 8c-d), as demonstrated by the ability to detect 0.5 percent of positive cells (calculated from a maximal 61.2 percent transfection efficiency of JY cells; Figure 8d).

These results demonstrate the ease with which anti specific MHC:peptide complex Fab's can reveal a cell subpopulation bearing a specific endogenously generated MHC:peptide complex.

*15 Immunohistochemical detection of cells displaying HLA-A2:Tax<sub>11-19</sub> complex generated by intracellular antigen processing:* Another major potential use for anti specific MHC:peptide complex antibodies is *in situ* immunohistochemical analysis of specific MHC:peptide complexes in tissues. As a first step to assess this potential, the capacity of T3F2 Fab to detect *in situ* HLA-A2:Tax<sub>11-19</sub> complex displayed on JY cells by intracellular antigen processing was determined. Tax transfected JY cells were subjected to single step immunohistochemical analysis using horseradish peroxidase conjugated T3F2 Fab. As shown in Figures 9a-f, these experiments showed the capacity of the Fab to strongly and specifically stain Tax transfected (Figures 9a-b) but not control non transfected JY cells (Figure 9c).  
20 Negative control Fab G2D12 specific for HLA-A2:G9-154 complex did not exhibit any significant immune reactivity on Tax transfected JY cells (Figure 9d). Further evidence for the specific, MHC restricted reactivity of Fab T3F2 in these *in situ* immunohistochemistry experiments is provided by the lack of reactivity of the Fab with Tax transfected (Figure 9e) and non transfected (Figure 9f) HLA-A2 negative/HLA-A1 positive APD cells. These data demonstrate the capacity of the T3F2 Fab to specifically detect HLA-A2:Tax<sub>11-19</sub> complex generated by intracellular antigen processing *in situ* on cells and potentially in tissue sections. To the present inventors' knowledge, this is the first demonstration of *in situ* detection of a specific

human MHC:peptide complex.

**Specific cytolysis of cells displaying HLA-A2:Tax<sub>11-19</sub> complex by T3F2-PE38 immunotoxin:** The capacity of an anti specific human MHC:viral peptide complex immunotoxin to cytolise cells displaying such a complex was determined by 5 testing the capacity of T3F2-PE38 to kill/damage peptide loaded APCs. The killing assay was performed by loading JY cells with Tax<sub>11-19</sub> peptide, or control HLA-A2 restricted peptides, including the gp100-derived G9-209 peptide. As shown in Figure 10, T3F2-PE38 was capable of killing JY cells loaded with Tax<sub>11-19</sub> peptide with an IC<sub>50</sub> of 2,500 nanograms per milliliter. No T3F2-PE38 mediated cytolysis of JY cells 10 loaded with control HLA-A2 restricted peptides, or of cells not loaded with peptide occurred.

Thus, the capacity to specifically and efficiently kill/damage target cells displaying a specific human MHC:viral peptide complex using cytotoxic conjugates targeted using an antibody specific for such a complex was demonstrated for the first 15 time.

**Discussion:** The above described results demonstrate for the first time generation of recombinant antibody-derived molecules, such as Fab's, capable of specifically binding specific human MHC:pathogen-derived peptide complexes, such as MHC:viral peptide complexes, and of cytotoxic conjugates including such 20 molecules to specifically kill/damage cells displaying such complexes. Until now, anti specific MHC:pathogen-derived peptide complex antibodies have been generated against murine forms of such complexes only (Andersen, P.S. *et al.*, 1996. Proc. Natl. Acad. Sci. U. S. A 93:1820-1824; Day, P.M. *et al.*, 1997. Proc. Natl. Acad. Sci. U. S. A. 94:8064-8069; Porgador, A. *et al.*, 1997. Immunity 6:715-726; Reiter, Y. *et al.*, 25 Proc. Natl. Acad. Sci. U. S. A. 94:4631-4636).

These novel molecules exhibit high affinity, high specificity binding to specific human MHC:pathogen-derived peptide complexes, and hence display TCR like specificity for such complexes. However, in contrast to the inherently low affinity of TCRs for MHC:peptide complexes, these molecules display the high 30 affinity antigen binding characteristics of antibodies, while retaining TCR specificity. By virtue of such characteristics, such molecules have very promising utility in the numerous diagnostic, therapeutic and scientific applications which would benefit from the capacity to specifically label or target specific human MHC:pathogen-derived

peptide complexes such as those comprising viral peptides.

Crucial features of these Fab's were identified, including the capacity to: (a) bind with high sensitivity and specificity particular human MHC:pathogen-derived peptide complexes, such as HLA-A2:Tax<sub>11-19</sub> complex, expressed or displayed by 5 cells which are infected with a pathogen such as HTLV-1, peptide loaded, in suspension, and/or surface immobilized using immunohistochemical techniques; and (b) the capacity to deliver molecules, such as toxins, to cells displaying a specific human MHC:pathogen-derived peptide complex, such as HLA-A2:Tax<sub>11-19</sub> complex.

An important feature of these molecules is their capacity to detect specific 10 human MHC:pathogen-derived peptide complexes at surface densities near the threshold limit required for triggering signaling via the TCR. Studies from other laboratories using a monoclonal antibody specific for mouse MHC class I (H-2K<sup>b</sup>) in complex with an ovalbumin peptide indicated that the lower limit of sensitivity of flow cytometry detection is in the range of 100 to 500 specific MHC:peptide 15 complexes per cell using single step or sandwich staining techniques (Porgador, A. *et al.*, 1997. *Immunity* 6:715-726). The data presented herein for anti specific human MHC:pathogen-derived peptide Fab's are in good agreement with these numbers since the HLA-A2:Tax<sub>11-19</sub> complex specific Fab was able to detect in a reproducible manner as few as 100 complexes per cell. These numbers agree with several 20 estimates of the threshold number of specific MHC:peptide complexes on APCs required to elicit effector responses from T-lymphocytes, such as cytokine secretion (Demotz, S. *et al.*, 1990. *Science* 249:1028-1030; Harding, C.V., and Unanue, E.R., 1990. *Nature* 346:574-576), and are about 10 fold greater than what may be required 25 for cytotoxic T-lymphocyte mediated cell lysis (Christinck ER. *et al.*, 1991. *Nature* 352:67-70; Sykulev Y. *et al.*, 1996. *Immunity* 4:565-71). Using flow cytometry, it was possible to use an anti specific human MHC:pathogen-derived peptide complex 30 Fab to detect such complexes on cells pulsed with peptide concentrations being similar to those required to trigger cytokine secretion by T-lymphocyte hybridoma or cytotoxic T-lymphocyte lines, and being within a few fold of concentrations required for sensitizing target T-lymphocytes for lysis in a short term assay by APCs (Porgador, A. *et al.*, 1997. *Immunity* 6:715-726). The presently described data indicate that when applied to dissociated cell populations using flow cytometry, the Fab's can detect specific human MHC:pathogen-derived peptide complexes at

densities approaching those required for activating T-lymphocytes. Hence these molecules are suitable reagents for evaluating specific human MHC:pathogen-derived peptide complex expression at low but physiologically relevant levels.

This principle was applied here to mixtures of the parental JY APCs and its 5 Tax gene transfected derivative. The latter intracellularly processes Tax antigens and displays the relevant HLA-A2:Tax<sub>11-19</sub> complex at the cell surface, as demonstrated by positive staining of Tax transfected but not control cells using T3F2 Fab. Even when using T3F2 Fab in a single step staining for flow cytometry, it was possible to readily identify Tax transfected cells admixed with non transfected JY cells in a 10 proportion as low as 1 percent. The extreme ease with which precise quantitation of cell surface expressed specific human MHC:pathogen-derived peptide complexes can be accomplished using this approach also makes it an invaluable tool for analyzing 15 antigen processing and presentation. Increasingly, such analyses are aimed at determining quantitative differences in antigen display resulting from use of distinct forms of an antigen, of various antigen delivery methods, or of cells deficient in some known or suspected component of the antigen processing machinery. Without 20 reagents such as the presently described anti specific human MHC:viral peptide complex Fab's, the quantitation of cell surface levels of specific human MHC:pathogen-derived peptide complexes relies on biochemical isolation of antigenic peptides. This is an expensive and laborious process subject to numerous experimental artifacts and cannot distinguish between intracellular pools of loaded molecules and those on the cell surface accessible to TCRs.

In the data presented here, anti HLA-A2:Tax<sub>11-19</sub> complex Fab's enabled 25 quantitation of such complexes generated by intracellular antigen processing on the surface of cells transfected with the Tax gene or on HTLV-1 infected cells. This analysis demonstrated that intracellular antigen processing in Tax transfected cells led to a display of about 10<sup>4</sup> specific MHC:peptide complexes per cell. Comparison with total HLA-A2 staining showed that nearly 90 percent of the HLA-A2 molecules were 30 occupied with a single peptide species (not shown). These data agree with previous studies in which the number of H-2K<sup>b</sup>:ovalbumin-derived peptide complexes on the surface of cells following infection with recombinant *Vaccinia* virus encoding the peptide was analyzed in a variety of contexts (Porgador, A. *et al.*, 1997. *Immunity* 6:715-726). These data also agree with results from studies investigating the

occupancy of MHC class I molecules by peptides derived from virally encoded proteins displayed by infected cells (Antón, L.C. *et al.*, 1997. *J. Immunol.* 158:2535-42). Such occupancy estimates were obtained by analysis of stabilization of newly synthesized MHC class I heavy chain-beta<sub>2</sub>-microglobulin complexes, or by elution 5 of peptides from expressed MHC class I molecules and reconstruction experiments to determine the peptide concentration in the eluates. The ability of Fab T3F2 to detect the heterogeneity of HLA-A2:Tax<sub>11-19</sub> complex expression levels in a population of virally infected cells was shown. Such novel and striking data highlight the potential utility of such antibodies for studying specific human MHC:pathogen-derived peptide 10 complex expression in contexts such as diagnosis of infection with a pathogen.

Immunohistochemical staining with T3F2 Fab permitted *in situ* detection of HLA-A2:Tax<sub>11-19</sub> complex generated by intracellular 'antigen' processing on the surface of Tax transfected JY cells. Staining of background HLA display levels with the Fab was insignificant under these conditions because neither non transfected cells 15 nor HLA-A2 negative cells transfected with Tax exhibited positive staining. Such data represent the first immunohistochemical visualization of a specific human MHC:peptide complex on immobilized biological samples.

Such an approach could be applied to confocal immunofluorescence microscopy, which, using anti specific human MHC:pathogen-derived peptide 20 complex antibodies, would permit analysis of the intracellular site(s) of assembly and trafficking of such complexes. *In situ* localization of APCs displaying or expressing specific human MHC:pathogen-derived peptide complexes would be especially valuable in characterizing the intercellular interactions between APCs and T-lymphocytes involved in initiation, propagation, and maintenance of anti viral T- 25 lymphocyte immune responses. Multicolor histochemistry could be used to reveal not only the type and location of viral APCs but also the phenotype of interacting anti viral T-lymphocytes, including the set of cytokines elicited.

The fact that 62 percent of the HLA-A2:Tax<sub>11-19</sub> complex binding Fab's were peptide specific and MHC restricted was unexpected since these antibodies were 30 selected from a non immune repertoire considered not to be biased toward such specificity. The fact that it was possible to isolate from the same phage library recombinant Fab's capable of specifically binding a large variety of specific MHC:peptide complexes comprising various cancer associated or viral HLA-A2

restricted peptides (Denkberg, G. *et al.*, 2002. Proc. Natl. Acad. Sci. U. S. A. 99:9421-9426; Lev, A. *et al.*, 2002. Cancer Res. 62:3184-3194) indicates that the capacity to isolate anti MHC:Tax<sub>11-19</sub> complex antibodies from such a library was not Tax or peptide related. It is possible that one particular antibody family or antibody V gene segment could have an intrinsic propensity to bind HLA-A2 molecules, and that the high frequency could be explained by a high abundance of such antibodies in the non immune library. However, the sequences of the selected clones are derived from many different antibody families and germline segments, without any biases visible in the complementarity determining regions (CDRs) either (Table 3). The high frequency and high affinities for some of the antibodies isolated herein suggest that these molecules may be present at a high frequency in the antibody repertoires from the B cell donors of the phage library, however an *in-vivo* role for such antibodies remains unclear.

Whatever the reason for this high frequency of Fab's to bind specific MHC:peptide complexes may be, it appears that this phage based approach can be successfully applied to identify recombinant antibodies capable of specifically binding to a large variety of specific human MHC:pathogen-derived peptide complexes. Thus, it may now be possible to elucidate the role of pathogen-derived antigens not only from the perspective of the T-lymphocyte, using MHC:pathogen-derived peptide complex based TCR detection reagents such as tetrameric single chain MHC:pathogen-derived peptide complexes, but also from the perspective of pathogen-derived APCs and diseased cells, using the novel antibody type described herein.

A further application for anti specific human MHC:pathogen-derived peptide complex antibodies is in structure function studies of specific interactions between such complexes and cognate TCRs. By mutating particular residues in the MHC restricted pathogen-derived peptide and testing the influence of these mutations on the binding of the Fab's and peptide specific T-lymphocyte clones, it may be possible to obtain important data regarding the structure function relationship and the different nature of the recognition process between such Fab's and the native TCR (Stryhn A. *et al.*, 1996. Proc. Natl. Acad. Sci. U. S. A. 93:10338-10342).

**Conclusion:** By virtue of the capacity of the presently described Fab's to specifically bind with optimal affinity and specificity particular human

APM:pathogen-derived antigen complexes, such reagents are uniquely suitable and optimal relative to all prior art compounds for: (a) identification, and characterization of cells/tissues expressing or displaying such complexes; (b) specific killing of cells displaying such complexes by targeting cytotoxic drugs or radionuclides to pathogen infected cells analogously to previously described methodologies (Boon, T. and van der Bruggen, P., 1996. *J. Exp. Med.* 183:725-729; Renkvist, N. *et al.*, 2001. *Cancer Immunol. Immunother.* 50:3-15; Rosenberg, S.A., 2001. *Nature* 411:380-384); (c) confocal microscopic visualization and characterization of the intracellular localization and trafficking of such complexes; (d) tracking of cells displaying such complexes in real-time via confocal microscopy and *in-vivo*; and (e) modulation of immune responses by blocking interactions between specific human APM:pathogen-derived antigen complexes and cognate TCRs, analogously to previously described methodologies practiced by the present inventors (Denkberg, G. *et al.*, 2002. *Proc. Natl. Acad. Sci. U. S. A.* 99:9421-9426; Lev, A. *et al.*, 2002. *Cancer Res.* 62:3184-3194). For example, the presently described reagents could be used to control pathogenic T-lymphocyte mediated anti pathogen immune responses without the risk of antigen administration to an infected individual, and without the loss of function of an entire MHC allele, as would be the case with prior art anti MHC antibodies.

Thus, the presently described compounds are uniquely and optimally suitable for diagnosing, characterizing and treating diseases in humans caused by pathogens such as viruses, and for studying aspects of such diseases involving antigen presentation.

#### ***EXAMPLE 2***

25 ***Optimal prediction, diagnosis, staging, monitoring and prognosis of a pathogen-associated disease using a detection reagent specific for a complex of a human antigen-presenting molecule and a pathogen-derived antigen***

***Background:*** As described above, there are currently no satisfactory treatment methods, nor does the state of the art enable optimal prediction, diagnosis, 30 staging, monitoring and prognosis for diseases associated with HTLV-1 infection, such as HAM/TSP, in human patients. The pathogenesis of such diseases is associated with T-lymphocyte mediated autoimmune responses primarily directed against peptides of the HTLV-1 Tax protein. Hence, an optimal strategy for

diagnosing, staging and characterizing patients having such a disease would be to obtain and employ a detection reagent capable of specifically detecting a complex of an antigen-presenting molecule (APM) and a Tax-derived peptide antigen displayed by cells infected with HTLV-1. It will be appreciated that the optimal diagnosis, 5 staging and monitoring capacity which could be afforded by such a reagent would in turn enable the optimal development of therapy for such a disease. While various molecules capable of binding particular APM:antigen complexes have been proposed in the prior art, none have been shown to be capable of detecting a complex of a human antigen-presenting molecule and a pathogen-derived antigen, and hence of 10 enabling characterization of a pathogen-induced disease. As described below, the present inventors have devised for the first time relative to the prior art a method of utilizing a detection reagent specific for a complex of a human APM and an HTLV-1 Tax peptide for optimally characterizing an HTLV-1-associated disease, such as HAM/TSP, in a human, thereby overcoming the limitations of the prior art.

15 *Materials and Methods:*

*Harvesting of peripheral blood and cerebrospinal fluid lymphocytes:*

Peripheral blood is harvested via routine blood collection and cerebrospinal fluid (CSF) is harvested via lumbar puncture from HLA-A2 positive HAM/TSP patients. 20 Peripheral blood mononuclear cells (PBMCs) are isolated from the harvested peripheral blood by centrifugation over a Ficoll cushion following hypotonic erythrocyte lysis. CD4+, CD4+CD25+, and CD8+ T-cell subsets are isolated from the harvested blood and CSF via magnetic cell sorting using MACS beads.

*Flow cytometric analysis of HLA-A2:Tax<sub>11-19</sub> complexes on peripheral blood and cerebrospinal fluid T-cell subsets from HAM/TSP patients:* The isolated CD4+, 25 CD4+CD25+ and CD8+ T-cell subsets are analyzed for surface expression of HLA-A2:Tax<sub>11-19</sub> peptide complex via flow cytometry, performed essentially as described above in Example 1, using as complex detection reagent phycoerythrin-conjugated T3F2 Fab tetramer (refer to Example 1, above). Alternately, CD4+, CD4+CD25+ and 30 CD8+ T-cell subsets from the harvested blood and from the harvested CSF are analyzed for surface expression of HLA-A2:Tax<sub>11-19</sub> complex via multicolor flow cytometry, essentially as previously described (Kivisakk P. et al., 2003. Proc. Natl. Acad. Sci. U. S. A. 100:8389-8394), using as detection reagents phycoerythrin-conjugated T3F2 Fab tetramer with: FITC-conjugated anti-human CD4 antibody;

FITC-conjugated anti-human CD8 antibody; or FITC-conjugated anti-human CD4 antibody and PE-Cy5-conjugated anti-human CD25 antibody. As described in Example 1 above, Tax<sub>11-19</sub> peptide-loaded or gp100-derived G9-154 peptide-loaded HLA-A2-positive RMAS-HHD cells are employed as positive and negative controls, 5 respectively, for surface expression of the HLA-A2:Tax<sub>11-19</sub> complex.

*Analysis of HTLV-1 proviral DNA load, and HTLV-1 tax mRNA load in lymphocytes:* Analysis of HTLV-1 proviral DNA load is performed via PCR, essentially as previously described (Thorstensson R. *et al.*, Transfusion 42:780-91; Coste J., 2000. Transfus Clin Biol. 7 Suppl 1:11s-17s; Nakamura S. and Nakayama 10 T., 1997. Nippon Rinsho. 55:833-8; Kazanji M. *et al.*, 2000. J Virol. 74:4860-7). Analysis of HTLV-1 tax mRNA<sub>1</sub> load is performed via RT-PCR essentially as previously described (Kazanji M., 2000. AIDS Res Hum Retroviruses 16:1741-6; Higashiyama Y. *et al.*, 1994. Clin Exp Immunol. 96:193-201; Kazanji M. *et al.*, 2000. J Virol. 74:4860-7).

15 *Determination of HAM/TSP disease severity:* Disease severity in HAM/TSP patients is measured according to expanded disability status scale, essentially as previously described (EDSS; Kurtzke J., 1983. Neurology 33:1444-1452).

*Results:*

Profiles of HLA-A2:Tax<sub>11-19</sub> complex surface expression on CD4+, 20 CD4+CD25+ and CD8+ T-cell subsets isolated from peripheral blood and CSF of HAM/TSP patients are determined with high sensitivity via flow cytometry. CD4+, CD8+, and CD4+CD25+ cells are found to specifically display HLA-A2:Tax<sub>11-19</sub> complex surface expression. The highest levels of surface complex expression are detected in CD4+CD25+ cells, in accordance with such T-cells being the major 25 reservoir of HTLV-1 provirus. Correlations are analyzed and determined between levels of HLA-A2:Tax<sub>11-19</sub> complex expression on CD8+, CD4+, and CD4+CD25+ cells with HTLV-1 proviral DNA load, HTLV-1 tax mRNA load, and HTLV-1 Tax-specific CD8+ T-cell frequencies. Correlation of surface expression levels of the complex on the various cell T-cell subsets with disease severity is analyzed and 30 determined. Levels of HLA-A2:Tax<sub>11-19</sub> complex surface expression on CD4+CD25+ T-lymphocytes are found to correlate with disease severity.

*Conclusion:* The anti-APM:antigen complex antibodies of the present invention can be used for enabling optimal prediction, diagnosis, staging, monitoring

and prognosis of a pathogen-associated disease such as an HTLV-1 associated disease, thereby overcoming numerous limitations of the prior art. In particular, the anti-HLA-A2:Tax<sub>11-19</sub> complex antibodies of the present invention can be used for enabling optimal prediction, diagnosis, staging, monitoring and prognosis of HAM/TSP in humans, thereby overcoming numerous limitations of the prior art. It will be appreciated that such antibodies enable optimal elucidation of the pathogenesis of HTLV-1 associated diseases, enable optimal development of therapy for such diseases, and can be employed as therapeutic agents to treat such diseases according to the presently disclosed teachings.

10

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.

Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents, patent applications and sequences identified by their accession numbers mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent, patent application or sequence identified by its accession number was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention.

## WHAT IS CLAIMED IS:

1. A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen.
2. The composition-of-matter of claim 1; wherein said antibody is a monoclonal antibody.
3. The composition-of-matter of claim 1, wherein said antibody fragment is a monoclonal antibody fragment.
4. The composition-of-matter of claim 1, wherein said antibody fragment is an Fab or a single chain Fv.
5. The composition-of-matter of claim 1, wherein said antigen-binding region includes an amino acid sequence selected from the group consisting of SEQ ID NOs: 14 to 97.
6. The composition-of-matter of claim 1, wherein said antibody or antibody fragment, or a part of said antibody or antibody fragment is of human origin.
7. The composition-of-matter of claim 6, wherein said part of said antibody or antibody fragment is a portion of a constant region of said antibody or antibody fragment, or a constant region of said antibody or antibody fragment.
8. The composition-of-matter of claim 1, wherein said binding of said antibody or antibody fragment to said antigen-presenting portion of said complex is characterized by an affinity having a dissociation constant selected from the range consisting of  $1 \times 10^{-2}$  molar to  $5 \times 10^{-16}$  molar.
9. The composition-of-matter of claim 1, further comprising a toxin or

detectable moiety attached to said antibody or antibody fragment.

10. The composition-of-matter of claim 9, wherein said detectable moiety is selected from the group consisting of a recognition sequence of a biotin protein ligase, a biotin molecule, a streptavidin molecule, a fluorophore, an enzyme, and a polyhistidine tag.

11. The composition-of-matter of claim 10, wherein said biotin protein ligase is BirA.

12. The composition-of-matter of claim 10, wherein said fluorophore is phycoerythrin.

13. The composition-of-matter of claim 10, wherein said enzyme is horseradish peroxidase.

14. The composition-of-matter of claim 9, wherein said toxin is *Pseudomonas* exotoxin A or a portion thereof.

15. The composition-of-matter of claim 14, wherein said portion of *Pseudomonas* exotoxin A is a translocation domain and/or an ADP ribosylation domain.

16. The composition-of-matter of claim 1, wherein said human antigen-presenting molecule is a major histocompatibility complex molecule.

17. The composition-of-matter of claim 16, wherein said major histocompatibility complex molecule is a major histocompatibility complex class I molecule.

18. The composition-of-matter of claim 17, wherein said major histocompatibility complex class I molecule is an HLA-A2 molecule.

19. The composition-of-matter of claim 1, wherein said human antigen-presenting molecule is a single chain antigen-presenting molecule.

20. The composition-of-matter of claim 1, wherein said pathogen is a viral pathogen.

21. The composition-of-matter of claim 20, wherein said viral pathogen is a retrovirus.

22. The composition-of-matter of claim 21, wherein said retrovirus is human T lymphotropic virus-1.

23. The composition-of-matter of claim 1, wherein said antigen derived from a pathogen is restricted by said antigen-presenting molecule.

24. The composition-of-matter of claim 1, wherein said antigen derived from a pathogen is a polypeptide.

25. The composition-of-matter of claim 24, wherein said polypeptide is selected from the group consisting of a segment of a viral oncoprotein, a segment of a Tax protein, and a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 3.

26. A pharmaceutical composition comprising as an active ingredient the composition-of-matter of claim 1 and a pharmaceutically acceptable carrier.

27. A composition-of-matter comprising a multimeric form of an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen.

28. The composition-of-matter of claim 27, wherein said antibody is a monoclonal antibody.

29. The composition-of-matter of claim 27, wherein said antibody fragment is a monoclonal antibody fragment.

30. The composition-of-matter of claim 27, wherein said antibody fragment is an Fab or a single chain Fv.

31. The composition-of-matter of claim 27, wherein said antigen-binding region includes an amino acid sequence selected from the group consisting of SEQ ID NOs: 14 to 97.

32. The composition-of-matter of claim 27, wherein said antibody or antibody fragment, or a part of said antibody or antibody fragment is of human origin.

33. The composition-of-matter of claim 32, wherein said part of said antibody or antibody fragment is a portion of a constant region of said antibody or antibody fragment, or a constant region of said antibody or antibody fragment.

34. The composition-of-matter of claim 27, wherein said binding of said antibody or antibody fragment to said antigen-presenting portion of said complex is characterized by a binding affinity having a dissociation constant selected from the range consisting of  $1 \times 10^{-2}$  molar to  $5 \times 10^{-16}$  molar.

35. The composition-of-matter of claim 27, further comprising a toxin or detectable moiety attached to said antibody or antibody fragment.

36. The composition-of-matter of claim 35, wherein said detectable moiety is selected from the group consisting of a recognition sequence of a biotin protein ligase, a biotin molecule, a streptavidin molecule, a fluorophore, an enzyme, and a polyhistidine tag.

37. The composition-of-matter of claim 36, wherein said biotin protein ligase is BirA.

38. The composition-of-matter of claim 36, wherein said fluorophore is phycoerythrin.

39. The composition-of-matter of claim 36, wherein said enzyme is horseradish peroxidase.

40. The composition-of-matter of claim 35, wherein said toxin is *Pseudomonas* exotoxin A or a portion thereof.

41. The composition-of-matter of claim 40, wherein said portion of *Pseudomonas* exotoxin A is a translocation domain and/or an ADP ribosylation domain.

42. The composition-of-matter of claim 27, wherein said human antigen-presenting molecule is a major histocompatibility complex molecule.

43. The composition-of-matter of claim 42, wherein said major histocompatibility complex molecule is a major histocompatibility complex class I molecule.

44. The composition-of-matter of claim 43, wherein said major histocompatibility complex class I molecule is an HLA-A2 molecule.

45. The composition-of-matter of claim 27, wherein said human antigen-presenting molecule is a single chain antigen-presenting molecule.

46. The composition-of-matter of claim 27, wherein said pathogen is a viral pathogen.

47. The composition-of-matter of claim 46, wherein said viral pathogen is a retroviral pathogen.

48. The composition-of-matter of claim 47, wherein said retroviral

pathogen is human T lymphotropic virus-1.

49. The composition-of-matter of claim 27, wherein said antigen derived from a pathogen is restricted by said antigen-presenting molecule.

50. The composition-of-matter of claim 27, wherein said antigen derived from a pathogen is a polypeptide.

51. The composition-of-matter of claim 50, wherein said polypeptide is selected from the group consisting of a segment of a viral oncoprotein, a segment of a Tax protein, and a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 3.

52. A pharmaceutical composition comprising as an active ingredient the composition-of-matter of claim 27 and a pharmaceutically acceptable carrier.

53. An isolated polynucleotide comprising a nucleic acid sequence encoding an antibody fragment, said antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen.

54. The isolated polynucleotide of claim 53, further comprising a nucleic acid sequence encoding a polypeptide selected from the group consisting of a coat protein of a virus, a detectable moiety, and a toxin.

55. The isolated polynucleotide of claim 54, wherein said nucleic acid sequence encoding a polypeptide is translationally fused with said nucleic acid sequence encoding an antibody fragment.

56. The isolated polynucleotide of claim 53, wherein said antibody fragment is an Fab or a single chain Fv.

57. The isolated polynucleotide of claim 54, wherein said virus is a filamentous phage and whereas said coat protein of said virus is pIII.

58. The isolated polynucleotide of claim 54, wherein said detectable moiety is a polyhistidine tag or a recognition sequence of a biotin protein ligase.

59. The isolated polynucleotide of claim 58, wherein said biotin protein ligase is BirA.

60. The isolated polynucleotide of claim 54, wherein said toxin is *Pseudomonas* exotoxin A or a portion thereof.

61. The isolated polynucleotide of claim 60, wherein said portion of *Pseudomonas* exotoxin A is a translocation domain and/or an ADP ribosylation domain.

62. The isolated polynucleotide of claim 53, wherein said antigen-binding region includes an amino acid sequence selected from the group consisting of SEQ ID NOs: 14 to 97.

63. The isolated polynucleotide of claim 53, wherein said antibody fragment, or a part of said antibody fragment is of human origin.

64. The isolated polynucleotide of claim 63, wherein said part of said antibody fragment is a portion of a constant region of said antibody fragment, or a constant region of said antibody fragment.

65. The isolated polynucleotide of claim 53, wherein said binding of said antibody fragment to said antigen-presenting portion of said complex is characterized by a binding affinity having a dissociation constant selected from the range consisting of  $1 \times 10^{-2}$  molar to  $5 \times 10^{-16}$  molar.

66. The isolated polynucleotide of claim 53, wherein said human antigen-

presenting molecule is a major histocompatibility complex molecule.

67. The isolated polynucleotide of claim 66, wherein said major histocompatibility complex molecule is a major histocompatibility complex class I molecule.

68. The isolated polynucleotide of claim 67, wherein said major histocompatibility complex class I molecule is an HLA-A2 molecule.

69. The isolated polynucleotide of claim 53, wherein said human antigen-presenting molecule is a single chain antigen-presenting molecule.

70. The isolated polynucleotide of claim 53, wherein said pathogen is a viral pathogen.

71. The isolated polynucleotide of claim 70, wherein said viral pathogen is a retroviral pathogen.

72. The isolated polynucleotide of claim 71, wherein said retroviral pathogen is human T lymphotropic virus-1.

73. The isolated polynucleotide of claim 53, wherein said antigen derived from a pathogen is restricted by said antigen-presenting molecule.

74. The isolated polynucleotide of claim 53, wherein said antigen derived from a pathogen is a polypeptide.

75. The isolated polynucleotide of claim 74, wherein said polypeptide is a segment of a Tax protein, or a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 3.

76. A nucleic acid construct comprising the isolated polynucleotide of claim 53 and a promoter sequence for directing transcription of the isolated

polynucleotide in a host cell.

77. The nucleic acid construct of claim 76, wherein said promoter sequence is a T7 promoter sequence.

78. The nucleic acid construct of claim 76, wherein said promoter sequence is capable of driving expression of said nucleic acid sequence in a prokaryote.

79. The nucleic acid construct of claim 76, wherein said promoter sequence is capable of driving inducible expression of said nucleic acid sequence.

80. A host cell comprising the nucleic acid construct of claim 76.

81. The host cell of claim 80, wherein the host cell is a prokaryotic cell.

82. The host cell of claim 81, wherein said prokaryotic cell is an *E. coli* cell.

83. A host virus comprising the nucleic acid construct of claim 76.

84. The host virus of claim 83, wherein the host virus is a filamentous phage.

85. A virus comprising a coat protein fused to an antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen.

86. The virus of claim 85, wherein the virus is a filamentous phage and whereas said coat protein is pIII.

87. The virus of claim 85, wherein said antibody fragment is an Fd

fragment or an Fab.

88. The virus of claim 85, wherein said antigen-binding region includes an amino acid sequence selected from the group consisting of SEQ ID NOs: 14 to 97.

89. The virus of claim 85, wherein said binding of said antibody fragment to said antigen-presenting portion of said complex is characterized by an affinity having a dissociation constant selected from the range consisting of  $1 \times 10^{-2}$  molar to  $5 \times 10^{-16}$  molar.

90. The virus of claim 85, further comprising a detectable moiety attached to said antibody fragment.

91. The virus of claim 85, wherein said human antigen-presenting molecule is a major histocompatibility complex molecule.

92. The virus of claim 91, wherein said major histocompatibility complex molecule is a major histocompatibility complex class I molecule.

93. The virus of claim 92, wherein said major histocompatibility complex class I molecule is an HLA-A2 molecule.

94. The virus of claim 85, wherein said human antigen-presenting molecule is a single chain antigen-presenting molecule.

95. The virus of claim 85, wherein said pathogen is a viral pathogen.

96. The virus of claim 95, wherein said viral pathogen is a retroviral pathogen.

97. The virus of claim 96, wherein said retroviral pathogen is human T lymphotropic virus-1.

100

98. The virus of claim 85, wherein said antigen derived from a pathogen is restricted by said antigen-presenting molecule.

99. The virus of claim 85, wherein said antigen derived from a pathogen is a polypeptide.

100. The virus of claim 99, wherein said polypeptide is a segment of a Tax protein, or a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 3.

101. A method of detecting an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen, the method comprising:

- (a) exposing the antigen-presenting portion of the complex to a composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding the antigen-presenting portion of the complex, to thereby obtain a conjugate of the antigen-presenting portion of the complex and said antibody or antibody fragment; and
- (b) detecting said antibody or antibody fragment of said conjugate, thereby detecting an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen.

102. The method of claim 101, wherein the complex is displayed or expressed by a target cell, and whereas step (a) is effected by exposing said target cell to said composition-of-matter.

103. The method of claim 102, further comprising:
  - (c) obtaining said target cell from an individual.

104. The method of claim 102, wherein said exposing said target cell to said composition-of-matter is effected by administering said composition-of-matter to an

individual.

105. The method of claim 102, wherein said target cell is a T-lymphocyte or an antigen presenting cell.

106. The method of claim 105, wherein said antigen presenting cell is a B cell or a dendritic cell.

107. The method of claim 101, wherein said composition-of-matter further comprises a detectable moiety attached to said antibody or antibody fragment, and whereas step (b) is effected by detecting said detectable moiety attached to said antibody or antibody fragment of said conjugate.

108. The method of claim 107, wherein said detectable moiety is selected from the group consisting of a recognition sequence of a biotin protein ligase, a biotin molecule, a streptavidin molecule, a fluorophore, and an enzyme.

109. The method of claim 101, wherein said antibody fragment is an Fab.

110. The method of claim 101, wherein said antigen-binding region includes an amino acid sequence selected from the group consisting of SEQ ID NOs: 14 to 97.

111. The method of claim 101, wherein said binding of said antibody or antibody fragment to the antigen-presenting portion of the complex is characterized by an affinity having a dissociation constant selected from the range consisting of  $1 \times 10^{-2}$  molar to  $5 \times 10^{-16}$  molar.

112. The method of claim 101, wherein the human antigen-presenting molecule is a major histocompatibility complex molecule.

113. The method of claim 112, wherein said major histocompatibility complex molecule is a major histocompatibility complex class I molecule.

114. The method of claim 113, wherein said major histocompatibility complex class I molecule is an HLA-A2 molecule.

115. The method of claim 101, wherein the human antigen-presenting molecule is a single chain antigen-presenting molecule.

116. The method of claim 101, wherein said pathogen is a viral pathogen.

117. The method of claim 116, wherein said viral pathogen is a retrovirus.

118. The method of claim 117, wherein said retrovirus is human T lymphotropic virus-1.

119. The method of claim 101, wherein the antigen derived from a pathogen is restricted by the antigen-presenting molecule.

120. The method of claim 101, wherein the antigen derived from a pathogen is a polypeptide.

121. The method of claim 120, wherein said polypeptide is a segment of a Tax protein, or a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 3.

122. A method of diagnosing an infection by a pathogen in an individual, the method comprising:

- (a) exposing a target cell of the individual to a composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from the pathogen, to thereby obtain a conjugate of said antigen-presenting portion of said complex and said antibody or antibody fragment; and
- (b) detecting said antibody or antibody fragment of said conjugate, thereby

diagnosing an infection by a pathogen in an individual.

123. The method of claim 122, further comprising:

(c) obtaining said target cell from the individual.

124. The method of claim 122, wherein step (a) is effected by administering said composition-of-matter to the individual.

125. The method of claim 122, wherein said target cell is a T-lymphocyte or an antigen presenting cell.

126. The method of claim 122, wherein said antigen presenting cell is a B cell or a dendritic cell.

127. The method of claim 122, wherein said composition-of-matter further comprises a detectable moiety attached to said antibody or antibody fragment, and whereas step (b) is effected by detecting said detectable moiety attached to said antibody or antibody fragment of said conjugate.

128. The method of claim 127, wherein said detectable moiety is selected from the group consisting of a recognition sequence of a biotin protein ligase, a biotin molecule, a streptavidin molecule, a fluorophore, and an enzyme.

129. The method of claim 122, wherein said antibody fragment is an Fab.

130. The method of claim 122, wherein said antigen-binding region includes an amino acid sequence selected from the group consisting of SEQ ID NOs: 14 to 97.

131. The method of claim 122, wherein said binding of said antibody or antibody fragment to the antigen-presenting portion of the complex is characterized by an affinity having a dissociation constant selected from the range consisting of  $1 \times 10^{-2}$  molar to  $5 \times 10^{-16}$  molar.

132. The method of claim 122, wherein the human antigen-presenting molecule is a major histocompatibility complex molecule.

133. The method of claim 132, wherein said major histocompatibility complex molecule is a major histocompatibility complex class I molecule.

134. The method of claim 133, wherein said major histocompatibility complex class I molecule is an HLA-A2 molecule.

135. The method of claim 122, wherein said pathogen is a viral pathogen.

136. The method of claim 135, wherein said viral pathogen is a retrovirus.

137. The method of claim 136, wherein said retrovirus is human T lymphotropic virus-1.

138. The method of claim 122, wherein the antigen derived from a pathogen is restricted by the antigen-presenting molecule.

139. The method of claim 122, wherein the antigen derived from a pathogen is a polypeptide.

140. The method of claim 139, wherein said polypeptide is a segment of a Tax protein, or a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 3.

141. A method of killing or damaging a target cell expressing or displaying an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen, the method comprising exposing the target cell to a composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding the antigen-presenting portion of the complex, thereby killing or damaging a target cell expressing or displaying an antigen-presenting portion of a complex composed of a

human antigen-presenting molecule and an antigen derived from a pathogen.

142. The method of claim 141, wherein said composition-of-matter further comprises a toxin attached to said antibody or antibody fragment.

143. The method of claim 142, wherein said toxin is *Pseudomonas* exotoxin A or a portion thereof.

144. The method of claim 141, further comprising the step of obtaining the target cell from an individual.

145. The method of claim 141, wherein said exposing the cell to said composition-of-matter is effected by administering said composition-of-matter to an individual.

146. The method of claim 141, wherein the target cell is infected with the pathogen.

147. The method of claim 141, wherein the target cell is a T-lymphocyte or an antigen presenting cell.

148. The method of claim 141, wherein said antigen presenting cell is a B cell or a dendritic cell.

149. The method of claim 141, wherein said antibody fragment is a single chain Fv.

150. The method of claim 141, wherein said antigen-binding region includes an amino acid sequence selected from the group consisting of SEQ ID NOS: 14 to 97.

151. The method of claim 141, wherein said binding of said antibody or antibody fragment to said antigen-presenting portion of said complex is characterized by an affinity having a dissociation constant selected from the range consisting of 1 ×

$10^{-2}$  molar to  $5 \times 10^{-16}$  molar.

152. The method of claim 141, wherein said human antigen-presenting molecule is a major histocompatibility complex molecule.

153. The method of claim 152, wherein said major histocompatibility complex molecule is a major histocompatibility complex class I molecule.

154. The method of claim 153, wherein said major histocompatibility complex class I molecule is an HLA-A2 molecule.

155. The method of claim 141, wherein said pathogen is a viral pathogen.

156. The method of claim 155, wherein said viral pathogen is a retrovirus.

157. The method of claim 156, wherein said retrovirus is human T lymphotropic virus-1.

158. The method of claim 141, wherein said antigen derived from a pathogen is restricted by the antigen-presenting molecule.

159. The method of claim 141, wherein said antigen derived from a pathogen is a polypeptide.

160. The method of claim 159, wherein said polypeptide is a segment of a Tax protein, or a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 3.

161. A method of treating a disease associated with a pathogen in an individual, the method comprising administering to the individual a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient, a composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion

of a complex composed of a human antigen-presenting molecule and an antigen derived from the pathogen, thereby treating a disease associated with a pathogen in an individual.

162. The method of claim 161, wherein said composition-of-matter further comprises a toxin attached to said antibody or antibody fragment.

163. The method of claim 162, wherein said toxin is *Pseudomonas* exotoxin A or a portion thereof.

164. The method of claim 161, wherein said antibody fragment is an Fab or a single chain Fv.

165. The method of claim 161, wherein said antigen-binding region includes an amino acid sequence selected from the group consisting of SEQ ID NOs: 14 to 97.

166. The method of claim 161, wherein said binding of said antibody or antibody fragment to said antigen-presenting portion of said complex is characterized by an affinity having a dissociation constant selected from the range consisting of  $1 \times 10^{-2}$  molar to  $5 \times 10^{-16}$  molar.

167. The method of claim 161, wherein said human antigen-presenting molecule is a major histocompatibility complex molecule.

168. The method of claim 167, wherein said major histocompatibility complex molecule is a major histocompatibility complex class I molecule.

169. The method of claim 168, wherein said major histocompatibility complex class I molecule is an HLA-A2 molecule.

170. The method of claim 161, wherein said pathogen is a viral pathogen.

171. The method of claim 170, wherein said viral pathogen is a retrovirus.

172. The method of claim 171, wherein said retrovirus is human T lymphotropic virus-1.

173. The method of claim 161, wherein said antigen derived from a pathogen is restricted by the antigen-presenting molecule.

174. The method of claim 161, wherein said antigen derived from a pathogen is a polypeptide.

175. The method of claim 174, wherein said polypeptide is a segment of a Tax protein, or a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 3.

176. A method of detecting in a biological sample an antigen-presenting portion of a complex composed of an antigen-presenting molecule and an antigen, the method comprising:

- (a) attaching the biological sample to a surface;
- (b) exposing the biological sample to a composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding the antigen-presenting portion of the complex, to thereby obtain a conjugate of the antigen-presenting portion of the complex and said antibody or antibody fragment; and
- (c) detecting said antibody or antibody fragment of said conjugate, thereby detecting in a biological sample an antigen-presenting portion of a complex composed of an antigen-presenting molecule and an antigen.

177. The method of claim 176, further comprising:

- (d) obtaining the biological sample from an individual.

178. The method of claim 176, wherein step (b) is effected by administering said composition-of-matter to an individual.

179. The method of claim 176, wherein said composition-of-matter further

comprises a detectable moiety attached to said antibody or antibody fragment, and whereas step (c) is effected by detecting said detectable moiety attached to said antibody or antibody fragment of said conjugate.

180. The method of claim 179, wherein said detectable moiety is selected from the group consisting of a recognition sequence of a biotin protein ligase, a biotin molecule, a streptavidin molecule, a fluorophore, and an enzyme.

181. The method of claim 176, wherein the antigen is derived from a pathogen.

182. The method of claim 181, wherein the biological sample is infected with said pathogen.

183. The method of claim 182, wherein said pathogen is a viral pathogen.

184. The method of claim 183, wherein said viral pathogen is a retrovirus.

185. The method of claim 184, wherein said retrovirus is human T lymphotropic virus-1.

186. The method of claim 176, wherein the biological sample is a cell sample or a tissue sample.

187. The method of claim 176, wherein said antibody fragment is selected from the group consisting of a light chain, an Fd fragment, and an Fab.

188. The method of claim 176, wherein said antigen-binding region includes an amino acid sequence selected from the group consisting of SEQ ID NOs: 14 to 97.

189. The method of claim 176, wherein said binding of said antibody or antibody fragment to the antigen-presenting portion of the complex is characterized by an affinity having a dissociation constant selected from the range consisting of

$1 \times 10^{-2}$  molar to  $5 \times 10^{-16}$  molar.

190. The method of claim 176, wherein the antigen-presenting molecule is a major histocompatibility complex molecule.





191. The method of claim 190, wherein said major histocompatibility complex molecule is a major histocompatibility complex class I molecule.




192. The method of claim 191, wherein said major histocompatibility complex class I molecule is an HLA-A2 molecule.




193. The method of claim 176, wherein the antigen is restricted by the antigen-presenting molecule.






194. The method of claim 176, wherein the antigen is a polypeptide.




195. The method of claim 194, wherein said polypeptide is a segment of a Tax protein, or a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 3.




**Fig. 1****Fig. 2a****Fig. 2b****Fig. 2c**


**Fig. 3a****Fig. 3b****Fig. 3c**




**Fig. 4a****Fig. 4b****Fig. 4c**

**Fig. 5a****Fig. 5c****Fig. 5e****Fig. 5b****Fig. 5f**


**Fig. 6a****Fig. 6b****Fig. 6c**

**Fig. 7a****Fig. 7b****Fig. 7c**

**Fig. 7d**

**Fig. 8a****Fig. 8b****Fig. 8c****Fig. 8d**

Transfected cells within Heterogeneous population (%)	Positive cells detected within Heterogeneous population (%)	Detection sensitivity (Max=61.2% transfected)
100	61.2	100
33	17.8	29.1
10	6.0	9.8
5	2.7	4.4
2.5	0.9	1.5
1	0.3	0.5

**Fig. 9a****A**


x40

JY/pCTAX

**Fig. 9b****B**


x60

JY/pCTAX

**Fig. 9c****C**


x40

JY/pCDNA

**Fig. 9d****D**


x40

JY/pCTAX

**Fig. 9e****E**


x40

APD/pCTAX

**Fig. 9f****F**

x40

APD/pCDNA

**Fig. 10**

1  
SEQUENCE LISTING

<110> Reiter , Yoram  
Cohen, Cyril J.

<120> ANTIGEN-PRESENTING COMPLEX-BINDING COMPOSITIONS AND USES THEREOF

<130> 27040

<160> 97

<170> PatentIn version 3.2

<210> 1

<211> 23

<212> DNA

<213> Artificial sequence

<220>

<223> Single strand DNA oligonucleotide

<400> 1

agcggataac aatttcacac agg

23

<210> 2

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Single strand DNA oligonucleotide

<400> 2

tttgtcgtct ttccagacgt tagt

24

<210> 3

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> HLA-A2 restricted peptide

<400> 3

Leu Leu Phe Gly Tyr Pro Val Tyr Val  
1 5

<210> 4

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> HLA-A2 restricted peptide

<400> 4

Leu Leu Leu Thr Val Leu Thr Val Val  
1 5

<210> 5

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> HLA-A2 restricted peptide

<400> 5

Asn Leu Thr Ile Ser Asp Val Ser Val  
1 5

<210> 6  
<211> 9  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> HLA-A2 restricted peptide  
  
<400> 6

Asn Leu Val Pro Met Val Ala Thr Val  
1 5

<210> 7  
<211> 9  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> HLA-A2 restricted peptide  
  
<400> 7

Ser Val Arg Asp Arg Leu Ala Arg Leu  
1 5

<210> 8  
<211> 9  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> HLA-A2 restricted peptide  
  
<400> 8

Ile Leu Ala Lys Phe Leu His Trp Leu  
1 5

<210> 9  
<211> 9  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> HLA-A2 restricted peptide  
  
<400> 9

Arg Leu Val Asp Asp Phe Leu Leu Val  
1 5

<210> 10  
<211> 9  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> HLA-A2 restricted peptide  
  
<400> 10

Ile Met Asp Gln Val Pro Phe Ser Val  
1 5

<210> 11  
<211> 9

<212> PRT  
<213> Artificial sequence

<220>  
<223> HLA-A2 restricted peptide

<400> 11

Tyr Leu Glu Pro Gly Pro Val Thr Val  
1 5

<210> 12  
<211> 9  
<212> PRT  
<213> Artificial sequence

<220>  
<223> HLA-A2 restricted peptide

<400> 12

Lys Thr Trp Gly Gln Val Trp Gln Val  
1 5

<210> 13  
<211> 10  
<212> PRT  
<213> Artificial sequence

<220>  
<223> HLA-A2 restricted peptide

<400> 13

Glu Ala Ala Gly Ile Gly Ile Leu Thr Val  
1 5 10

<210> 14  
<211> 5  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 14

Ser Tyr Thr Ile Ser  
1 5

<210> 15  
<211> 17  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 15

Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln  
1 5 10 15

Gly

<210> 16  
<211> 13

<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 16

Asp Thr Asp Ser Ser Gly Tyr Tyr Gly Ala Val Asp Tyr  
1 5 10

<210> 17  
<211> 11  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 17

Arg Ala Ser Gln Ser Val Gly Ser Tyr Leu Ala  
1 5 10

<210> 18  
<211> 7  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 18

Asp Ala Ser His Arg Ala Thr  
1 5

<210> 19  
<211> 11  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 19

Gln Gln Arg Ser Asn Trp Pro Pro Met Tyr Thr  
1 5 10

<210> 20  
<211> 5  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 20

Ser Tyr Gly Met His  
1 5

<210> 21  
<211> 17

<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 21

Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 22  
<211> 15  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 22

Asp Phe Asp Tyr Gly Asp Ser Tyr Tyr Tyr Gly Met Asp Val  
1 5 10 15

<210> 23  
<211> 12  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 23

Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr  
1 5 10

<210> 24  
<211> 7  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 24

Leu Gly Ser Asn Arg Ala Ser  
1 5

<210> 25  
<211> 9  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 25

Met Gln Ala Leu Gln Thr Pro Arg Thr  
1 5

<210> 26  
<211> 5  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 26

Asn Tyr Gly Ile Asn  
1 5

<210> 27  
<211> 17  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 27

Trp Ile Ser Ala Tyr Asn Gly Asp Thr Lys Tyr Ala Gln Arg Leu Gln  
1 5 10 15

Asp

<210> 28  
<211> 12  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 28

Gly Asp Ser Thr Val Gly Tyr Glu Tyr Leu Gln Tyr  
1 5 10

<210> 29  
<211> 11  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 29

Gln Ala Ser Gln Gly Ile Gly Lys Tyr Leu Asn  
1 5 10

<210> 30  
<211> 7  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 30

Val Ala Ser Ser Leu Gln Ser  
1 5

<210> 31

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 31

Gln Gln Thr Ser Ser Phe Pro Pro Thr  
1 5

<210> 32

<211> 5

<212> PRT

<213> Artificial sequence

<220>

<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 32

Ser Tyr Ala Ile Ser  
1 5

<210> 33

<211> 17

<212> PRT

<213> Artificial sequence

<220>

<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 33

Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln  
1 5 10 15

Gly

<210> 34

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 34

Gln Gly Gly Asp Tyr Ser Asn Tyr Tyr Tyr Tyr Met Asp Val  
1 5 10

<210> 35

<211> 11

<212> PRT

<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 35

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala  
1 5 10

<210> 36  
<211> 7  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 36

Asp Ala Ser Asn Arg Ala Thr  
1 5

<210> 37  
<211> 9  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 37

Gln His Arg Phe Asn Trp Pro Val Thr  
1 5

<210> 38  
<211> 5  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 38

Ser Tyr Gly Met His  
1 5

<210> 39  
<211> 17  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 39

Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 40  
<211> 16

<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 40

Asp Gln Thr Tyr Tyr Gly Ser Gly Ser Pro Arg Gly Gly Leu Asp Tyr  
1 5 10 15

<210> 41  
<211> 13  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 41

Thr Gly Ser Ser Gly Ser Ile Ala Asn Asn Tyr Val Gln  
1 5 10

<210> 42  
<211> 7  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 42

Glu Asp Asp Gln Arg Pro Ser  
1 5

<210> 43  
<211> 11  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 43

Gln Ser Tyr Asp Asn Ser Asn Ser Phe Val Val  
1 5 10

<210> 44  
<211> 7  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 44

Ser Asn Ser Ala Ala Trp Asn  
1 5

<210> 45  
<211> 17

10

<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 45

Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Val Ser Val Lys  
1 5 10 15

Ser

<210> 46  
<211> 15  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 46

Gly Pro Tyr Asp Thr Thr Gly Pro Trp Gly Asn Trp Phe Asp Pro  
1 5 10 15

<210> 47  
<211> 11  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 47

Arg Ala Ser Gln Ser Val Ser Ser Asp Leu Ala  
1 5 10

<210> 48  
<211> 7  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 48

Gly Ala Ser Tyr Arg Ala Thr  
1 5

<210> 49  
<211> 9  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 49

Gln Gln Tyr Gly Ser Ser Pro Arg Thr  
1 5

<210> 50  
<211> 5  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 50

Ser Tyr Gly Met His  
1 5

<210> 51  
<211> 17  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 51

Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 52  
<211> 15  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 52

Asp Phe Asp Tyr Gly Asp Ser Tyr Tyr Tyr Gly Met Asp Val  
1 5 10 15

<210> 53  
<211> 16  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 53

Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp  
1 5 10 15

<210> 54  
<211> 7  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

&lt;400&gt; 54

Leu Gly Ser Asn Arg Ala Ser  
1 5

&lt;210&gt; 55

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

&lt;400&gt; 55

Met Gln Ala Leu Gln Thr Pro Arg Thr  
1 5

&lt;210&gt; 56

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

&lt;400&gt; 56

Ser Tyr Ala Met Ser  
1 5

&lt;210&gt; 57

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

&lt;400&gt; 57

Ala Ile Ser Gly Ser Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

&lt;210&gt; 58

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

&lt;400&gt; 58

Asp Ser Leu Ala Gly Ala Thr Gly Thr Asp Phe Asp Tyr  
1 5 10

&lt;210&gt; 59

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 59

Arg Ala Ser Gln Thr Val Thr Ala Asn Tyr Leu Ala  
1 5 10

<210> 60  
<211> 7  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 60

Asp Ala Ser Val Arg Ala Thr  
1 5

<210> 61  
<211> 9  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 61

Gln Gln Tyr Gly Ser Ser Pro Ile Thr  
1 5

<210> 62  
<211> 5  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 62

Ser Tyr Ala Met Ser  
1 5

<210> 63  
<211> 17  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 63

Gly Ile Ser Gly Ser Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 64  
<211> 14

<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 64

Asp Phe Asp Tyr Gly Gly Asn Ser Gly Ser Leu Phe Asp Tyr  
1 5 10

<210> 65  
<211> 12  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 65

Gly Ala Ser Glu Ser Val Gly Gly Asn Tyr Leu Ala  
1 5 10

<210> 66  
<211> 7  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 66

Asp Ala Ser Thr Arg Ala Thr  
1 5

<210> 67  
<211> 10  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 67

Gln His Tyr Gly Ser Ser Pro Ser Thr Tyr  
1 5 10

<210> 68  
<211> 6  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 68

Ser Ser Asn Trp Trp Ser  
1 5

<210> 69  
<211> 16

15

<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 69

Glu Ile Tyr His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser  
1 5 10 15

<210> 70  
<211> 14  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 70

His Ser Tyr Asp Tyr Leu Trp Gly Thr Tyr Arg Phe Asp Tyr  
1 5 10

<210> 71  
<211> 11  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 71

Arg Ala Ser Gln Asp Ile Gly Thr Trp Leu Ala  
1 5 10

<210> 72  
<211> 7  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 72

Ala Ala Thr Thr Leu Glu Ser  
1 5

<210> 73  
<211> 9  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 73

Gln Gln Ala Arg Ser Leu Pro Tyr Thr  
1 5

<210> 74  
<211> 5

16

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Sequence of complementarity determining region of Fab specifically binding HLA-A2:Tax11-19 complex.

&lt;400&gt; 74

Asn Tyr Gly Ile Asn

1 5

&lt;210&gt; 75

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Sequence of complementarity determining region of Fab specifically binding HLA-A2:Tax11-19 complex.

&lt;400&gt; 75

Trp Ile Ser Ala Tyr Asn Gly Asp Thr Lys Tyr Ala Gln Arg Leu Gln

1 5 10 15

Asp

&lt;210&gt; 76

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Sequence of complementarity determining region of Fab specifically binding HLA-A2:Tax11-19 complex.

&lt;400&gt; 76

Gly Asp Ser Thr Val Gly Tyr Glu Tyr Leu Gln Tyr

1 5 10

&lt;210&gt; 77

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Sequence of complementarity determining region of Fab specifically binding HLA-A2:Tax11-19 complex.

&lt;400&gt; 77

Gln Ala Ser Gln Gly Ile Gly Lys Tyr Leu Asn

1 5 10

&lt;210&gt; 78

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Sequence of complementarity determining region of Fab specifically binding HLA-A2:Tax11-19 complex.

&lt;400&gt; 78

Val Ala Ser Ser Leu Gln Ser

1 5

<210> 79  
<211> 9  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 79

Gln Gln Thr Ser Ser Phe Pro Pro Thr  
1 5

<210> 80  
<211> 5  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 80

Ser Tyr Gly Met His  
1 5

<210> 81  
<211> 17  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 81

Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 82  
<211> 12  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

<400> 82

Asp Tyr Asn Gly Tyr Gly Asp Tyr Val Leu Gly Tyr  
1 5 10

<210> 83  
<211> 11  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

18

&lt;400&gt; 83

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala  
1 5 10

&lt;210&gt; 84

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

&lt;400&gt; 84

Asp Ala Ser Asn Arg Ala Thr  
1 5

&lt;210&gt; 85

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

&lt;400&gt; 85

Gln Gln Arg Ser Asn Trp Ala Ser Tyr Thr  
1 5 10

&lt;210&gt; 86

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

&lt;400&gt; 86

Ser Tyr Tyr Met His  
1 5

&lt;210&gt; 87

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

<223> Sequence of complementarity determining region of Fab  
specifically binding HLA-A2:Tax11-19 complex.

&lt;400&gt; 87

Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln  
1 5 10 15

Gly

&lt;210&gt; 88

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab specifically binding HLA-A2:Tax11-19 complex.

<400> 88

Asp Arg Gly Gly Gly Tyr Asp Val Ser Pro Tyr Gly Met Asp Val  
1 5 10 15

<210> 89  
<211> 11  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab specifically binding HLA-A2:Tax11-19 complex.

<400> 89

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn  
1 5 10

<210> 90  
<211> 7  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab specifically binding HLA-A2:Tax11-19 complex.

<400> 90

Ala Ala Ser Asn Leu Gln Thr  
1 5

<210> 91  
<211> 8  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab specifically binding HLA-A2:Tax11-19 complex.

<400> 91

Gln Gln Thr Tyr Ser Leu Pro Thr  
1 5

<210> 92  
<211> 5  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Sequence of complementarity determining region of Fab specifically binding HLA-A2:Tax11-19 complex.

<400> 92

Ser Tyr Ala Ile Ser  
1 5

<210> 93  
<211> 17  
<212> PRT  
<213> Artificial sequence

20

&lt;220&gt;

&lt;223&gt; Sequence of complementarity determining region of Fab specifically binding HLA-A2:Tax11-19 complex.

&lt;400&gt; 93

Gly Ile Ile Pro Ile Pro Gly Ile Thr Asn Tyr Ala Gln Lys Phe Gln  
1 5 10 15

GLY

&lt;210&gt; 94

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Sequence of complementarity determining region of Fab specifically binding HLA-A2:Tax11-19 complex.

&lt;400&gt; 94

Arg Val Gly Tyr Tyr Gly Met Asp Val  
1 5 10

&lt;210&gt; 95

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Sequence of complementarity determining region of Fab specifically binding HLA-A2:Tax11-19 complex.

&lt;400&gt; 95

Ala Gly Ser Gly Gly Asp Ile Ala Ser Asn Phe Val Gln  
1 5 10

&lt;210&gt; 96

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Sequence of complementarity determining region of Fab specifically binding HLA-A2:Tax11-19 complex.

&lt;400&gt; 96

Glu Glu Asn Arg Arg Pro Ser  
1 5

&lt;210&gt; 97

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Sequence of complementarity determining region of Fab specifically binding HLA-A2:Tax11-19 complex.

&lt;400&gt; 97

Gln Ser Tyr Asp Gly Ser Ala Trp  
1 5